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Foreword
The Commission has prepared this research report in response to a request from the
Assistant Treasurer. The study originated from meetings of the Pharmaceutical
Industry Working Group, which is a consultative forum comprising government and
pharmaceutical industry representatives. In its discussions, the Group identified a
need for improved estimates of pharmaceutical price differences between Australia
and other countries, given concerns about previous price comparisons.
The report compares the prices that manufacturers receive for 150 pharmaceuticals
under Australia’s Pharmaceutical Benefits Scheme with those obtained in seven
other countries. It finds that, on a bilateral basis, prices for these products in
Australia are much lower than those in the United States, Canada, the United
Kingdom and Sweden but closer to those in France, Spain and New Zealand.
The report has drawn on information obtained from consultations with government
officials, industry representatives and academics both in Australia and overseas.
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Glossary
Active  ingredient The primary chemical substance contained in
pharmaceuticals. Some pharmaceuticals contain more
than one active ingredient (combination molecules).
Anatomical Therapeutic
Chemical (ATC) codes
ATC codes provide a method of grouping
pharmaceuticals according to their anatomical site of
action, and therapeutic and chemical characteristics.
Bioequivalence Two or more brands of a molecule (in the same
dosage type and strength) are released into, and
absorbed by the body at the same rate.
Brand  premium Premium charged by a manufacturer above the
reimbursed price of the bioequivalent brands of the
PBS items, and is paid by the patient.
Brand substitution Substitution of a generic bioequivalent version by the
pharmacist where the patient agrees, when not
disallowed by the prescriber.
Combination  molecules Pharmaceuticals that contain more than one active
ingredient. An example is the pharmaceutical
containing amoxycillin and clavulanic acid.
Concessional  benefit Under the PBS, holders of a Commonwealth
concession card are entitled to a lower copayment on
purchases of PBS-listed pharmaceuticals (currently
$3.50 per script).
Copayment A patient contribution towards the cost of subsidised
pharmaceuticals. In Australia the copayment is a
maximum of $21.90 for general patients, and a
maximum of $3.50 for concession card holders.
Cost-effectiveness
analysis
Compares therapies which have the same outcomes,
but the outcomes can be achieved to different degrees
(for example, the number of lives saved). It aims to
identify the most efficient therapy that minimises cost
per unit of outcome.XII GLOSSARY
Deductible The yearly out-of-pocket payment by a member of a
health plan (for example, HMOs in the United States),
which is required before the health plan will make a
payment.
Economic evaluation Economic evaluation aims to examine the clinical and
economic impact of pharmaceuticals, requiring an
assessment of the costs and health benefits to patients.
Federal Supply Schedule
(FSS)
In the US, Federal departments and agencies can
purchase pharmaceuticals at prices listed in the FSS.
Form Pharmaceuticals come in different dosage types (for
example, tablet, capsule or injection), strengths and
pack sizes. Each combination of these is considered a
form of a particular pharmaceutical product.
Generic  pharmaceutical Pharmaceuticals subject to competition from
bioequivalent versions. In this report it applies to both
originator brands and copies of the originator
pharmaceutical.
Indications Denotes the situations (such as symptoms) in which a
pharmaceutical may be used.
International price
benchmarking
The practice of comparing pharmaceutical prices
across countries, usually for the purpose of
determining reimbursement prices.
List price The manufacturers’ posted price. This price does not
include any discounts or other incentives offered by
manufacturers.
Manufacturer  price Also referred to as the ex-factory price. This is the
price that pharmaceutical companies receive for their
products.
Marketing approval Before a new pharmaceutical is sold in the market, the
supplier first must obtain marketing approval from the
relevant authority. The quality, safety, and efficacy of
the product is assessed before awarding marketing
approval.
Me-too pharmaceuticals Pharmaceuticals for which alternatives are available.
Molecule All forms of a particular pharmaceutical.
New innovative
pharmaceuticals
Pharmaceuticals for which there are no reasonable
alternatives, and also those with efficacy, quality of
life and/or safety improvements, including better
modes of delivery of active ingredients.GLOSSARY XIII
Pharmaceutical Chemical entities that are designed to treat or prevent
a variety of illnesses and conditions. May be available
in many different forms.
Price-volume agreement The agreed price of a pharmaceutical is based on a
forecast volume of sales. If the actual sales volume
exceeds the forecast, the price of the pharmaceutical is
usually reviewed downwards.
Reference pricing The practice of setting a ceiling on the amount that
will be reimbursed to patients or pharmacists, for
defined groups of molecules. For example, it might
involve setting a maximum reimbursement price for a
group of molecules based on the price of the cheapest
product in the group.
Reimbursement price This is the maximum amount that the insurer will pay
towards the cost of a subsidised pharmaceutical. This
amount is usually paid to the pharmacist rather than
the patient. The manufacturer may be free to price
above the reimbursement price, with the patient
required to pay the difference.
Retail price The price charged by retail pharmacists to the general
public. It includes any pharmacy mark-up, dispensing
fees, and may include a brand or therapeutic premium.
Therapeutic group Group of molecules, for treating the same condition.
Therapeutic  premium Premium charged by a manufacturer above the
reimbursed price of a molecule in one of the four
therapeutic groups under the therapeutic group
premium policy of the PBS, and is paid by the patient.
Therapeutically
interchangeable
When two molecules both deliver the same therapeutic
(health) benefits to patients.
Wholesale  price The price charged by wholesalers to the retailers





International Pharmaceutical Price Differences
PRODUCTIVITY COMMISSION ACT 1998
The Productivity Commission is requested to undertake a research study examining the differences
between the prices of pharmaceutical benefit items in Australia (those listed on the Pharmaceutical
Benefits Scheme (PBS)) and the prices of the same items in comparable overseas countries, and to
identify as far as possible the reasons for any differences.
In undertaking this study, the Commission’s analysis should have regard to the following:
2.  The basket of drugs to be examined should include new, innovative drugs (those for which
there is no reasonable alternative and also those with efficacy, quality of life and/or safety
improvements, including better modes of delivery of active ingredients), new chemical entities
for which alternatives are available (so called ‘me-too’ items) and drugs subject to generic
competition. At least ten of the major drugs in each group should be examined.
3.  The group of countries to be considered in the price comparison should include a sample of
those which offer similar subsidy arrangements for drugs as Australia and those which adopt
different arrangements.
4.  Price comparisons should be made at the ex-factory levels so as to avoid any confusion that
may arise due to the application of wholesalers’ mark-ups/margins and fees/allowances, and
mark-ups added by pharmacists or other retailers.
5.  Some form of weighted average prices should be estimated, using for example, Australian sales
volumes as weights.
6.  The Commission should also take account of:
(a) both the price of generic brands and the original brand for drugs subject to generic
competition;
(b) the range of medical conditions for which a drug is subsidised;
(c) discounts, bonuses and other incentives offered by industry;
(d) risk sharing arrangements (price/quality arrangements); and
(e) the regulatory arrangements and the underlying cost structures in the countries for which
prices are compared.
7.  The Commission is required to provide regular progress reports. The Final Report is to be
published within nine months of commencing the study.
ROD KEMP
1 September 2000XVI KEY MESSAGES
Key messages
•   The pricing of pharmaceuticals listed on the Pharmaceutical Benefits Scheme (PBS)
is an important issue for Australia. Between 1992-93 and 1999-2000, government
spending on pharmaceuticals rose from under 12 per cent of public expenditure on
health to over 15 per cent. In 2000-01, the cost to the Commonwealth Government
of the PBS increased by around 20 per cent, to over $4 billion.
•   This study examines differences between manufacturer prices in Australia and
seven other countries for 150 PBS-listed pharmaceuticals, as at 30 June 2000.
These items account for over 80 per cent of total expenditure on PBS-listed
pharmaceuticals.
•   The bilateral comparisons show that manufacturer prices in Australia for the top 150
pharmaceuticals are much lower than in the United States, Canada, the
United Kingdom and Sweden. Prices in Australia are closer to those in France, and
about the same as those in Spain and New Zealand.
•   The price differences vary across different categories of pharmaceuticals. Prices for
new innovative pharmaceuticals are much closer to those in the other countries.
The largest price differences are observed for ‘me-too’ pharmaceuticals and they
are also significant for generic pharmaceuticals.
•   It is difficult to identify robust specific explanations for the observed bilateral price
differences.
– Rather, the price differences are probably due to a combination of factors,
including differences in health systems, subsidy and cost-containment
mechanisms, market conditions and production costs.
– There is, nevertheless, some evidence to support the view that Australia’s
cost-containment arrangements, particularly reference pricing, may have
contributed to keeping prices relatively low.OVERVIEW XVII
Overview
Pharmaceutical products and their pricing are an important issue for Australia.
Between 1992-93 and 1999-2000, total spending by Australian governments on
pharmaceuticals rose from under 12 per cent of total public expenditure on health to
over 15 per cent.
In Australia, around 75 per cent of all pharmaceuticals prescribed outside of
hospitals are eligible for subsidisation under the Pharmaceutical Benefits Scheme
(PBS). In  2000-01, the Commonwealth Government is estimated to have spent
around $4.2 billion subsidising PBS-listed pharmaceuticals, an increase of around
$700 million over the previous 12 months, and more than three and a half times the
cost ten years earlier (figure 1).























a The cost of the PBS to the Commonwealth Government is estimated to have grown by around 20 per cent in
2000-01.
Data source: DHAC (2001).
Once a prescription pharmaceutical is approved for marketing in Australia,
companies usually seek to have the item listed on the PBS. Because of the attractionXVIII OVERVIEW
of the scheme to consumers, it is usually necessary for the company to do so for
viable marketing to occur.
Once listing has been recommended by the Pharmaceutical Benefits Advisory
Committee, the price of the pharmaceutical is negotiated with the company.
The  Pharmaceutical Benefits Pricing Authority is responsible for advising the
Government on the price at which pharmaceuticals should be listed on the PBS. Its
objective is to secure a reliable supply of pharmaceuticals at the most reasonable
cost to Australian taxpayers and consumers, consistent with maintaining a
sustainable pharmaceutical industry in Australia.
Australia’s pharmaceutical industry is small in global terms — with around
one per cent of global pharmaceutical output in 1999. Europe, the United States
(US) and Japan account for the majority of world pharmaceutical production.
The local pharmaceutical industry comprises around 120 companies with an annual
turnover of around $6 billion. The industry is dominated by subsidiaries of some of
the largest multinational enterprises but there are a small number of significant
locally-based companies. Most pharmaceuticals are manufactured locally, primarily
from imported active ingredients. Australia is a net importer of medical and
pharmaceutical products — in 1999-2000, exports were valued at $1.7  billion
whereas imports were worth $3.5 billion.
Purpose of the study
The purpose of this study is to compare the prices that manufacturers receive for
pharmaceutical products in Australia under the PBS with those obtained in countries
with similar and dissimilar subsidy arrangements, and to identify, as far as possible,
the reasons for any differences.
It has been argued that the Government has used its power to determine which
pharmaceuticals will be eligible for subsidisation under the PBS, to negotiate
manufacturer prices for PBS-listed items that are significantly below prices in other
countries (IC 1996). While this may benefit taxpayers and consumers, it has led to
concerns about the potential for low prices to undermine investment in the
Australian pharmaceutical industry.
However, the study does not assess the effects of the PBS on the pharmaceutical
industry. Examining this broader issue would require an understanding of the many
factors that can affect the potential net returns to investment by pharmaceutical
companies in Australia, such as the patent system, the quality and availability of
skilled workers, the nature of links with educational and research institutions, theOVERVIEW XIX
tax system, pharmaceutical evaluation processes, industry policy arrangements, as
well as pharmaceutical subsidy and cost-containment mechanisms.
This study draws on information provided to the Commission by a market research
company, IMS Health, publicly available data sources, and information provided by
several Australian government departments, the pharmaceutical industry and several
overseas agencies. It reports the results of a comparison of prices for a sample of
pharmaceuticals listed on the PBS.
Methodology and data
Several aspects of the methodology affect how the results can be interpreted,
including the:
•   sample of pharmaceuticals;
•   ratios used to compare prices;
•   choice of countries;
•   categories of pharmaceuticals covered; and
•   use of ‘list’ prices.
Sample of pharmaceuticals
Following the terms of reference, the study focuses on the prices of items listed on
the PBS. The sample comprises the top 150 chemical entities (hereafter referred to
as molecules) listed on the PBS during the financial year 1999-2000, ranked by total
expenditure. These molecules account for over 80 per cent of total expenditure on
PBS-listed pharmaceuticals.
Therefore, the results of this study apply to the top-selling PBS-listed
pharmaceuticals and cannot be generalised to all pharmaceuticals that are
available in Australia.
The 150 top-selling PBS molecules are marketed in Australia in 584 forms (that is,
different dosage types, strengths and pack sizes). As far as possible, the
Commission identified matching forms in each country so as to enable price
comparisons on a like-for-like basis. However, only 18 of these 584 forms are
available in all comparison countries, thus precluding multilateral comparisons.
Instead, the Commission has estimated pair-wise comparisons between Australia
and selected other countries, based on prices of forms common to both countries.XX OVERVIEW
Therefore, the results can only be used for bilateral comparisons between Australia
and individual countries. Multilateral comparisons are not possible.
To increase the number of matches, there were some occasions where the
Commission assumed a linear relationship between pack size and price (if the pack
size of the matching form was sufficiently close to the Australian pack size). If there
were several different pack sizes in the comparison country that were significantly
different from those available in Australia, higher and lower estimates of price
comparisons were reported. Higher and lower estimates also were reported if it was
found that several manufacturers produced the matching forms, but with each
charging a different price.
Price ratios
The terms of reference require the Commission to calculate some form of weighted
average price. This is required to ensure that the results are not distorted by the
inclusion of forms that have a large price differential but a small market share.
Australian sales volumes were used to weight manufacturer prices. This choice
reflects the purpose of the study, which is to compare the prices for a sample of
PBS-listed items in Australia with those obtained in comparison countries.
The price comparisons are reported using a ratio of prices between Australia and
each comparison country. These ratios were calculated by dividing an overseas
revenue estimate by an estimate of Australian revenue for those forms that were
available in both Australia and the comparison country. The overseas revenue
estimate is derived by multiplying overseas prices for each matched form by the
corresponding Australian sales volumes. This yields an estimate of the revenue that
could have been obtained by pharmaceutical companies if they had sold their
Australian volumes at the overseas prices. Similarly, the Australian revenue
estimate is derived by multiplying Australian prices, for the same forms, by the
Australian sales volumes. The price ratio, therefore, provides an indication of how
the revenues of companies operating in Australia would change if they had achieved
overseas prices (rather than Australian prices) on their Australian sales.
The sales volumes also act as weights on the prices. For example, a high priced item
may make a small contribution to the revenue estimates for Australia and
comparison countries if it has a low volume of sales in Australia. The price ratio
also can be interpreted as showing whether Australian prices for the matched
pharmaceuticals are higher or lower than those overseas.OVERVIEW XXI
Choice of countries
The terms of reference require the Commission to compare Australian prices with
those in countries with similar and dissimilar subsidy arrangements. The seven
comparison countries included in this study are: the US, Canada, the
United Kingdom (UK), France, Spain, Sweden and New Zealand (NZ).
Whereas all Australians are eligible for subsidies under the PBS, the coverage of
government subsidies is narrower in the US and Canada. The UK is dissimilar to
Australia in that pharmaceutical companies are relatively free to set prices (subject
to an overall profit constraint). The UK also automatically reimburses all new
products that have been approved for marketing, unless the Government decides to
remove eligibility for subsidisation (by registering the product on a ‘negative list’).
Sweden, France, Spain and NZ are similar to Australia as they offer universal
eligibility for pharmaceutical subsidies. However, they differ in the ways in which
their governments seek to influence the prices of subsidised pharmaceuticals.
Pharmaceutical categories
Unlike the majority of previous studies of international pharmaceutical price
differences, the Commission is required to estimate separate price differences for
new innovative,  ‘me-too’  and  generic  categories of pharmaceuticals. These
categories are defined below. The top 150 molecules on the PBS were allocated into
these categories by the Department of Health and Aged Care (DHAC) (figure 2).
List prices
This study, like most previous cross-country comparisons of pharmaceutical prices,
has, in the first instance, used ‘list’ prices as the basis of comparison. The list price
is the manufacturer’s posted price, exclusive of any discounts or other incentives.
Data on manufacturer prices in Australia as at 30 June 2000 were obtained from
DHAC. Manufacturer prices in Sweden were obtained from the Swedish National
Social Insurance Board. Price data for the US, Canada, the UK, France, Spain and
NZ were obtained from IMS Health. Manufacturer prices from IMS Health do not
take into account manufacturer incentives (discounts) that are offered in some
countries to large private and public sector buyers (such as Health Maintenance
Organisations in the US).XXII OVERVIEW
Figure 2 Breakdown of total expenditure on the top 150 PBS
pharmaceuticals, as at 30 June 2000
New 10%
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Data source: PC estimates.
The Commission sought information on the actual prices received by suppliers.
Anecdotal information suggests that discounting is not widespread in Australia,
Canada and Sweden but may be more common in the UK, especially for generics.
Information on discounts in NZ, France and Spain was unavailable.
Discounts to large buyers in the US were estimated using the Federal Supply
Schedule (FSS), which lists prices for pharmaceuticals purchased by the US
Department of Veterans Affairs and other Federal agencies. While the FSS prices
are not necessarily the lowest prices available in the US market, information on
these lower prices is usually confidential.
Manufacturer prices in local currencies in the comparison countries were converted
into Australian dollars using the average exchange rate over the month of
June 2000. Sensitivity analyses showed that using nominal exchange rates covering
different periods does not alter the results in a significant way.
Key results
The Commission has undertaken price comparisons for all available forms of
Australia’s 150 top-selling pharmaceuticals (all categories), and for three individualOVERVIEW XXIII
categories of new innovative, ‘me-too’ and generic pharmaceuticals. These results
show whether manufacturer prices in Australia for the top-selling (matched)
pharmaceuticals are higher or lower than the relevant foreign price as at
30 June 2000. A value greater than one indicates that manufacturer prices for the
matched forms in the comparison country are greater than the prices of those items
in Australia.
Price differences — all categories of pharmaceuticals
Figure 3 provides results for all categories of pharmaceuticals based on list prices
and other sources and, where available, prices taking into account manufacturer
discounts. As noted above, the results cannot be used to compare price levels across
the comparison countries.





















Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
The results show that manufacturer prices for Australia’s top-selling items are:
•   at least 162 per cent higher in the US (based on the lower estimate of list prices);
•   at least 84 per cent higher in the US when discounts are taken into account
(using the FSS prices);XXIV OVERVIEW
•   at least 48 to 51 per cent higher in the UK, Canada and Sweden; and
•   much closer to the prices received in France, Spain and NZ.
The estimate of US prices using the FSS prices provides a more reasonable
indication of price differences between Australia and the US. However, accounting
for discounts does not alter the finding that prices are significantly higher in the US.
New innovative pharmaceuticals
New innovative pharmaceuticals are chemical entities for which there is no
reasonable alternative and also those with efficacy, quality of life and/or safety
improvements, including better modes of delivery of active ingredients.
As new innovative pharmaceuticals possess significant additional benefits over
alternative treatments, or are the only ones available to treat a particular disease,
manufacturers may have some capacity to set different prices in each country,
reflecting differences in the price sensitivity of demand. However, regulatory
constraints, such as the use of international benchmarking by governments to set
prices, may reduce the scope for them to do this.



















Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.OVERVIEW XXV
The results for Australia’s top-selling new innovative pharmaceuticals presented in
figure 4 show that compared with the results for all categories of pharmaceuticals:
•   manufacturer prices in Australia are much closer to those in the comparison
countries but prices in the US and the UK are higher than those in Australia by
104 per cent and 25 per cent respectively (based on the lower estimates);
•   differences between the higher and lower estimates are smaller (mostly due to a
higher proportion of direct matches and fewer manufacturers of each form); and
•   large buyers in the US are able to obtain smaller discounts off list prices
(between three and six per cent).
‘Me-too’ pharmaceuticals
‘Me-too’ pharmaceuticals are chemical entities for which therapeutic alternatives
are available. These pharmaceuticals may face different levels of competition from
therapeutic alternatives within a country and may be subject to different levels of
price regulation. Therefore, it is difficult to arrive at in-principle predictions about
relative prices across countries.
For Australia’s top-selling ‘me-too’ pharmaceuticals, figure 5 shows that compared
with all categories of pharmaceuticals:
•   manufacturer prices in Australia are lower than those in the comparison
countries (except NZ based on the lower estimate of prices);
•   very large discounts were obtained by large institutional buyers in the US
(between 34 to 39 per cent). Prices for the top-selling Australian ‘me-toos’ are
likely to be between 70 and 94 per cent higher in the US than in Australia; and
•   the gap between prices in Australia and the comparison countries is greater for
the ‘me-too’ category (based on the lower estimate of prices). Prices for the
top-selling Australian ‘me-toos’ are around 60 per cent higher in Canada, the
UK and Sweden (based on the lower estimates).
Generic pharmaceuticals
Generic pharmaceuticals are chemically-equivalent items and in this study include
the originator brand. Studies for the US have found that as patents on originator
brands expire, generic copies have been able to capture a significant share of the
market at much lower prices. However, manufacturers of originator brands may
prefer to maintain higher prices despite a reduction in market share, in order to
preserve perceptions of higher quality. International trade in generics might beXXVI OVERVIEW
expected to offer less scope for price differentiation across countries than is possible
for patented (new innovative and ‘me-too’) pharmaceuticals.




















Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
However, this expectation is not completely borne out by the results. Figure  6
shows that:
•   while manufacturer prices for Australia’s top-selling generics in Spain and NZ
are below those in Australia, generic prices are between ten and 108 per cent
higher (based on the lower estimates of IMS and FSS prices) in the US, Canada,
the UK, Sweden and France;
•   the range between the higher and lower estimates of manufacturer prices is
greater for generic pharmaceuticals than for other categories. In part, this result
is due to the inclusion of high-priced originator brands in the generic category.
This effect is most pronounced for the US; and
•   larger institutional buyers in the US can obtain discounts off manufacturers’ list
prices of between 14 and 24 per cent.OVERVIEW XXVII
























Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
Much of the observed large price range for generic pharmaceuticals was due to the
availability of multiple manufacturer prices for many generic pharmaceuticals.
For  example, in some cases, the highest price for a generic pharmaceutical was
several times the price of the cheapest. A comparison of higher and lower estimates
with prices weighted by market shares for a sample of generic pharmaceuticals
found that manufacturer price differences between Australia and the US, Canada
and the UK are likely to be better reflected by the lower estimate of prices.
Even if the lower estimate of price comparisons is used, the significant price
differences between Australia and the US, Sweden, Canada and the UK are
surprising. For the UK, this result may be due, in part, to the use of list (not actual)
prices. But this does not appear to be an important factor explaining the results for
Sweden and Canada. Anecdotal evidence for these two countries suggests that
discounting of generics is rare.
There are also some interesting differences between the results for individual
categories. For instance:
•   the gap between prices in Australia and the comparison countries (with the
possible exception of NZ) is larger for ‘me-too’ pharmaceuticals than for otherXXVIII OVERVIEW
categories (based on the more reasonable lower estimate of price comparisons);
and
•   discounts available to large purchasers in the US are also greatest for ‘me-too’
pharmaceuticals (ranging from 34 to 39  per  cent compared with discounts of
between 3 and 6 per cent for new innovative, and 14 and 24 per cent for generic
pharmaceuticals).
Reasons for price differences
A number of potential reasons for the observed price differences were identified at a
roundtable meeting of industry experts held to discuss the preliminary results. Two
key ones were:
•   differences in the broad features of pharmaceutical subsidy and cost-containment
policies in Australia and the comparison countries; and
•   specific features of Australia’s cost-containment arrangements.
In addition, roundtable participants identified additional factors that may have
contributed to the results for the individual categories, such as international price
benchmarking.
Pharmaceutical subsidy and cost-containment policies
Some participants considered that differences in the broad characteristics of the
subsidy and cost-containment policies in comparison countries may have influenced
the results.
In very broad terms, it is difficult to find any obvious associations between the
observed price differences and the types of subsidy and cost-containment policies
adopted in the comparison countries. Large price differences were found for some
countries that possess quite different subsidy arrangements (notably the US and
Canada). But prices in Sweden and, to a lesser extent, France were also higher than
in Australia even though they have similar subsidy arrangements.
Finding a correlation between the cost-containment mechanisms employed and the
price differences was also problematic. The largest price differences were observed
for those countries that allow relatively free pricing of pharmaceuticals — the US,
the UK and Canada (at the Federal level). However, prices in Sweden also were
significantly higher than Australia’s, even though companies are required to
negotiate a price before the product will be subsidised.OVERVIEW XXIX
The difficulties in finding a close association between price differences and policy
regimes suggest that other factors have also played a role. These could include
differences in demand conditions, volume restrictions (such as restrictions on
approved uses), delays due to marketing approval requirements, patent
arrangements, the level of competition amongst pharmaceuticals within therapeutic
groups, and production and marketing costs.
Specific features of Australia’s cost-containment policies
Participants considered that the strong emphasis on cost-containment within
Australia’s subsidy arrangements, especially the requirement for economic
evaluations and reference pricing, has had an important influence upon the results.
Economic evaluations involve an assessment of the relative costs and health
benefits of a pharmaceutical, and a comparison of these with alternatives. Australia,
NZ and the Canadian provinces of Ontario and British Columbia are the only
jurisdictions to require companies to submit an economic evaluation with
applications for listing new pharmaceuticals, or for increasing the price or clinical
uses of items already listed. Prices in Australia were close to those in NZ but not to
those in Canada.
In Australia, reimbursement prices (the maximum amount the Government pays) for
defined sub-groups of therapeutically-equivalent pharmaceuticals are set using a
comparatively strict form of reference pricing. These sub-groups may contain
patented and generic pharmaceuticals. Reimbursement prices for all items in a
particular sub-group are set on the basis of the lowest cost item. While a similar
approach is used in NZ and British Columbia, it has not been applied in the other
comparison countries.
To look at the possible contribution of these cost-containment mechanisms, the
sample of ‘me-too’ pharmaceuticals was divided into those that were directly
affected by reference pricing prior to 30 June 2000 — using the weighted average
monthly treatment cost (WAMTC) methodology — and products that were not.
The results indicate that for all countries, except NZ, greater price differences were
observed for those ‘me-too’ items subject to reference pricing, than for products that
were not. This provides some support for the contention that Australia’s reference
pricing system has contributed to the reported price differences for ‘me-too’
pharmaceuticals. However, due to concerns about the representativeness of the
sample, the extent of the contribution remains unclear.XXX OVERVIEW
Conclusions
It is difficult to identify robust specific explanations for the observed bilateral price
differences. Rather, the price differences are probably due to a combination of
influences, including systemic differences in health systems, pharmaceutical
subsidy and cost-containment mechanisms, and production costs (including
marketing and liability costs).
The overall results also may reflect the influence of factors affecting the prices of
particular pharmaceuticals, or therapeutic groups, including differences in demand
conditions, volume controls, patent arrangements, and competition from
therapeutically similar molecules.
There is, nevertheless, some evidence to support the view that Australia’s
cost-containment arrangements may have contributed to keeping prices relatively
low. The application of reference pricing in particular, may have been significant,
although to what extent remains unclear.INTRODUCTION 1
1 Introduction
On 1 September 2000 the Productivity Commission was asked by the
Commonwealth Government to undertake a research study into international
pharmaceutical price differences. The terms of reference for the study direct the
Commission to examine differences between the prices of pharmaceutical benefit
items received by manufacturers in Australia and the prices of the same items in
comparable overseas countries, and to identify as far as possible the reasons for any
differences.
This study arose out of meetings of the Pharmaceutical Industry Working Group
(PIWG). The  PIWG was established to facilitate consultation between the
pharmaceutical industry and the Commonwealth Government on the long-term
operating and policy environment facing the industry.1 This study was
commissioned to inform these consultations, and to respond to concerns about
previous price comparisons.
This report draws on information provided by IMS Health2 and publicly available
data sources in reporting the results of a comparison of prices for a sample of
pharmaceuticals listed on the Pharmaceutical Benefits Scheme (PBS). The report
also explores some of the many possible reasons for the observed price differences
between countries. However, in doing so, the report does not seek to evaluate, or
make recommendations on the PBS.
1.1 Background to the study
The health care system in Australia is an important part of Australia’s economy. It
provides a variety of services including hospitals, community services, nursing
home services and health programs, and associated service providers such as
general practitioners, medical specialists, nurses and pharmacists.
                                             
1 The Group comprises the Ministers for Industry, Science and Resources, and Health and Aged
Care, officers of the two Commonwealth Departments, and representatives of the Australian
pharmaceutical industry.
2 IMS Health is a private company specialising in the provision of marketing information to the
pharmaceutical industry.2 PHARMACEUTICAL
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Pharmaceutical products are an integral part of this system.3 Total government
spending on pharmaceuticals accounted for over 15.3  per  cent of total public
spending on health in 1999-2000. Other significant components of public health
expenditure in 1999-2000 were community health services (35 per cent) and acute
care institutions (29 per cent) (ABS 2001a).
Moreover, pharmaceuticals are one of the fastest growing components of public
health expenditure. For instance, between 1992-93 and 1999-2000 public spending
on pharmaceuticals rose from just under 11.6  per  cent of public expenditure on
health to around 15.3 per cent (ABS 1999a, 2001a).
In Australia, around 75 per cent of all outpatient prescription pharmaceuticals are
eligible for subsidisation under the PBS and the Repatriation Pharmaceutical
Benefits Scheme (RPBS).4 The PBS was established to provide the community with
access to necessary medicines, which are affordable, available and of acceptable
standards (box 1.1). In 2000-01, it is projected that the Commonwealth Government
will spend around $4.2 billion subsidising pharmaceuticals, an increase of around
$700 million over the previous 12 months. Overall, nominal expenditure under the
scheme has risen by 261 per cent since 1990-91 (figure 1.1). In comparison, general
prices in the economy have risen by 18.4  per  cent over the same period
(ABS 2001c).
Australia accounts for a small share of global pharmaceutical output (around
one  per  cent in 1998). According to the European Federation of Pharmaceutical
Industries and Associations (EFPIA  2000), Europe, the United States and Japan
accounted for over 90 per cent of world pharmaceutical production in 1998 (by
value).
According to the Australian Pharmaceutical Manufacturers Association
(APMA 2000), the local pharmaceutical industry comprises around 120 companies
with an annual turnover of around $6  billion. The industry is dominated by
subsidiaries of some of the largest multinational pharmaceutical enterprises but
there are a small number of significant locally-owned companies. Nonetheless, the
pharmaceutical industry accounts for around four  per  cent of Australia’s total
                                             
3 The term ‘pharmaceutical’ is used to describe a large number of chemical entities that are
designed to treat or prevent a variety of illnesses and conditions. Pharmaceutical products can
be divided into items that are available only on prescription, and those that are available over
the counter.
4 The RPBS is a separate system to the PBS that provides access to pharmaceuticals determined
necessary to ensure the best treatment for entitled veterans, war widows and widowers. People
eligible for the RPBS pay a maximum of $3.50 for prescribed medicines covered by the
scheme. In 1998, over 90 per cent of RPBS prescriptions were for PBS-listed pharmaceuticals
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business expenditure on research and development (ABS 1999b). The majority of
pharmaceuticals supplied to the local market are manufactured in Australia,
primarily from imported active ingredients (IC 1996). Australia is a net importer of
medical and pharmaceutical products — in the 12  months ended March  2001,
exports were valued at $2.1  billion and imports were worth $4.2  billion
(ABS 2001b).























a The cost of the PBS to the Commonwealth Government is estimated to grow at 19.9 per cent in 2000-01.
Data sources: CDHFS (1996, 1995); DHAC (2001a, 2001b and pers. comm., 3 July 2001).
Given the significance of the pharmaceutical industry to Australia’s economy and
health care system, and the rapid growth in pharmaceutical spending, it is not
surprising that pharmaceutical prices are a major issue for Australia.
Once a prescription pharmaceutical is approved for marketing in Australia,
companies usually seek to have the item listed on the PBS. Because of the attraction
of the scheme to consumers, it is usually necessary for the company to have the
item listed on the PBS for viable marketing to occur (DHAC 1999b).4 PHARMACEUTICAL
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Box 1.1 Australia’s Pharmaceutical Benefits Scheme
The PBS has been in operation since 1948. Initially, the scheme’s coverage was
limited largely to supplying products listed in the British Pharmacopoeia to pensioners,
and 139 life-saving and disease-preventing pharmaceuticals to others in the
community.
Since then, the coverage of the scheme has been extended. Currently, all members of
the community are eligible for subsidies under the PBS. According to the Department
of Health and Aged Care (DHAC 2001a), as at February 2001 the PBS covered 593
molecules, available in 1469 forms and marketed as 2351 different products (brands).5
The stated purpose of the PBS is to provide the Australian community with timely,
reliable and affordable access to necessary and cost-effective prescription medicines.
In financial year 1999-2000, the cost to the Government of the PBS was $3.5 billion,
representing an increase of 13.6 per cent over the previous year. In the same period,
total expenditure on PBS-listed pharmaceuticals (Government plus patient
contributions) was $4.1  billion. Concessional benefit prescriptions (that is, scripts
written for holders of a Commonwealth concession card) accounted for more than
80  per  cent of the Government expenditure on the PBS (DHAC  ,
pers.  comm.,  3  July  2001). The cost to the Government of the PBS is expected to
increase by a further 19.9 per cent in 2000-01 (DHAC, pers. comm., 3 July 2001).
Before a new pharmaceutical can be listed on the PBS, the supplier first must obtain
marketing approval from the Therapeutic Goods Administration (TGA). The TGA
analyses the product’s quality, safety and efficacy before awarding marketing approval.
The approval specifies, amongst other things, the approved uses (indications) for the
pharmaceutical. Pharmaceutical manufacturers also must be licensed by the TGA and
ensure that their manufacturing processes comply with principles of Good
Manufacturing Practice.
Once approved for sale, suppliers may seek to have their products listed on the PBS
by applying to the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC is
a statutory committee of independent experts that reviews applications against a
number of criteria including: the need for the product; the outcomes and costs of a
particular pharmaceutical when weighed against other available therapies; and
whether any restrictions should be imposed on new listings (such as limits on the
number of items that may be prescribed or restrictions on the indications for which a
PBS subsidy is available).
(Continued next page
                                             
5 These figures exclude pharmaceuticals provided under special arrangements, such as section
100 pharmaceuticals. Section 100 pharmaceuticals are highly specialised items, used to treat
chronic conditions and are restricted to supply through hospitals with access to specialised
facilities (DHAC 2000, p. 251).INTRODUCTION 5
Box 1.1 (continued)
In reviewing applications for listing, the PBAC is required to consider both the
effectiveness and cost of therapy involving the use of new pharmaceuticals. Under the
National Health Act 1953, the PBAC cannot recommend listing unless the
pharmaceutical provides ‘a significant improvement in efficacy or a reduction in toxicity
over the alternative therapy’. To this end, an important feature of Australia’s system for
listing new pharmaceuticals on the PBS is the reliance on requiring evidence that new
pharmaceuticals offer significant benefits over those available from alternative forms of
therapy. If the PBAC recommends that an item be listed on the PBS, the
Pharmaceutical Benefits Pricing Authority (PBPA) will recommend a reimbursement
price which may include a price-volume arrangement.6 According to Professor David
Henry (pers. comm., 14 May 2001) (a former member of the PBAC), the price at which
a pharmaceutical is considered to be of acceptable cost-effective (that is, the cost of
the item is justifiable based on the clinical outcomes which it is likely to deliver) by the
PBAC has typically been the starting point for negotiations with manufacturers.
The reimbursement price is the maximum amount that the Government will reimburse
to pharmacists, and it may be set with reference to the price of identical or similar
pharmaceuticals that are already available under the PBS.
The PBPA recommends to the Government the price at which pharmaceuticals should
be listed on the PBS. DHAC negotiates, on behalf of the Government, with
pharmaceutical manufacturers the price of the pharmaceuticals using the PBPA
recommendations as its basis. The Government then makes the final determination on
whether to list a product at a particular price (although it cannot list a new
pharmaceutical unless the PBAC has made a positive recommendation) (DHAC  ,
pers. comm., 3 July 2001).
In some instances a company has the option, under the Brand Premium Policy and/or
Therapeutic Group Premium (TGP) Policy, of charging a price above the
reimbursement price agreed with the PBPA. However, patients must pay any
difference between the company’s price and the reimbursed price.
The PBPA also conducts annual reviews of the prices of products listed on the PBS.
Also, suppliers may request a price review or seek to have pharmaceuticals already
listed on the PBS approved by the PBAC for use to treat other conditions.
Sources: DHAC (2001a, 2001b and pers. comm., 3 July 2001); PBPA (2000).
                                             
6 Under a price-volume agreement, the agreed price of a pharmaceutical is based on a forecast
volume of sales. If the actual sales volume exceeds the forecast, the price of the pharmaceutical
is usually reviewed downwards.6 PHARMACEUTICAL
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Once listing has been recommended by the Pharmaceutical Benefits Advisory
Committee (PBAC), the price of the pharmaceutical is negotiated with the
company. The Pharmaceutical Benefits Pricing Authority is responsible for advising
the Government on the price at which pharmaceuticals should be listed on the
PBS.7 Its objective is to secure a reliable supply of pharmaceuticals at the most
reasonable cost to Australian taxpayers and consumers, consistent with maintaining
a sustainable pharmaceutical industry in Australia (PBPA 2000).
It has been argued that the Australian Government has used its power to determine
which pharmaceuticals will be eligible for subsidisation under the PBS to negotiate
manufacturer prices for PBS-listed items that are significantly below prices in other
countries (IC  1996).8 While the use of buying power to hold down prices may
benefit taxpayers and consumers, it has led to concerns about the potential for low
prices to undermine investment in the pharmaceutical industry in Australia.
The results of this study are therefore intended to shed some light on how
manufacturer prices in Australia, for PBS-listed items, compare with the prices
received by pharmaceutical companies in comparable countries.
By themselves, the price comparisons results cannot be used to assess the
attractiveness of the investment environment facing pharmaceutical companies
operating in Australia. Assessing this broader issue would require an assessment of
all of the factors that can affect the potential net returns to investment by
pharmaceutical companies in Australia, such as the patent system, the quality and
availability of skilled workers, the nature of links with educational and research
institutions, the tax system, pharmaceutical evaluation processes, pharmaceutical
subsidy and cost-containment mechanisms, and industry policy arrangements.
1.2 Scope of the study
The purpose of this study is to estimate, for selected comparator countries,
differences in the prices received by manufacturers for pharmaceutical products
listed on the PBS, and to examine the reasons for any differences.
                                             
7 For most pharmaceuticals, the Government does not directly determine the manufacturer’s
price but rather, it negotiates a price that will be reimbursed to pharmacists (box 2.2). However,
the Government does negotiate manufacturer prices for highly specialised pharmaceuticals
(section 100 items).
8 In this report, the term manufacturer price is used to denote the prices received by companies
which manufacture or supply pharmaceuticals to wholesalers and pharmacists. It can be
distinguished from the prices charged by these buyers (which may include wholesale and retail
mark-ups, wholesale and retail discounts, dispensing fees and other allowances).INTRODUCTION 7
The terms of reference require the Commission to compare prices for a group of
countries that offer similar and dissimilar subsidy arrangements to Australia. The
seven countries included for comparison are: the United States (US), the United
Kingdom (UK), Canada, New Zealand (NZ), France, Spain and Sweden. The
rationale for selecting these countries is outlined in chapter 3.
In any study of international pharmaceutical prices, the major requirement is to
obtain reliable information on prices that is consistent across countries.
This study draws extensively upon information provided by IMS Health. IMS
Health data have been used in most previous studies examining international price
differences. Alternative sources of information are publicly available in many
countries and, where possible, this information was used to supplement and verify
data obtained from IMS Health. For example, information from the Federal Supply
Schedule, which is maintained by the US Department of Veterans Affairs, was used
to look at the potential impact on the price comparisons of manufacturer discounts
offered to large buyers of pharmaceuticals.
Interpreting the results
The methodology employed in this study is described in more detail in chapter 3.
However, several key features have important implications for the way the results of
the study can be interpreted.
First, the study is confined to products listed on the PBS. As noted earlier, around
75 per cent of all pharmaceuticals prescribed outside of hospitals are eligible for
subsidisation under the PBS. The study does not cover sales of unsubsidised
over-the-counter (OTC) pharmaceuticals or prescription pharmaceuticals that are
not listed on the PBS. This study has been designed only to provide comparisons of
prices for items that are available on the PBS.
Second, the study uses a sample of pharmaceuticals comprising the top 150
PBS-listed molecules9 ranked by total (government plus consumer) expenditure.
These 150 molecules are available in 584  forms10 and account for around
83 per cent of expenditure on PBS items. According to the Department of Health
and Aged Care (DHAC), the PBS lists approximately 820  molecules (including
highly specialised items) available in a large number of different forms. Therefore,
                                             
9 In this study, the term ‘molecule’ has been used to mean a generically-named pharmaceutical
product, which in turn can be available in many forms.
10 ‘Forms’ covers the different dosage types, strengths and pack sizes in which a particular
molecule is available in Australia. For example, the pharmaceutical simvastatin is available in
tablets with strengths of 5, 10, 20, 40 and 80 mg and in packs of 30.8 PHARMACEUTICAL
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while the study can be used to say something about international price differences
for the top-selling PBS items, the results cannot be used to draw conclusions about
price differences for those molecules not covered by the study.
Third, pharmaceuticals have been matched on the basis of dosage type, strength and
pack size, to ensure as far as possible ‘like-with-like’ comparisons. In those
instances where different prices were observed in comparison countries for an
identical form or where the pack size was close to Australia’s, higher and lower
estimates of price comparisons were reported.
Consequently, the methodology used in this study permits country-specific,
pair-wise comparisons of prices for those products covered by the study, and which
are available in both countries.11  The results provide an indication of how
Australian prices compare with those in each country covered by the study, based
on Australian volumes purchased. They cannot be used to draw inferences about
price levels across the comparison countries.
Finally, this study reports the results of a comparison of prices at (or as close as
possible to) 30 June 2000. Previous studies have utilised different methodologies
and samples of pharmaceuticals. Some studies have attempted to cover a large
number of countries but, as a result, have covered relatively few molecules. In
undertaking this study, the Commission has attempted to achieve a broad coverage
of the high volume molecules on the PBS, focusing on a smaller number of key
countries.  Due to differences in methods, samples and data, the results are not
directly comparable with those of previous studies discussed below.
1.3 Previous studies
A significant body of literature exists on international comparisons of
pharmaceutical prices. Much of this work was undertaken over the 1990s, and
focused on prices in the US compared with a range of other countries (see, for
example, GAO  1992,  1994,  2000c, Andersson  1995, Danzon and Kim  1998, and
Danzon and Chao  2000). Danzon (1996) also gave evidence to the US Senate
Committee on Health, Education, Labor and Pensions on, among other things, the
key criteria necessary to conduct valid international comparisons of pharmaceutical
prices.
As discussed above, it is commonly held that manufacturer prices in Australia for
PBS-listed pharmaceuticals are lower than those in many other developed countries.
                                             
11 The number of products available in all of the comparison countries was too small to allow
meaningful comparisons on a multi-country basis (section 3.1).INTRODUCTION 9
This view is based on previous price comparison studies that have included
Australia. These are listed in table  1.1, and were summarised by the Industry
Commission in its inquiry into The Pharmaceutical Industry (IC 1996).
Table 1.1 International pharmaceutical price comparisons










PBPA 1996 1996 2c 165 91
APMA 1996 1995 18 38 73
Balasubramaniam 1995 nes 29 22 75
BIE 1991 1990 17 53 69
Parry & Creyke 1991 1990 nes 80 50
Peat Marwick 1991 1988 12 22 59
Parry & Thwaites 1988 1987 12 80 55
IAC 1986 1985 2d 97 3
Merck, Sharp & Dohme 1986 1985 20 17 47
APMA 1982 1982 13 58 56
a Sample includes Australia. b Percentage of international prices. All unweighted price comparisons except for
IAC (1986). c Comparison country is the UK. d Comparison country is NZ. nes Not elsewhere specified.
Source: IC (1996).
On face value, the comparisons suggest that pharmaceutical prices in Australia have
been anywhere from 47 to 91 per cent of the level of overseas prices.
Many of these previous studies suffer from significant methodological flaws, calling
into question the accuracy of their results. For instance, the Industry Commission
had particular concerns about the selection of countries in benchmark groups and
the practice of aggregating all products in terms of a single, unweighted average
price.
The Industry Commission concluded that Australian pharmaceutical prices were
well below international prices but that the difference appeared to be declining over
time. It also concluded that price differences were likely to be smaller for new
innovative pharmaceuticals compared to items in other categories.
1.4 The Commission’s approach
Although this study is not a formal public inquiry, the Commission has undertaken
extensive consultations with, and encouraged input from, a number of interested
parties.10 PHARMACEUTICAL
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After receipt of the terms of reference, the Commission held discussions with
officials from Government (the Department of Industry, Science and Resources, and
DHAC) and the pharmaceutical industry, including the Australian Pharmaceutical
Manufacturers Association. The Commission also convened a roundtable meeting
with interested parties to discuss its proposed approach to undertaking the study.
This roundtable provided a number of valuable suggestions for improving the
Commission’s approach.
In late April 2001, the Commission circulated a work-in-progress report to a range
of interested parties. Preliminary results were discussed at a further roundtable
meeting held on 29 May 2001. This meeting provided an opportunity for industry
and government officials to provide comments on the methodology, preliminary
results and reasons for the observed price differences.
In addition, the Commission also sought information from sources in each of the
comparison countries, on the subsidy and cost-containment policies prevailing in
those countries. These sources provided a range of useful information and assisted
the Commission in understanding the regulatory mechanisms affecting
pharmaceutical prices in these countries.
The Commission would like to take this opportunity to thank the many people, in
Australia and overseas who contributed through providing information and
comment on aspects of the study.
Further details on the consultations undertaken by the Commission are set out in
appendix A.
1.5 Outline of the report
The pharmaceutical industry is characterised by extensive government interventions
affecting the demand and supply of pharmaceuticals. Chapter  2 discusses those
government interventions in the industry which have direct implications for the
international pricing of pharmaceuticals. Amongst other things, this discussion
assists in identifying suitable countries to include in price comparisons.
The key features of the methodology for undertaking the comparison of
manufacturer prices, and the results are set out in chapter 3. The chapter reports a
comparison of manufacturers’ prices as at 30  June  2000 for all categories of
Australia’s top-selling 150  molecules, as well as for individual pharmaceutical
categories (new innovative, me-too and generics).INTRODUCTION 11
The terms of reference also require the Commission to explain, if possible, the
reasons for any price differences. Chapter 4 identifies the principal methods that can
be used to assess the results, and examines some of the many factors that may have
contributed to the price differences identified in the previous chapter. Given the
difficulties in attributing causes to the observed price differences, the chapter also




Prior to examining the evidence on international price differences for
pharmaceuticals listed on the Pharmaceutical Benefits Scheme (PBS), this chapter
examines some of the government interventions that may give rise to price
differences, drawing on examples from various countries. The chapter also attempts
to identify an appropriate group of countries on which to base price comparisons.
Most major pharmaceuticals available in Australia are traded internationally.
International trade normally tends to equalise manufacturer prices across various
markets. However, a number of government interventions may affect
pharmaceutical prices, such as patents, trade restrictions, pharmaceutical approval
procedures, subsidies and cost-containment measures.
Differences across countries in the nature and effectiveness of these interventions
may explain any observed inter-country price differences.
2.1 Patent protection
Patent protection (often combined with restrictions on parallel importing) may
allow pharmaceutical manufacturers to price discriminate across markets, with
higher prices charged in those countries and markets where demand is relatively
insensitive to price changes.1
The process of developing a new pharmaceutical commonly involves the
identification of potentially useful chemical substances, the synthesis and extraction
of these substances, and their testing in animals, and ultimately in humans, to assess
their therapeutic effects and commercial value. Due to the significant costs and lags
involved in the identification, development and testing of pharmaceuticals, the
industry looks to the patent system to provide it with a means to recoup these
up-front expenditures (box 2.1).
                                             
1 Parallel importing occurs when an intermediary (usually a wholesaler or a retail pharmacist)
buys a patented pharmaceutical in one country, and exports it to a second country, without the
consent of the patent holder. To provide an incentive for parallel trade to occur, the price
difference between countries must be sufficiently large to outweigh transport and other
trade-related costs.14 PHARMACEUTICAL
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Box 2.1 Pharmaceutical research expenditure
The costs of manufacturing pharmaceuticals are considered to be low relative to total
production costs (Schweitzer 1997, p. 101). According to Danzon, on average, R&D
expenditure accounts for around 30  per  cent, marketing cost accounts for around
25  per  cent, and all manufacturing and distribution costs account for around
25  per  cent of the total lifetime costs of creating, producing and distributing
pharmaceuticals (cited in CSES 1999, p. 9).
According to the US Office of Technology Assessment, the cost of R&D per successful
new pharmaceutical, at the time of market approval in 1993, was US$359 million (cited
in Lofgren 1996, p.  89). Further, only around three out of ten pharmaceuticals
marketed cover their development costs (Schweitzer 1997, p. 27).
A few countries account for a large share of the new pharmaceutical patents that are
awarded around the world. The US has the highest proportion of patent applications at
61.6 per cent, followed by the European Union at 24.5 per cent, Japan at 4.8 per cent,
and the rest of the world at 9.1 per cent (EFPIA 2000, p. 24).
Sources: CSES (1999); (EFPIA 2000); Lofgren (1996); Schweitzer (1997).
Patents may enable manufacturers to charge higher prices for some items and hence
have implications for the international pricing of pharmaceuticals.
A patent confers monopoly rights on the holder by excluding others from making or
selling a patented product without the holder’s consent. In most developed countries
(including Australia), the patent term for pharmaceuticals and for other products
and processes, is 20 years.2 The principal economic rationale for awarding patents
is to stimulate investment in research and innovation. It is argued that, without
patents, others may be able to imitate new products, thereby limiting the innovator’s
ability to recoup these research and development (R&D) expenditures.
Through enhancing the ability of companies to finance pharmaceutical R&D,
patents may indirectly contribute to increased life expectancy, improvements in
peoples’ quality of life, and to the possible eradication of life threatening diseases.
In exchange, patents may enable the holder to earn monopoly profits for a limited
                                             
2 Each country establishes its own intellectual property laws. A company that wishes to market a
new product in several countries must obtain separate patents in each country. Many countries
also permit period extensions to compensate for delays in obtaining marketing approvals. In
Australia, if the period between the filing of the Australian patent application and the granting
of marketing approval exceeds five years, the patent term may be extended by up to five years.
In the United States (US), pharmaceuticals containing a new chemical entity never before
approved by the Food and Drug Administration (FDA) may qualify for an extended patent term
of up to five years (appendix B).GOVERNMENT
INTERVENTIONS
15
period through charging prices that appear to be high in relation to the unit costs of
production.
At any time, there may be a number of companies developing new pharmaceuticals
to treat a particular condition. The company which is first to patent and market a
new  ‘breakthrough’ pharmaceutical, which faces little or no competition from
alternative therapies, may have the ability to exploit the advantage of being first
onto the market, by charging a price which maximises its profits for the duration of
the patent.
However, the ability of others to develop and market products with a different
chemical structure but with the same or similar therapeutic effects (me-too
products) may limit the ability of pharmaceutical patent holders to earn monopoly
profits for the duration of the patent.3
Competition from ‘therapeutic alternatives’ is considered to be relatively
widespread in the pharmaceutical industry. According to the Boston Consulting
Group (BCG 1999, p. 8), because patent laws allow access to patent information
after a short period, competitors can use this information to inform their own
research. As a result, new pharmaceuticals tend to be followed by me-toos
(competitive modifications of the originator). For the US market, the Congressional
Budget Office estimated that a breakthrough pharmaceutical usually has between
one and six years on the market before a me-too version is introduced
(CBO 1998, p. xi).
In principle, companies will seek to set a price for patent-protected products that
maximises their profit — taking into account the price sensitivity of demand for the
pharmaceutical, the costs of developing and manufacturing it, and competition from
broadly equivalent products (me-too pharmaceuticals). If the conditions facing the
holder of a pharmaceutical patent vary across countries then the holder may want to
set a different price in each country where the product is marketed.
For example, consumers in countries which have a strong preference for
pharmaceuticals over other forms of treatment, may be less sensitive on average to
price changes. Consequently, companies may be able to sustain higher prices in
these countries compared to those where consumer preferences for pharmaceuticals
are not as strong.
                                             
3 Generally, pharmaceutical patents cover the chemical composition but not the therapeutic uses.
Therefore, other firms may be able to develop a chemically distinct but therapeutically similar
pharmaceutical which also could be awarded a patent.16 PHARMACEUTICAL
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Demographic factors also may affect pharmaceutical consumption and therefore
prices in a particular country. Older people (aged 65 and over) tend to account for a
relatively large share of pharmaceutical consumption in developed countries. If
older patients are on average less sensitive to prices, patent holders may seek to
recover a larger share of their R&D costs in those countries with a larger share of
older persons. However, the reverse may hold if older persons are actually more
price sensitive. This could occur if the elderly tend to consume treatments for
chronic rather than acute illnesses, and the price sensitivity of demand for
pharmaceuticals designed to treat chronic illnesses is greater than that for acute
forms of treatment.
In principle, as products move through their life-cycle, international price
differences could be expected to diminish over time, despite inter-country
differences in demand conditions, through mechanisms such as parallel trading.
However, manufacturers may be able to sustain the practice of setting different
prices across countries because patent laws generally protect patented
pharmaceuticals against parallel importation. Despite some legal debate it generally
is considered that patent and design legislation in Australia provides the exclusive
right over importation of a product to the patent holder (Revesz 1999, p. 44). Thus,
if the price of a patented pharmaceutical product in Australia is above the price in
another country, a foreign distributor could be in breach of the patent if it tried to
import a product protected by an Australian patent (without the permission of the
Australian patent holder).4
The World Trade Organization (WTO) agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) attempts to harmonise intellectual property
protection in most developed countries. The TRIPS agreement requires countries to
grant patent protection to pharmaceutical products for a minimum period of
20 years. The agreement also encourages member countries to respect patent laws
across countries, including enabling manufacturers of patented pharmaceuticals to
prevent parallel trade in their products. There are important exceptions, including in
the area of compulsory licensing.5
                                             
4 Patent rights may be over-ridden by international trading agreements and/or national laws. For
example, the European Union (EU) allows parallel trade within the Union. Under EU law,
patent holders exhaust their exclusive rights to prevent movement of their products once they
are placed on the market in any Member State. Unauthorised imports from outside the EU,
however, are prohibited (Kanavos  1999b,  pp.  161–162). In addition, NZ permits parallel
importation of patented pharmaceutical products.
5 Under compulsory licensing, governments or a company may be permitted to manufacture and
sell pharmaceuticals without the patent holder’s permission. Compulsory licenses are generally




In principle, when a pharmaceutical patent has expired in all countries, its price
could be expected to converge internationally. Any attempt by a pharmaceutical
company to charge a high price in one country would encourage buyers to import
the product from lower-priced countries.
However, several factors may prevent complete convergence in generic prices,
including the legislative, legal and regulatory obstacles that may discourage generic
suppliers from entering a market (Goldberg  1997). Also, the imposition by one
country of specific regulatory requirements may increase local prices relative to
overseas prices if they increase costs for all domestically produced and imported
generic pharmaceuticals (section 2.4).
In addition, advertising by manufacturers6 and first-mover advantages may enable
originator brands of generic pharmaceuticals to maintain high prices for sustained
periods. According to Dong-Churl Suh (2000), an off-patent originator can maintain
a high price and a significant share of the market because:
•   patents, in effect, give an originator a first-mover advantage, especially if the
originator invests heavily in promotional expenditures to develop brand loyalty;
and
•   new entrants incur high costs associated with disseminating the information
necessary to assure consumers that their products are therapeutically equivalent
to the original product.
2.2 Pharmaceutical subsidy arrangements
Pharmaceutical subsidy arrangements (including associated cost-containment
mechanisms) is another key area of government intervention in the pharmaceutical
industry. Most developed countries are similar to Australia in that governments, for
social welfare and equity reasons, subsidise the consumption of prescription
pharmaceuticals that have been approved for marketing by regulatory authorities.
The effect of subsidy arrangements on manufacturer prices is likely to depend on
how subsidies are designed and administered.
Subsidy arrangements that provide universal coverage and subsidise an extensive
list of pharmaceuticals are likely to stimulate a greater increase in demand for
pharmaceuticals (and depending on the price, potentially increase the revenue of
producers) compared to narrower subsidy schemes. The potential for an increase in
                                             
6 Most countries in the OECD prohibit direct advertising of pharmaceuticals to consumers
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the volume of sales encourages companies to submit their products for listing under
a subsidy scheme.
Many Organisation for Economic Co-operation and Development (OECD)
countries have established universal subsidy arrangements, covering an extensive
range of products, that effectively enable the government to act as the principal
purchaser of pharmaceuticals. These countries may have a positive list (companies
must apply to have their products listed for subsidy), a negative list (where the
government decides which products it will not subsidise) or a combination.
Countries that control access to the subsidy list (positive list) may have relatively
greater bargaining power compared to countries that agree to subsidise all new
pharmaceuticals except those placed on a negative list. This could arise if it is
relatively difficult to place products on the negative list (due to consumer and
political resistance) and the list is relatively small.
The extent to which governments wish to use their power to negotiate lower
pharmaceutical prices also may depend on the objectives of the government
purchaser. For some governments, the principal objective may be to obtain access to
necessary medicines at the lowest possible cost. Alternatively, some governments
may choose not to use their buying power to negotiate the lowest possible prices.
For instance, the UK Government may not be willing to use its bargaining power
fully because one of its objectives is to encourage industry development
(section 2.4).
There may be a direct relationship between the extent of subsidies and the
downward pressure that governments may wish to exert on manufacturer prices
through cost-containment arrangements, at least for patented (new innovative and
me-too) pharmaceuticals. Cost-containment arrangements (such as price controls
and prescribing guidelines) may be designed to lower manufacturer prices, to
restrict the volume of sales of subsidised pharmaceuticals or to lower prices
indirectly through influencing the price sensitivity of purchasers. Inter-country
differences in the cost-containment mechanisms accompanying pharmaceutical
subsidies may therefore give rise to international differences in manufacturer prices
(section 2.3).
Before examining how differences in cost-containment mechanisms across
countries may give rise to international price differences, it is worthwhile
examining the main features of subsidy arrangements in OECD countries. This
assists in identifying a suitable group of countries to include in price comparisons.GOVERNMENT
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Pharmaceutical subsidy arrangements in the OECD
Pharmaceutical subsidy arrangements exist in all major OECD countries. The major
differences, however, are with respect to:
•   whether public or private arrangements predominate (that is, the percentage of
the population covered by public or private schemes);
•   eligibility for public subsidies (for example, the proportion of the population
covered by the public subsidy scheme);
•   the level of public subsidy offered (in terms of the size of subsidy list and the
level of patient copayment);7 and
•   the type of subsidy list (positive, negative or both).
Australia has a public subsidy scheme for pharmaceuticals (the PBS), with universal
coverage (all Australian residents and eligible foreign visitors, other than those
treated by public hospitals). In 1996, the public sector accounted for around half of
total expenditure on pharmaceuticals (table 2.1).8
In Australia, patients contribute around 20 per cent of the total cost of the PBS.
Patients pay a maximum copayment for each PBS item, based on their welfare
situation. There are two levels of maximum copayment, one for general patients
($21.90) and a lesser one for concessional patients ($3.50).9 Copayments are
generally not refundable from private health insurance.
Many developed OECD countries either rely on public pharmaceutical subsidy
arrangements or have a mixture of public and private schemes. Within the group of
countries where public schemes predominate, most are similar to Australia in that
the subsidy arrangements provide universal coverage, with subsidies available on
most pharmaceutical products, and patients are required to make some form of
contribution towards the cost of purchases (table 2.1).
                                             
7 Copayments are out-of-pocket contributions made by patients when purchasing a
pharmaceutical. Copayments are intended to reduce unnecessary or excessive pharmaceutical
consumption by making consumers bear at least part of the cost.
8 Private expenditure includes patient copayments for items subsidised under the PBS,
pharmaceuticals supplied in private hospitals and non-PBS items purchased by consumers
(including over –the-counter (OTC) products).
9 Individuals and families are protected from large overall expenses for PBS-listed medicines by
an expenditure safety net. For general patients, once the eligible expenditure of a person and/or
their immediate family exceeds $669.70 in a calendar year, the maximum patient copayment
per item decreases from $21.90 to the concessional rate. For concessional patients, the $3.50
copayment per prescription item is removed once their total eligible expenditure exceeds $182
within a calendar year.20 PHARMACEUTICAL
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1999 1999 1999 1997 1999 1997
Ireland Public Universal Yes 83.3 Fixed 16.2
Austria Public Universal na 74.4 (’98) Fixed 25.6 (’98)
Spain Public Universal Yes 72.6 Proportional 27.4
Sweden Public Universal No 71.3 Proportional 28.7
NZ Public Universal No 70.9 Fixed 29.1
Germany Public Universal Yes 70.0 Proportional 30.0
Netherlands Public Limitedc Yes 64.4 (’98) Proportional 35.6 (’98)
UK Public Universal No 64.2 Fixed 35.8
France Public Universal Yes 58.2 (’98) Proportional 41.8 (’98)
Australia Public Universal No 52.5 Fixed 47.5
Finland Public Universal na 48.1 (’98) Proportional 51.9 (’98)
Belgium Public Universal na 44.7 Proportional 55.3
Italy Public Universal No 40.6 Proportional 59.4
Canada Private Mixedd Yes 32.0 (’99) Proportional 68.0 (’99)
US Private Limitede Yes 15.4 (’98) Mixed/
Proportional
84.6 (’98)
a Indicates whether a public or private pharmaceutical subsidy scheme covers the largest proportion of the
population. b Pharmaceutical expenditure comprises prescription medicines, OTC products and expenditure
on other medical non-durables (such as bandages, elasticised stockings, incontinence articles, condoms and
other mechanical contraceptive devices). Pharmaceuticals consumed in hospitals are excluded. c High
income earners in the Netherlands are excluded from statutory health insurance and must hold private health
insurance. d Some provincial schemes in Canada are universal (eg Alberta, British Columbia and Quebec),
while others are limited to particular groups (eg Ontario). Eligibility for Federal Government subsidies is limited
to the First Nations and Inuit, war veterans and members of the Royal Canadian Mounties and armed forces.
e The US Government generally subsidises pharmaceuticals for the poor (through Medicaid) and veterans of
military service and members of the armed forces (through the Department of Veterans Affairs). Medicaid
accounts for around 12 per cent of the US market by sales. Sales through the Department of Veterans Affairs
account for approximately 1.5 per cent of the market. na Not available.
Sources: GAO (2000a); HC (2000); Jacobzone (2000); Kanavos (1999b); Ministry of Health and Long-Term
Care (2001); OECD (1998).
Only the US and Canada appear to be significantly different from Australia in terms
of eligibility for public subsidies. Private insurance schemes cover a large
proportion of people in these countries, and eligibility for public pharmaceutical
subsidies is limited to certain segments of the population.10 Consequently, the
shares of public expenditure in total US and Canadian pharmaceutical spending are
low compared to Australia and many other countries.
                                             




There is significant variation in the respective shares of the public and private
sectors in funding pharmaceutical expenditure amongst the group of countries that
provide universal pharmaceutical subsidies (table 2.1). For these countries, private
insurance schemes exist in Ireland, Spain, Germany and France, which partly cover
the cost to consumers of pharmaceuticals. In those countries without private
insurance coverage, the private expenditure on pharmaceuticals reflects mostly
consumer copayments and expenditure on non-subsidised products.
The predominant form of copayment system for the countries reported in table 2.1
is proportional to the final price.11 A fixed or flat rate system exists for some of the
countries, while the US may have a mixture of fixed and proportional systems.
Within the OECD, countries maintain a mix of positive and negative subsidy lists.
However, many countries have a positive list only (including Australia, NZ, France,
Canada, and the US). Some countries (such as the UK) subsidise all prescription
pharmaceuticals once they have been approved for marketing but may decide to
remove the subsidy on some products or groups of products (involving placing them
on a negative list). Other countries (such as Sweden and Spain) have a combination
of positive and negative lists.
2.3 Cost-containment policies
The introduction of new, more expensive pharmaceuticals, combined with growth
in demand from aging populations, have caused government outlays on
pharmaceuticals to increase rapidly in most OECD countries. Between 1990 and
1997, a number of OECD countries experienced average annual nominal growth
rates in public expenditure on pharmaceuticals of eight per cent or more, including
the US (13.5 per cent), Australia (11.4 per cent), Denmark (11.1 per cent), Austria
(9.5 per cent), Ireland (9.0 per cent), Japan (8.0 per cent) and the UK (8.0 per cent)
(OECD 2000).12
In response to growing budgetary pressures, governments have implemented a
range of cost-containment measures. Some measures (such as price controls) may
influence manufacturer prices directly. Others are designed to limit growth in
demand by restricting the volume of sales for a given subsidy level. A third group
of measures is designed to affect manufacturer prices indirectly by influencing the
demand for pharmaceuticals (such as physician budgets and generic substitution
                                             
11 Most countries also have safety net arrangements to protect individuals or families from large
expenditure on pharmaceuticals.
12 The expenditure figures also include spending on a wide range of other medical items, such as
bandages, elasticised stockings, incontinence articles, and contraceptive devices.22 PHARMACEUTICAL
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policies). Taken together, differences in the nature and application of these
cost-containment mechanisms may contribute to international price differences.
Price and profit controls
In most OECD countries, manufacturers are free to set the price of their
pharmaceuticals when the product is launched in the market. However, if
manufacturers want their pharmaceuticals subsidised by the government (or a
private insurer in countries such as the US), they also may have to agree to accept a
lower price for their products.
Reimbursement pricing system
In the past, direct price controls (involving the fixing of prices on a product by
product basis) were relatively common in the OECD. However, most OECD
countries have moved away from these controls in favour of reimbursement pricing
systems.
Under reimbursement pricing systems, public or private pharmaceutical insurers set
price ceilings for subsidised items (where the list of subsidised items is commonly
referred to as a formulary). Insurers agree to cover or reimburse the cost of listed
pharmaceuticals up to the ceiling (reimbursement price). Manufacturers are free to
price above the reimbursement price but the patient usually must pay the difference
between the reimbursement price and the manufacturer’s price (Dickson and
Redwood 1998, p. 472). Box 2.2 describes the relationship between reimbursement
and manufacturer prices in Australia.
Most governments in the OECD have established reimbursement pricing systems.
However, they may use different methods to set reimbursement prices. For
example, reimbursement prices can be determined using information from:
economic evaluations; reference pricing; and international price benchmarking.
Economic evaluation
Economic evaluations aim to examine the clinical and economic impact of
pharmaceuticals, requiring an assessment of the costs and health benefits to patients.
Costs may include those associated with follow-up visits to and from physicians,
other pharmaceutical use (for example, to treat side effects), hospital out-patient




Box 2.2 Reimbursement and manufacturer prices in Australia
When a PBS-listed pharmaceutical is purchased, the patient pays a copayment to the
pharmacist (up to a fixed amount), and any delivery and after hours fee, brand or
therapeutic premium, or special patient contribution that may be applicable. The
pharmacist in turn is reimbursed by the Government for any difference between the
total patient copayment and the reimbursement price of the pharmaceutical. This
reimbursement price set by the Government includes the manufacturer price, retail
mark-ups (to wholesaler and pharmacist) and dispensing fees.
The mark-ups to retailers in Australia are a set percentage of the agreed price to the
pharmacist. The dispensing fee also is a set amount per item. The greatest proportion
of the Government’s agreed price to pharmacists goes to the manufacturer
(90 per cent) (DHAC 1999a, p. 11).
Although the reimbursement price (set by the Government) is not the same as the
manufacturer’s price, there is a strong relationship between the two. The Government
sets the reimbursement price, taking into account what is charged by the manufacturer.
The manufacturer, if it wants its product listed on the PBS, will negotiate a price that is
acceptable to itself and the Government.
Sources: DHAC (1999a, 1999b).
There are four principal types of economic evaluation of pharmaceuticals. While the
costs of a particular therapy usually are measured in monetary terms, the outcomes
may be expressed in monetary or non-monetary terms (for example, lives saved).
According to McKie et al. (1998), the main techniques are:
•   cost-minimisation analysis, which compares the costs of two or more therapies
with identical outcomes (for example, an identical reduction in mortality rates
for patients);
•   cost-effectiveness analysis, may be used where therapies have the same
outcome, but the outcome can be achieved to different degrees (for example, the
level of reduction in a patient’s blood pressure). It aims to identify the most
efficient therapy that minimises cost per unit of outcome (for example, minimise
costs per life saved). A product may be considered to be cost-effective compared
to alternatives if it is less expensive but just as effective as its comparator, more
expensive while providing an additional benefit that is worth the extra cost, or it
has the same cost but is more effective than its comparator;
•   cost-benefit analysis, may be used to compare therapies that have multiple
outcomes and these outcomes may be achieved to different degrees. Outcomes
such as improvements in a patient’s quality of life are expressed in monetary
terms and compared with monetary costs. The objective is to select the therapy
that provides the largest net monetary benefit; and24 PHARMACEUTICAL
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•   cost-utility analysis, compares therapies that have multiple outcomes which may
be achieved to different degrees. The quality of life is explicitly quantified and
included in this analysis. Rather than using a monetary value, outcomes are
expressed using a measure of the improvement in health status (usually the
Quality Adjusted Life Years gained or QALYs).13 The method is useful when
evaluating alternatives that are life-extending, yet with significant side effects,
such as chemotherapy. Alternative projects can be ranked to select the one that
minimises cost per QALY gained.
Several countries require companies seeking listing for new products (or changes in
prices or approved uses) to submit an economic evaluation. This analysis may form
the basis for decisions about reimbursement prices. Economic evaluations are
mandatory in very few countries, such as Australia (since 1993), NZ and some parts
of Canada (British Columbia and Ontario). Economic evaluations have been
undertaken on an ad hoc basis in the UK, Sweden, Spain and France.
The type of analysis used in Australia to establish or review reimbursement prices
may depend on the characteristics of the pharmaceutical. For example, when
deciding whether a new pharmaceutical is to be listed on the PBS, the manufacturer
has to provide information to the Pharmaceutical Benefit Advisory Committee
(PBAC) on the cost-effectiveness of its product relative to that of therapeutic
alternatives. According to Birkett et al. (2001,  p.  110), 37  per  cent of
pharmaceuticals listed on the PBS have been subjected to economic evaluation —
most involving cost minimisation or cost-effectiveness analyses. However, the
proportion of cost-utility analyses has been on the rise since 1996.
If an alternative therapy is not available, pricing negotiations for a new innovative
product may consider the cost of production (including R&D) and prices in
comparable countries. Price-volume agreements also may be used to determine the
reimbursement price. Under a price-volume agreement, the agreed price of a
pharmaceutical is based on a forecast volume of sales. If the actual sales volume
exceeds the forecast, the price of the pharmaceutical is usually reviewed
downwards.
In providing comments on the Commission’s preliminary analysis, some roundtable
participants considered that Australia’s requirements for evidence-based economic
evaluations are amongst the most stringent in the world.
In Australia, the use of cost-effectiveness analysis involves evaluating an extensive
set of outcomes, including the changes in the use of resources (which includes
                                             
13 Results are usually expressed as cost per QALY gained. QALYs express life years gained
weighted by a utility index of health-related quality of life.GOVERNMENT
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medical services that are not subsidised through the PBS) that are likely to result
from the introduction of the proposed pharmaceutical (DHAC 1999c).14
According to Cookson (2000), there is a preference for ‘hard’ evidence from trials
rather than ‘softer’ evidence used in economic modeling (unless used in conjunction
with trial data) or less rigorous scientific evidence, such as observational studies and
expert opinion. With the ‘hard’ trial-based evidence, Australia’s listing and pricing
committees prefer the results obtained from ‘head-to-head randomised’ control
trials that directly compare the proposed pharmaceutical with the existing
pharmaceutical therapy used by most prescribers in Australia for the same
indication.15
In Australia, if a pharmaceutical that has been shown to be therapeutically more
effective than its comparator and it is priced above the existing treatment, the
manufacturer is requested to quantify the extra health benefits and weigh them
against the higher cost. In doing so, patient-relevant outcomes are preferred
(particularly final outcomes such as deaths prevented) based on a preliminary trial-
based economic analysis, followed by a modelled analysis where appropriate
(Birkett et al. 2001, pp. 107–108).
As noted above, Australia is one of the few countries to require companies seeking
reimbursement for their products to submit an economic evaluation. In most other
countries, similar issues to those considered in Australia are incorporated in
decisions about reimbursement. For instance, in Spain and France, factors such as
the degree of ‘innovation’ and the prices of therapeutically similar treatments are
considered in pricing negotiations. The difference between Australia and these
countries appears to be that in Australia these methods are central to decision-
making and they are incorporated in a much more formal and rigorous way.
Reference pricing systems
A number of OECD countries establish reimbursement rates for new and
established pharmaceuticals using a reference pricing system (box  2.3). Under a
reference pricing system, reimbursement prices are commonly set for a group or
cluster of similar or identical pharmaceuticals. Using this approach, pharmaceuticals
that have the same chemical structure and/or those that are therapeutically
                                             
14 Manufacturers are encouraged to submit evaluations that are relevant to Australia, taking into
account the unit costs, the patterns of resources used and the way in which the Australian health
care system is funded (DHAC 1999c).
15 In circumstances where there is no pharmaceutical that can be used as a comparator, the main
comparator would be the standard non-pharmaceutical therapy currently used to manage the
indication (Birkett et al. 2001, p. 107).26 PHARMACEUTICAL
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interchangeable, may be grouped together to form a reference group. The
government may set a single reference (benchmark) price for the entire reference
group. If the reference price is set at the level of the lowest-priced item in the group,
manufacturers of the higher priced items may be required to lower their price to the
benchmark. In some cases, under the brand premium or therapeutic group premium
(TGP) policies, manufacturers may be permitted to sell at a higher price (with the
consumer paying the difference between the selling price and reference price). If
they decide to sell at a higher price they face the risk of losing market share to the
cheaper, more highly subsidised product.
Australia, based on the type of reference pricing system implemented, appears to
have a relatively strict price control system in place for subsidised pharmaceuticals.
The reimbursement prices for many items in Australia are determined by a
reference pricing system, which has reference groups that may include patented
products that are therapeutically interchangeable as well as generic products.
Originally, six therapeutic groups were subject to the reference pricing system in
Australia, using the weighted average monthly treatment cost (WAMTC)
methodology.16 However, pricing reviews for one group (selective serotonin re-
uptake inhibitors (SSRIs)) were suspended in mid-1999 pending a review of this
pricing methodology.17 Of the remaining five, four are also subject to the TGP.18
Like Australia, NZ and British Columbia (in Canada) also define reference groups
to include patented pharmaceuticals and off-patent pharmaceuticals that are
therapeutically interchangeable with different active ingredients.
In contrast to Australia, most OECD countries with reference pricing systems define
reference groups to include products that are off-patent and contain the same active
ingredients (such as Italy, Sweden and Spain). For these countries, suppliers of
originator brands may be unable to obtain significantly higher premiums for their
products, compared to countries that do not implement a reference pricing system.
                                             
16 The WAMTC methodology is used to compare the treatment cost of therapeutically equivalent
pharmaceuticals that are available in different dosage types, strengths and pack sizes. The aim
is to adjust the prices of these pharmaceuticals so that their cost per month of treatment is
equivalent (PBPA 2001, p. 6).
17 In 2001, pricing reviews for the remaining five were suspended as well, pending a review of the
WAMTC pricing methodology.
18 Suppliers of pharmaceuticals in one of the four groups covered by the TGP are permitted to
charge a premium, over the reimbursed price, which is paid by the consumer. The four groups
under the TGP are: ACE Inhibitors and Calcium Channel Blockers for cardiovascular disease
(hypertension), HMG CoA reductase inhibitors for lowering blood cholesterol and H2 receptor
antagonists for peptic ulcers.GOVERNMENT
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Box 2.3 Price and profit controls in selected OECD countries
Canada: Launch prices of patented products are reviewed at the federal level — prices
should not be higher than the median price in seven other developed countries. Prices
also are indexed to the CPI. The provinces also set reimbursement prices for
subsidised products. Ontario uses a reference pricing system for most generics —
reimbursing the lowest price offered in Canada. British Columbia sets reimbursed
prices in reference to the product ‘which is medically effective and the most cost
effective as determined by current published scientific studies’. Therapeutically
interchangeable/comparable pharmaceuticals (patent or off-patent) of different
chemical structures can be clustered together.
France: The ‘convention’ (five-year contract) is the main method by which prices of
reimbursed pharmaceuticals are set. Negotiations are based on sales forecasts, made
at the therapeutic class level. If actual sales exceed the targets, firms are required to
pay rebates. Prices of older products can be reduced in order to receive higher prices
for newer products. Reimbursed prices are based on a number of factors including:
prices of local comparators; prices of the product in other European markets; sales
forecasts for the next three years; and the degree of ‘innovativeness’ of the product
(the therapeutic improvement over existing products).
Germany: Until 1996, all listed pharmaceuticals (including patented items) were
allocated to one of three reference groups: the same active ingredients (level  1),
chemically different active ingredients (level  2); or pharmacologically comparable
effects (level 3). The reimbursement price for a pharmaceutical in a particular reference
group was then based on the price of all other pharmaceuticals in the group. Since
1996, new patented pharmaceuticals have not been included in the level  2 or 3
reference pricing groups until their patents expire.
Italy: Companies are free to set prices of pharmaceuticals unless reimbursement is
sought. Prices of reimbursed products reflect the average price charged in all other
European Community countries. Other factors taken into account include cost-benefit
ratios, sales forecasts, number of patients, and financial factors such as related
investments and increases in local employment. In 1996, a reference pricing system
was introduced. Chemically equivalent pharmaceuticals must have the same price per
unit of active ingredient. If prices are not lowered to the cheapest referenced value, the
product is de-listed and the patient is required to pay the full price for the product.
NZ: The reference pricing system is similar to that used in Australia in that reference
clusters can include patented and off-patent products. Since 1997, other methods have
been introduced in an effort to reduce manufacturer prices for off-patent products,
including the use of exclusive tenders and companies agreeing to reduce the price of
certain products, in exchange for Government agreement not to tender the products.
(Continued next page)28 PHARMACEUTICAL
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Box 2.3 (continued)
Spain: The Government controls the prices of all prescribed pharmaceuticals. A range
of factors are taken into account when setting the price of reimbursed products
including the ‘innovativeness’ of the product and the prices of therapeutic equivalents
available locally. Price-volume agreements are used frequently for more expensive
products. A reference pricing system was introduced in 1999, applying only to products
with a bioequivalent generic on the market.
Sweden: Reference pricing applies only to off-patent products (including originator
brands). International price comparisons also are used to set the price of a
pharmaceutical  — aiming to award a ‘European price’. Pricing of new innovative
pharmaceuticals are usually accompanied by a price-volume agreement.
The Netherlands: Companies are not allowed to sell pharmaceuticals (including non-
subsidised ones) at prices higher than the average of the pharmacy purchase prices of
‘comparable’ products in Belgium, France, Germany and the UK. In setting maximum
prices, the Government can include the price of generics in the reference countries
(even if the product is patented in the Netherlands).
UK: Companies are free to set prices for new products. But under a voluntary
agreement, the Government regulates the profitability of pharmaceutical companies
supplying branded products to the National Health Service under the Pharmaceutical
Price Regulation Scheme. Under this scheme, firms are prevented from raising the
prices of existing pharmaceuticals without Government permission.
US: Most government programs have some form of price control such as a mandatory
rebate, discount, price cap or limit on price increases. In the private sector, managed
care plans directly negotiate rebates from manufacturers based on their ability to use
their formularies to steer members toward a particular pharmaceutical.
Sources: BCG (1999); DHAC (1999b); Dickson et al. (1998); Jacobzone (2000); Kanavos (1999b).
Since newer patented products can be priced against older off-patent products in
countries such as Australia and NZ, it is possible that manufacturer prices for
patented pharmaceuticals included in the reference pricing system in these countries
may be lower than those in countries where the reference groups do not contain
patented products. This effect may be most pronounced if the reimbursement ceiling
for a reference group is fixed at the level of the lowest priced product in the group
(Australia and NZ). In some countries, the reimbursement price may be set using an
averaging process among the pharmaceuticals within a reference group (Germany
and Sweden) (Burstall et al. 1999, p. 672).
Many OECD countries also may take a range of other factors into account,
especially when determining reimbursement prices for new innovative products.
These additional factors include: production and R&D costs; the therapeutic value
of the product; evidence of clinical improvement (degree of innovation) of theGOVERNMENT
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product over existing similar products; and price-volume agreements (box 2.3). The
weights applied to other factors may differ across countries.
International price benchmarking
International price benchmarking (the practice of comparing pharmaceutical prices
across countries for the purpose of determining reimbursement prices) is also
commonly used in a number of OECD countries such as the Netherlands, Italy,
Japan, France, Sweden, Spain and Canada, and to a lesser degree in Australia and
NZ.19 The widespread use of international reference pricing could be expected to
reduce the scope for manufacturers of patented new innovative medicines to set
different prices across countries based on differences in demand sensitivity. This
could occur because a low manufacturer price in one country could be used to
establish prices in other countries. With widespread use of international reference
pricing, manufacturers may be more likely to set a single price across a number of
countries at launch that will give the highest returns when all markets are taken into
account.20
Direct price and profit controls
Some countries also use direct price and profit controls to supplement
reimbursement pricing. For instance, prior to marketing, the prices of all
pharmaceuticals (not just reimbursed products) must be approved by governments
in Spain and Belgium. Manufacturers in the UK (although not subject to direct price
controls) have entered into an agreement with the Government which involves
capping profit levels on sales to the National Health Service (box  2.3 and
appendix B).21
In the US market, manufacturers are largely free to set prices as they wish.
However, most government programs that cover prescription pharmaceuticals (such
                                             
19 According to Danzon (1997) the use of international price benchmarking also has been
proposed in the US. Under one proposal, the allowed prices of pharmaceuticals in the US
would be based on the lowest price paid across 22 countries, including countries such as NZ.
Several bills are before state legislatures in the US that would cap prices in those states at the
price in Canada.
20 International price benchmarking also may provide companies with an incentive to post high
list prices (especially in those countries that are used as international benchmarks) but to offer
discounts and other less transparent forms of price reductions to buyers.
21 Countries such as Spain and France also implement some form of profit control, although this
is not the only method used for price negotiations.30 PHARMACEUTICAL
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as Medicaid) use some form of price control.22 These controls can take the form of
mandatory discounts, price caps or limits on price increases (appendix B).
Other price control measures
A variety of other price control measures have been used from time to time by
governments in the OECD. They include price freezes, across-the-board price
reductions, price reductions for exceeding an agreed level of sales,23 fixed
expenditure budgets,24 and performance requirements (Kanavos 1999a). For
example, Germany, Italy, the UK (from 1993 to 1996) and Spain (from 1994 to
1997) have all used price freezes. Across-the-board price reductions have been used
as a cost control method in Italy (2.5  per cent price cut in 1995), Spain
(three per cent price cut in 1994), the UK (a price cut of 4.5 per cent in 1999) and
Belgium (in 1996). The use of measures such as price freezes and price reductions
by governments may contribute to the opening-up of price gaps between the
countries that have used them and those countries that do not.
Governments also have used volume controls to contain costs. This may involve
restricting the number of repeat prescriptions that may be used, limiting the uses
(indications) on subsidised items, or requiring authorisation before a pharmaceutical
can be prescribed for treating a particular condition. For example, in Australia,
some pharmaceuticals may be approved for use to treat several conditions.
However, the product may be subsidised for the treatment of only one of these
conditions.
Performance requirements are widely used to establish reimbursement prices in the
OECD (Kanavos 1999b). It involves governments setting reimbursement prices
partly on the basis of a company’s ability to increase the local employment level or
the level of R&D investment undertaken locally. Higher prices may be awarded to
companies that agree to undertake a certain level of local production or R&D. It
could be expected that countries with relatively large pharmaceutical industries
(such as the US, the UK, Switzerland, Germany, France, Sweden and Japan),
therefore, may award relatively higher reimbursement prices to pharmaceuticals that
are developed and manufactured locally.
                                             
22 Government programs in the US cover only a small percentage of the total US market
(appendix B).
23 Under this method, the government imposes a fixed budget for pharmaceutical expenditure and
any excess on that budget is paid back by the industry. This method of controlling expenditure
has been used in the UK, Germany, France, Italy and Spain.
24 Under a fixed budget system, governments seek to maintain a ceiling on total pharmaceutical
expenditure through increasing or decreasing the number of subsidised pharmaceuticals
available to consumers. This approach has been used in NZ (appendix B).GOVERNMENT
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There are differing views about the effectiveness of the various methods of
controlling prices. For instance, Danzon and Chao (2000,  p.  314) argue that
countries with strict forms of price control (such as Italy, France and Japan) tend to
have lower prices than countries with relatively free pricing (such as the US, the
UK, Canada and Germany). On the other hand, Dickson and Redwood
(1998, p. 476) argue that while the introduction of reference pricing systems caused
a once-off lowering in prices, they have not limited the rate of price increases.
Other cost-containment measures
In addition to price controls, governments and private insurers, in an attempt to
contain costs, have implemented a variety of measures essentially designed to
influence the demand for pharmaceuticals through altering the incentives facing
consumers, physicians and pharmacists. Variations across countries in the types of
mechanisms applied and their effectiveness could cause corresponding differences
in the demand conditions facing companies and, therefore, may give rise to
international price differences for patented pharmaceuticals that are subject to
limited competition from me-too products.
One way in which governments and private insurers seek to influence consumer
demand is through copayments (section  2.2). Demand for pharmaceuticals is
considered to be more sensitive to price in countries where copayments are
proportional to the final price because the out-of-pocket costs are linked to the total
cost of pharmaceuticals. Under a fixed copayment system, the consumer may pay
the same amount irrespective of the total cost of alternative pharmaceuticals.
According to the OECD (2001, pp. 40, 44), a subsidy arrangement that fully covers
the cost of pharmaceuticals may lessen the incentive to use cheaper alternatives.25
Further, the higher the marginal payment between two products that are considered
therapeutically comparable, the greater the incentive for consumers to use the
cheaper substitute (OECD 2001, p. 44).
Many governments and private insurers also seek to influence the behaviour of
physicians and pharmacists by employing a range of mechanisms in an effort to
make physicians’ prescribing decisions more sensitive to price (table 2.2).
Many countries have established prescribing guidelines in an effort to encourage
physicians to prescribe rationally and consistently according to the pharmaceutical’s
                                             
25 For example, in countries such as France, the copayment policy may not affect consumer
behaviour because consumers are able to seek reimbursement of most or all of the copayments
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indications and the therapeutic needs of their patients.26 Several countries also have
imposed spending limits on physicians (for example, through setting a budget for
each physician or medical practice). Most governments also impose direct limits on
the volume/repeats prescribed per day (or per physician).















Australiaa Yes/Sanctions may existb No Yes Yes
Canada Yes (in some provinces)/
Sanctions may exist
No Yes Yes
France Yes/Sanctions may exist Yes Yes Yes
Germany Yes/Sanctions may exist Yes na Yes
Netherlands Yes/No sanctions No Yes Yes
NZ Yes/No sanctions No Yes Yes
Spain Yes/No sanctions No No Yes
Sweden Yes/No sanctions No Yes Yes
UK Yes/No sanctions Yes na Yes
US Yes/Sanctions may exist na na Yes
a From 1 January 2001, consumers in Australia have to provide proof of their eligibility for the PBS when
collecting subsidised items from pharmacies. This enables the Health Insurance Commission
(Wooldridge 2000) to identify and check each claimant’s eligibility to receive a subsidy. b The HIC identifies
medical practitioners whose servicing, ordering or prescribing appear abnormal when compared with their
peers. Sanctions may be imposed if a medical practitioner has engaged in inappropriate practice (HIC 2001).
na Not available.
Sources: BCG (1999); Burstall et. al. (1999); HIC (2001); Jacobzone (2000); Kanavos (1999b); Wooldridge
(2000).
The success of these mechanisms in influencing physicians to prescribe more cost-
effective treatments and to prevent over-prescribing has been questioned. For
instance, Jacobzone (2000, p. 31) concluded that there has been limited economic
effects from attempts to place responsibility for the over-consumption of
pharmaceuticals and misplaced prescription onto prescribers.
In order to encourage more cost-effective spending on pharmaceuticals, most
OECD countries also have implemented policies that encourage the use of
cheaper-priced generics.
                                             
26 Although most OECD countries do not implement sanctions, countries such as France and
Germany do have financial and/or contractual sanctions in place if physicians do not prescribe
according to the guidelines (Jacobzone  2000,  p.  75). In the US, a third party (such as a
managed care plan) may influence prescribing habits of physicians more directly by making it
mandatory for participating physicians to prescribe generics where possible.GOVERNMENT
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Policies to encourage generic competition generally are administered at the
production, the approval and/or the retail stage. At the retail stage, most countries
allow pharmacists to dispense generic pharmaceuticals where possible. In Australia,
unless the prescribing physician has explicitly indicated that substitution is not
allowed, pharmacists are allowed to substitute a generic item for a brand name
pharmaceutical if: the patient agrees to the substitution; and there is more than one
brand available under the PBS identified as being interchangeable, and the
physician prescribes a more expensive brand (DHAC 2000).27
Policies that speed up the launching of generics onto a market also may encourage
manufacturers of originator brand pharmaceuticals, in their post-patent period, to
provide more competitive prices. For example, generic producers in countries such
as Canada can develop and stockpile copies of patented pharmaceuticals prior to
patent expiry.
The Congressional Budget Office (CBO  1998) found the prescribing of generic
copies over brand name products is more likely to lead to greater discounts being
offered by the suppliers of brand name products in order to maintain market share.
The study also found that as the number of generic manufacturers increased, the
average price decreased.
Generics tend to have a larger market share where strong financial incentives are in
place, with an impact on patients, pharmacists and/or prescribing physicians. The
share of pharmaceutical markets held by generics varies across countries. Countries
that are considered to have a relatively significant generic market include the US
(approximately 43  per  cent of prescription volumes in 1996), Canada (around
40 per cent of all prescriptions written in 1996-97), and the UK (51 per cent of filled
prescriptions in 1994). Australia also is considered to have a fairly significant
generic market but the exact share is not known (Jacobzone 2000).
Generic pharmaceuticals, however, make up a relatively small share of the market
in France, Sweden and Spain (appendix B). As of January 2000, generic versions of
off-patent products accounted for 5.6  per  cent of all pharmaceutical packs
prescribed in France, while the originator accounted for 10.3 per cent. In Spain, in
December 1999, generic prescribing accounted for only 3.5  per  cent of total
outpatient prescriptions (EGA  France  2001; EGA  Spain  2001). In 1999, generic
sales accounted for little more than five  per  cent of the Swedish pharmaceutical
market (Kanavos 1999b).
                                             
27 Although most OECD countries do not compel physicians to prescribe generics, in the US
many private health insurance schemes make it mandatory for their physicians to prescribe
generics where possible.34 PHARMACEUTICAL
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2.4 Other government interventions
A range of other government interventions may give rise to international price
differences through influencing the availability and cost of supplying
pharmaceuticals. This section considers four other interventions, namely:
•   pharmaceutical evaluation processes;
•   policies affecting the marketing of pharmaceuticals;
•   product liability legislation; and
•   industry policies.
Pharmaceutical evaluation processes
All OECD governments evaluate the safety, efficacy and quality of new
pharmaceutical products before they may be supplied. The primary objective of
such regulation is to protect consumers through ensuring that pharmaceuticals are:
safe for human consumption; that they have the intended effect on users; and meet
minimum quality standards. The justification for them is that many consumers may
be unable to assess the relative safety, efficacy and quality of various products prior
to use. Also, pharmaceutical evaluation procedures may minimise the cost to the
community of acquiring information on these dimensions (IC 1996, p. 44).
Evaluation procedures may affect manufacturer prices directly by increasing costs,
or indirectly, by reducing the effective life of pharmaceutical patents. The patent
life in most countries starts from the date the patent application is filed (or is
processed). If the manufacturer price of a patented product is linked to the effective
patent life, then differences in the duration of pharmaceutical evaluation procedures
could lead to variations in the effective patent life for a pharmaceutical and,
therefore, differences in manufacturer prices across countries.
There is some evidence that the length of time involved in pharmaceutical approvals
varies across countries. Schweitzer (1997) examined the issue of timing of
pharmaceutical approvals in eight developed countries and found that Switzerland,
the US, the UK, Canada and France were relatively fast in approving new
pharmaceuticals, while Sweden, Germany and Italy tend to be slower. In Australia,
from the time the drug is discovered and the first Australian patent is registered, to
the time the pharmaceutical is approved for sale on the Australian market is said to
take around 10–12 years (APMA 2000).
However, with the push to harmonise the evaluation process of pharmaceuticals
across OECD countries, differences in evaluation periods may be diminishing.GOVERNMENT
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Australia no longer develops its own standards for therapeutic goods (except for
uniquely Australian products). Instead, it accepts international standards that allow
the use of information developed overseas (IC  1996). The European Medicines
Evaluation Agency (EMEA) was established in 1993 to coordinate the evaluation of
new pharmaceuticals in all member countries in the EU. A new pharmaceutical
needs only to go through one registration process, and one safety, efficacy, and
labelling review. Once approved by the EMEA, the product can be put on the
market in all European countries, with standardised labelling and dosage.
Pharmaceutical evaluation processes also can affect manufacturer prices through
facilitating or delaying the entry of competing generic products. As noted above,
some countries permit the pharmaceutical evaluation authorities to commence
processing marketing applications for generics prior to the expiry of patents on the
originator pharmaceutical. The effect of this is to speed generic entry once patents
expire.
Some countries such as the US also have strict regulations and standards on the
manufacturing facilities of pharmaceutical companies. The US Food and Drug
Administration (FDA) regularly inspects the manufacturing facilities of all
pharmaceutical companies (including generic pharmaceutical companies) and can
recall any marketed product that does not meet production standards. Each
manufacturing plant must comply with FDA standards known as Good
Manufacturing Practices.
Marketing costs
Most governments allow manufacturers to market pharmaceuticals to doctors
(through medical journals and visits from sales representatives). Advertising
enables manufacturers to distinguish their products in an effort to influence
potential buyers. Advertising costs can form a large share of the cost of producing
and marketing pharmaceuticals. Some studies have suggested that marketing costs
can account for nearly one-quarter of total costs (box 2.1).
In addition, direct advertising to consumers also is allowed in the US via consumer
magazines, the television and the internet.28 In Australia, and most European
countries, direct marketing to consumers is prohibited for prescription
pharmaceuticals.
                                             
28 Direct to consumer advertising also is permitted in NZ and, to some extent, in Canada.36 PHARMACEUTICAL
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If allowing direct-to-consumer advertising causes a net increase in advertising and
marketing costs, differences in the regulation of advertising may contribute to cost
differences.
Liability costs
High liability costs in the US have been stated as one of the possible reasons why
pharmaceutical prices are relatively higher in the US compared to other developed
countries like Canada (Manning 1997). Further, with recent legislative changes in
the US which make it easier for injured parties to take action against pharmaceutical
manufacturers, the costs associated with bringing a new pharmaceutical into the US
market also are likely to be higher because of the further research required to ensure
safety (Schweitzer 1997, p. 36).
Industry policy
Governments generally recognise that their interventions in pharmaceutical markets
affect returns to pharmaceutical manufacturers, and therefore incentives to invest in
production and R&D. Hence, some countries have established policies that seek to
attract investments by pharmaceutical companies.
One way governments can do this is through taking domestic activity into account
when establishing reimbursement prices (section  2.3). For example, the French
Government takes proposed R&D investments into account when negotiating
pricing contracts for pharmaceuticals (Kanavos 1999b).
The UK Government recognises the cost of R&D within the prices paid for NHS
medicines — reflecting both a contribution to the worldwide cost of R&D and a
‘desire to provide an incentive for success in R&D’ (DoH  1999a). The
Pharmaceutical Price Regulation Scheme (PPRS) recognises the pharmaceutical
industry’s contribution to the UK economy and seeks to encourage its competitive
efficiency, both in the UK and abroad. The PPRS also encourages R&D into new
pharmaceuticals for the benefit of NHS patients — with a commitment to
‘minimum interference’ allowing companies the freedom to succeed in their R&D
activity (DoH 1999a). According to Kanavos (1999b, p. 179), the most recent PPRS
contract (valid from 1999 to 2004) is likely to grant a higher than average return on
capital29 for larger companies with a long established presence in the UK.
                                             
29 A more detailed description on ‘return on capital’ is discussed in appendix B.GOVERNMENT
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However, some governments also provide general and industry-specific forms of
support to the pharmaceutical industry (for example, through tax concessions and
R&D subsidies). By reducing production and R&D costs, inter-country differences
in the nature and significance of assistance to the pharmaceutical industry may
contribute to international price differences.
In Australia, the Government has developed the Pharmaceutical Industry
Investment Program (PIIP). The PIIP seeks to compensate participating
pharmaceutical companies, in part, for the impact on activity of the Government
exercising its purchasing power under the PBS. It does so by paying higher prices
on nominated products supplied by the participating companies in return for those
companies meeting commitments to undertake certain activities in Australia,
including manufacturing and R&D.
Some countries do not take industry development considerations into account in
setting reimbursement prices and do not offer assistance targeted at the
pharmaceutical industry. For example, according to Pharmac
(NZ,  pers.  comm.,  6  February  2001), there are no specific industry assistance
programs targeting the pharmaceutical industry in NZ.
2.5 Conclusion
Patents play an important role in the pharmaceutical industry through providing the
means for companies to recoup the costs of discovering and developing new
products. Patents may enable companies to set prices in a particular country which
are, to some extent, independent of those in other countries.
At the same time, there will be a host of factors that will limit the ability of
companies to set different prices in each country. For example, competition from
patented therapeutic substances may reduce the effectiveness of patents. Also, the
use of international benchmarking to establish reimbursement prices in some
countries may reduce the scope for differentiating prices across countries.
It is difficult to arrive at a definitive assessment of the net effect of various factors
on international pharmaceutical price differences. There are so many government
interventions in the pharmaceutical industry that it is hard to predict whether prices
for patented new innovative and me-too pharmaceuticals will be higher or lower in
Australia.
Provided barriers to trade are low, it might be expected that manufacturer prices for
generic pharmaceuticals in Australia will be comparable to those in other countries.
However, countries may impose different regulatory requirements on suppliers of38 PHARMACEUTICAL
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pharmaceuticals that affect production costs and/or competition between suppliers
of generics.
The terms of reference require that the study includes a group of countries with
similar and dissimilar subsidy arrangements.
The US, Canada and to some extent the UK are most dissimilar to Australia in
terms of their subsidy and cost-containment arrangements. The US and Canada are
quite different to Australia due to the limited coverage of their public subsidy
arrangements. While Australia and the UK both offer pharmaceutical subsidies to
all citizens, the UK is dissimilar because it allows relatively free pricing of
subsidised pharmaceuticals.
Many other OECD countries are similar to Australia in that the public sector
provides universal pharmaceutical subsidies, and a variety of cost containment
mechanisms are used to influence pharmaceutical prices and quantities. However,
there are many differences between these countries in terms of the types of
mechanisms used and the level of pressure applied to prices by governments.INTERNATIONAL
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3 International price comparisons
The principal purpose of this study is to estimate, for a group of countries,
differences in the prices received by manufacturers for pharmaceutical products
listed on the Pharmaceutical Benefits Scheme (PBS).
This chapter reports the results of a comparison of Australian manufacturer prices
with the prices of the same items in seven other countries. The comparison
countries are Canada, France, New Zealand (NZ), Spain, the United Kingdom (UK)
and the United States (US).
Before examining the results in detail, the next section identifies the key features of
the methodology used to undertake the price comparisons. Sections  3.2 and 3.3
report the results of the price comparisons using the categories defined in the terms
of reference, and using therapeutic groups respectively. The sensitivity of the price
comparisons to key aspects of the methodology is discussed in section  3.4. The
findings are then summarised in section 3.5.
3.1 Methodology
In comparing the prices of PBS-listed items with those in overseas countries, a
number of methodological issues need to be addressed. Factors that influence the
development and interpretation of price comparisons include:
•   choosing the basket of pharmaceuticals for comparison;
•   choosing pharmaceuticals in the basket;
•   matching pharmaceuticals;
•   choosing countries;
•   prices used;
•   converting prices to a common currency; and
•   weighting manufacturer prices.
The following sections briefly discuss each issue and the approach adopted. A more
detailed discussion of the issues and methodology is contained in appendix C.40 PHARMACEUTICAL
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Choosing the basket of pharmaceuticals for comparison
The terms of reference require that the study examine price differentials for items
listed on Australia’s PBS. A broader study of pharmaceutical prices in Australia
would encompass non-PBS pharmaceuticals in the comparison. This could allow for
inferences to be drawn on the impact of the PBS on prices for PBS-listed items and
the broader pharmaceutical market.
However, cost and time constraints precluded a broader study. Instead, the
comparison is limited to prices for a sample of PBS-listed pharmaceuticals. In doing
so, conclusions cannot be drawn about the impact of the PBS on Australia’s overall
pharmaceutical market. Inferences can only be drawn about those pharmaceuticals
listed on the PBS and included in the study.
Choosing pharmaceuticals in the basket
There are approximately 820 molecules listed on the PBS. Each of these molecules
is available in a number of different forms (dosage type, strength and pack size).
The practicalities of data availability preclude including all these pharmaceuticals in
the price comparison. Hence, it was necessary to identify a sample of PBS-listed
items for comparison.
Examination of PBS expenditure data shows that a small number of molecules
accounts for a large share of total expenditure under the scheme1 (appendix C). As
such, the top 150  PBS-listed molecules (ranked by total expenditure during
1999-2000) were selected for the price comparisons.2 These molecules account for
84 per cent of total expenditure under the PBS.
In taking this approach, firm conclusions cannot be drawn about the general level of
prices for PBS-listed pharmaceuticals between Australia and the comparison
countries. This is because the sample of pharmaceuticals may not be representative
of the entire PBS market. Instead, inferences can only be drawn for those
pharmaceuticals selected.
The terms of reference require that the basket of PBS pharmaceuticals examined
includes three categories:
                                             
1 Total expenditure is defined as the sum of patient and government contributions.
2 The composition of the top 150 PBS-listed molecules ranked by total expenditure in 2000-01 is
likely to have changed since 1999-2000 with the listing of new molecules. Changes in the




•   new innovative (that is, chemical entities for which there is no reasonable
alternative and also those with efficacy, quality of life and/or safety
improvements, including better modes of delivery of active ingredients);
•   me-toos (that is, chemical entities for which therapeutic alternatives are
available);3 and
•   generics (that is, chemically equivalent items, including the originator brand).
The terms of reference also specify that there be at least ten major forms in each of
these categories.
The top 150 molecules included in the price comparison were categorised by the
Department of Health and Aged Care (DHAC). The molecules are listed in
appendix  D. The me-too and generic categories account for the majority of
molecules and around 90 per cent of expenditure on the 150 top-selling PBS-listed
molecules (table  3.1). To ensure an adequate sample, some molecules listed
part-way through 1999-2000 were included in the new innovative category based on
their annualised expenditure.
Table 3.1 Molecules and expenditure share by pharmaceutical category,
Australia, 1999-2000
Category Molecules PBS expenditure
share
no. %





The molecules were classified into these categories as at 30 June 2000 (section 3.4).
Their current status may have changed reflecting the expiry of patents and/or the
launch of new alternative pharmaceuticals.
Matching pharmaceuticals
Pharmaceuticals are marketed to consumers in a wide variety of forms. Therefore,
the forms of a particular molecule can differ across countries by the dosage type
(for example, tablets, syrups and injections), by strength (the amount of active
                                             
3 Although most new innovative and me-too pharmaceuticals are on-patent, some items may be
off-patent but not subject to competition from generic versions. Information on the patent status
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ingredient) and by the pack size. In Australia, 584 different forms of the top 150
PBS-listed molecules were identified for 1999-2000.
The approach adopted by this study was to seek direct matches for each of the
584 forms of Australia’s 150 top-selling molecules in each comparison country (that
is, form matching). The form matching approach is designed to achieve meaningful
results through ensuring that, where possible, ‘like with like’ price comparisons are
undertaken. For instance, alternative approaches used in some previous studies have
directly compared prices associated with different delivery methods such as
injections, inhalers, tablets and syrups, despite possibly significant differences in
both the costs of producing these forms, and their clinical uses. Also, this study
compares prices at the level of individual packs rather than per tablet or other
measurement unit (appendix C). The relationship between prices and pack sizes is
determined by the interaction of demand and supply conditions in each market and
therefore may vary across countries. Comparing prices at the pack level avoids the
need to make simplifying assumptions about the relationship between prices and
pack sizes.
That said, the practicalities of matching many hundreds of forms necessitated
making some assumptions. While an attempt was made to match identical dosage
types, there often are many different forms within a particular dosage type. For
example, many types of tablets and capsules may be available in slightly different
forms, such as standard, slow-releasing or enteric-coated. In such cases, prices for
different forms within a given dosage type were considered comparable.
For some dosage types (for example, injections and inhalers), it was more difficult
to find direct matches in the comparison countries. As a result, there were relatively
fewer matches for these items than was achieved for tablets and capsules. The
ability to obtain direct matches for dosage types also was constrained by the
preference for different delivery methods in the comparison countries. For example,
suppositories tend to be more commonly used in some European countries than in
Australia.
In a number of instances, a direct match on the pack size available in Australia
could not be obtained for the overseas countries. Also, in some countries, there were
many manufacturers of the same form charging significantly different prices. When
overseas volume data were available, a weighted average price for that form of
pharmaceutical was calculated (section 3.2).
Higher and lower estimates of prices were reported when Australia’s pack size was
not available in the comparison country or there were multiple prices for the same
form without corresponding volume data in the comparison country. This avoidedINTERNATIONAL
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the need to make assumptions about the relationship between price and pack size or
to average the range of prices for the same form of a molecule.
Because only 18 forms could be matched across all comparison countries, the study
used a bilateral matching procedure. This approach achieves a much higher number
of matches, increasing the robustness of the price comparisons. It also means that
the sample for each pair-wise comparison is uniquely determined by the availability
of matched forms.
An important implication of using the bilateral (pair-wise) approach is that
conclusions about the prices of the top selling PBS-listed molecules cannot be
drawn across the comparison countries. For example, the price ratios for the US
relative to Australia and the UK relative to Australia cannot be used to draw
inferences about the level of pharmaceutical prices between the US and the UK.
This is because the sample for each pair-wise comparison is different, depending on
the ability to match pharmaceuticals. In addition, a comparison of, say, US and UK
prices using these results would be based on Australian consumption patterns,
which are likely to be very different to US and UK consumption patterns.
Choosing countries
The terms of reference state that the group of comparable countries to be considered
should include a sample of those that offer similar pharmaceutical subsidy
arrangements as Australia and those that adopt different arrangements.
The terms of reference do not specify how many countries should be included in the
study. The Commission decided to focus on a small group of countries, thereby
permitting a larger number of pharmaceuticals to be included in the study.
The group of comparable countries includes those middle and high income
countries with well-developed health care systems. Within this group, the factors
used to distinguish between countries which have similar and dissimilar subsidy
arrangements included:
•   whether public pharmaceutical subsidy or private insurance arrangements
dominate;
•   eligibility for public subsidies (for example, the proportion of the population
covered by the public subsidy scheme);
•   the level of public subsidy offered (in terms of the size of the subsidy list and the
level of patient copayment); and
•   cost-containment measures used by government and private insurers (especially
the degree of freedom that companies have to set prices).44 PHARMACEUTICAL
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As discussed in chapter 2, those countries that are most dissimilar to Australia are
the US, the UK and Canada. Amongst the large group of Organisation for Economic
Cooperation and Development (OECD) countries with similar subsidy
arrangements, the Commission decided to focus on Sweden, NZ, France and Spain.
These four countries differ from one another in the nature of the cost-containment
mechanisms used and in the stringency with which they are applied. Sweden
appears to be the least stringent of this group, possibly because it has a reasonably
large domestic pharmaceutical industry. It appears that NZ has the most stringent
approach to cost-containment, while France and Spain occupy an intermediate
position.
Prices used
The terms of reference specify that price comparisons should be made at the
ex-factory (manufacturer) level.
For all comparison countries except Sweden, manufacturer prices for
pharmaceuticals were obtained from IMS Health. For Sweden, manufacturer prices
were unavailable from IMS Health directly and therefore were obtained from the
National Social Insurance Board (the Riksförsäkringsverket, RFV).
IMS Health reports manufacturer prices for the relevant countries, which it says are
derived mostly from surveys of wholesalers (table 3.2). In some cases, manufacturer
prices are collected by the surveys while, in other cases, wholesale prices are
collected. In the latter case, manufacturer prices are estimated using a maximum or
average wholesale mark-up (varying from a maximum of 12.5 per cent in the UK to
an average of around five per cent in the US) (IMS Health, pers. comm., February
2001). Potentially, the use of maximum wholesale margins introduces a small
source of bias in the reported manufacturer prices since some wholesalers may
charge less than the maximum to some purchasers. The Commission was unable to
readily identify the prevalence of discounted wholesale margins.
The manufacturer prices obtained from IMS Health can be considered to be the
maximum potential prices received by manufacturers. They are usually obtained
from wholesale or manufacturer price lists (and are not actual invoice prices). InINTERNATIONAL
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some countries (such as the US), larger/institutional buyers obtain substantial
discounts off published list prices (section 3.2).4
Table 3.2 Description of IMS Health manufacturer price data
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a According to IMS Health, the retail channel accounts for 64 per cent of pharmaceutical sales in the US. The
principal retail outlets are: chain and independent pharmacies; mass merchandise stores; proprietary stores;
and foodstores with pharmacies. .. Not applicable.
Source: IMS Health (pers. comm., February 2001).
Government agencies in a number of countries publish the prices they pay for
pharmaceuticals. For example, in the US, the Federal Department of Veterans
Affairs maintains a catalogue of manufacturer pharmaceutical prices, known as the
Federal Supply Schedule (FSS). The prices negotiated under the FSS are intended to
equal or better the prices manufacturers charge their ‘most-favoured’ non-federal
customers under comparable terms and conditions (GAO 2000c). Hence, the FSS
provides an indication of prices obtained by larger/institutional buyers in the US.
                                             
4 Hospitals also may be able to obtain substantial discounts from manufacturers. However,
special factors may motivate the pricing of pharmaceuticals to hospitals. For example,
manufacturers may choose to subsidise hospital sales in order to encourage trainee doctors to
prescribe their products, or to get patients onto a particular treatment which they are then likely
to continue once they leave the hospital. Due to the special features of the hospital market and a
lack of hospital sales data in some of the comparison countries, hospital prices were excluded
from this study (appendix C).46 PHARMACEUTICAL
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Information on pharmaceutical pricing in the US indicates that FSS prices may not,
in fact, be the lowest price obtained by some buyers (appendix C).
Converting prices to a common currency
Price comparisons across countries require conversion of local currency prices into
a common currency. For this study, official exchange rates were used to convert
local currency prices into Australian dollars (table 3.3). This is because exchange
rates provide the most relevant information for examining the revenue and cost
implications for pharmaceutical companies and the Commonwealth Government
respectively, of pricing PBS-listed molecules at international, rather than
Australian, levels.
Table 3.3 Average exchange ratesa
$1A= US Canada UK Sweden France Spain NZ
June 2000 0.5941 0.8756 0.3929 5.1985 4.1062 104.0875 1.2615
a Each exchange rate is calculated as the average of the buying and selling rate for the month of June.  
Source: ABS (2000).
Official exchange rates also are one factor taken into consideration by the
Pharmaceutical Benefits Pricing Authority (PBPA) in reviewing the prices of
pharmaceuticals under the PBS.5
An alternative conversion procedure is to use purchasing power parities (PPPs).
These conversion factors are designed to reflect the purchasing power of a currency
within its national market. They serve two purposes — to convert one currency into
another (usually US dollars) and to adjust for differences in relative price levels
(taking into account traded and non-traded goods and services).
However, the decision not to use PPPs reflects the purpose of this study which is to
compare the prices that manufacturers receive for pharmaceuticals in Australia
under the PBS with those obtained overseas. Exchange rates are appropriate
conversion factors as they reflect the purchasing power of a national currency on
international markets for traded goods, such as pharmaceuticals. The use of PPPs
might be appropriate if the purpose were to assess the broader welfare implications
of price differences (such as whether consumers are better off under Australian or
overseas prices).
                                             
5 Consideration of official exchange rates occurs under ‘factor g’ in reviewing prices for existing
and new pharmaceuticals (PBPA 2000).INTERNATIONAL
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For the results presented in the following section, the exchange rates applied were
the average exchange rates for the month of June 2000. This month was chosen as it
is the closest average exchange rate to the time period over which the
pharmaceutical prices were collected. The sensitivity of the results to this exchange
rate assumption is explored in section 3.4.
Weighting manufacturer prices
The terms of reference require the Commission to calculate some form of weighted
average price. This is required to ensure that the results are not distorted by the
inclusion of forms which have a large price differential but account for a small
share of the market.
A number of weighting systems could be applied, including the volume of sales in
Australia and the number of PBS scripts (appendix  C). According to Pekarsky
(pers. comm., May 2001), the PBS script data understate actual volumes for some
pharmaceuticals because they do not include scripts priced below the patient
copayment and some items commonly dispensed through hospitals. Consequently,
if PBS scripts are used, the weights on these pharmaceuticals are likely to be biased
downward. The sales volume data also do not record items dispensed through
hospital pharmacies. Despite this limitation, these data are considered more
comprehensive than the PBS scripts data. As such, the results in the following
section are reported using the volume of Australian sales to weight prices. Results
with prices weighted by the number of PBS scripts can be found in appendix E. The
results differed little between the two systems.
The price comparisons are reported using a ratio of prices between Australia and
each comparison country. These ratios were calculated by dividing an overseas
revenue estimate by an estimate of Australian revenue for those forms that were
available in both Australia and the comparison country.6 The overseas revenue
estimate is derived by multiplying overseas prices for each matched form by the
corresponding Australian sales volumes. This yields an estimate of the revenue that
could have been obtained by pharmaceutical companies if they had sold their
Australian volumes at the overseas prices. Similarly, the Australian revenue
                                             















where  j i P,  = price of pharmaceutical  i in country  j;  A i P,  = price of pharmaceutical  i in
Australia; and  A i Q ,  = quantity of pharmaceutical i in Australia.48 PHARMACEUTICAL
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estimate is derived by multiplying Australian prices, for the same forms, by the
Australian sales volumes. The price ratio therefore provides an indication of how
the revenues of companies operating in Australia would change if they had been
able to achieve overseas prices (rather than Australian prices) on their Australian
sales.
However, the sales volumes also act as weights on the prices. For example, a high-
priced item may make a small contribution to the revenue estimates for Australia
and comparison countries if it has a low volume of sales in Australia. If the index is
greater than one, it indicates that Australian prices are, on average, below those in
the comparison country. Conversely, a value of less than one shows that Australian
prices are above those in the comparison country.
3.2 International price comparisons
In this section, the price comparisons with the seven overseas comparator countries
are presented. Initially, price comparisons are reported for all 150 PBS-listed
molecules and then for each of the three categories of pharmaceuticals: new
innovative; me-too; and generic. Prices paid by larger/institutional buyers are then
estimated for some of the comparison countries. Finally, this section examines
factors contributing to the large observed differences between the higher and lower
estimate of prices.
List price comparisons
The following results are based on ‘list’ prices, or the maximum prices received by
pharmaceutical companies. As noted above, a value greater than one indicates that
manufacturer prices for the matched forms in the comparison country are greater
than the prices of those items in Australia. Furthermore, the higher and lower
estimates of prices reflect differences in pack sizes and the existence of multiple
manufacturer prices for some matched forms.
In interpreting the price comparisons, it is worth reiterating some of the major
qualifications, namely that the conclusions:
•   are valid only for the top selling PBS-listed molecules in each category; and
•   cannot be used to compare price levels across the comparison countries, as
bilateral comparisons were undertaken.
In addition, the robustness of the results for the various categories is likely to be
positively related to the size of the sample and the level of matching. This means
that greater levels of confidence can be placed on the results for all categories thanINTERNATIONAL
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for the sub-categories. And, for any category, more confidence can be placed on the
price ratios which achieved a relatively high number of matches and coverage of
Australian revenue.7
The results cannot be used to predict the change in pharmaceutical company
revenue or government subsidies if the observed overseas prices were to prevail in
Australia. Any change in manufacturer prices in Australia would be likely to induce
corresponding changes in quantities demanded and supplied which may offset the
revenue and government subsidy effects of price changes.
All categories
Manufacturer prices in Australia for the 150 top-selling PBS-listed molecules are
low compared to all countries except NZ and Spain (table 3.4 and figure 3.1).
Table 3.4 Price ratios for all categories, list pricesa
Unit Aust US Canada UK Sweden France Spain NZ
Higher estimate ratio 1.00 3.48 1.81 1.64 1.57 1.17 1.02 0.98
Lower estimate ratio 1.00 2.62 1.51 1.48 1.48 1.12 0.96 0.92
No. of matches no. 584 273 242 326 187 176 204 266
Coverageb % 100 64 56 80 50 41 56 66
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. b Coverage shows the percentage of total Australian manufacturer revenue for the
150 molecules accounted for by the matched forms.
Source: PC estimates.
A very large price gap is observed for the US, where list prices are around
250  per  cent higher than those in Australia based on the higher estimate of
manufacturer prices, and still more than 160  per  cent higher based on the lower
estimate. Manufacturer prices in Canada, the UK, Sweden and France also are
greater than those in Australia (between 12 and 51 per cent based on lower
estimates).
Manufacturer prices in Spain and NZ are about the same, or slightly lower than
Australia’s.In the US, Canada, the UK and Sweden there is a marked difference
between the higher and lower estimates of prices. As discussed later in this section,
this is mainly due to large differences in the prices charged by the multiple
manufacturers of generic pharmaceuticals in these countries.
                                             
7 The results of statistical tests of the significance of price differences are reported below.50 PHARMACEUTICAL
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Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
The number of matched forms for each of the seven countries varied between a low
of 176 (France) to a high of 326 (UK). Except for France, matched forms accounted
for around half or more of Australian manufacturer revenue for the top  150
molecules.
In order to examine the robustness of these results, statistical tests were applied to
the unweighted price ratio series for each comparison country relative to Australia
(appendix E).8 The tests generally support the weighted price ratios reported in
table  3.4. They indicate that price differences with Australia are statistically
significant (at the one per cent level of significance) for all comparison countries
except NZ.
New innovative pharmaceuticals
New innovative pharmaceuticals are chemical entities for which there is no
reasonable alternative, as well as those with efficacy, quality of life and/or safety
improvements, including better modes of delivery of active ingredients.
                                             
8 Caution needs to be exercised in interpreting the results of statistical tests because of the
approach to sampling used by this study (appendix E).INTERNATIONAL
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As these pharmaceuticals possess significant additional benefits over alternative
treatments or are the only ones available to treat a particular disease, it could be
expected that manufacturers typically will have the ability to set different prices in
each country, reflecting differences in the price sensitivity of demand. However,
regulatory constraints, such as the use of international benchmarking to set prices,
may limit the ability of manufacturers to differentiate prices across countries
(chapter 2).
Compared to all categories, manufacturer prices in Australia for the top-selling new
innovative molecules are closer to those in the comparison countries (table 3.5 and
figure 3.2).
Table 3.5 Price ratios for new innovative pharmaceuticals, list pricesa
Unit Aust. US Canada UK Sweden France Spain NZ
Higher estimate Ratio 1.00 2.17 1.09 1.26 1.17 0.92 0.85 1.00
Lower estimate Ratio 1.00 2.04 1.09 1.25 1.10 0.92 0.85 1.00
No. of matches no. 79 37 29 39 39 24 19 27
Coverageb % 100 67 47 72 60 50 41 48
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. b Coverage shows the percentage of total Australian manufacturer revenue for
new innovative molecules accounted for by the matched forms.
Source: PC estimates.
The price gap for new innovative pharmaceuticals is still significant for the US,
where prices for matched forms are around double those in Australia. Prices in the
UK also are greater than in Australia, but the gap is less than for all categories.
Prices in Australia are close to those in Canada and Sweden, the same as those in
NZ, and just above those in France and Spain.
Compared to all categories, France moves from being slightly more expensive than
Australia to cheaper for new innovative pharmaceuticals. Prices in Spain also are
lower, at around 85 per cent of Australian prices.
In all comparison countries, the number of matched forms is nearly double that
required by the terms of reference (ten), and for the US, the UK and Sweden more
than 30 matches were achieved. That said, the matches obtained for Spain, NZ and
Canada were relatively low among the comparison countries and, in each case,
covered less than 50 per cent of Australian revenue.52 PHARMACEUTICAL
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Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
Statistical tests lend support to the weighted price ratios reported in table 3.5. The
tests indicate that price differences with Australia are significant for most
comparison countries (at the five per cent level of significance). For NZ and
Canada, the test results suggest that prices are statistically the same as prices in
Australia at the five and one per cent levels. In the case of France, prices were
found to be statistically the same as Australian prices at the one per cent level.
Based on the lower estimate, the weighted price ratios also show that prices in NZ,
France and Canada are closest to Australian prices for this category.
Me-too pharmaceuticals
Me-too pharmaceuticals are defined as chemical entities for which therapeutic
alternatives are available. It is difficult to arrive at in-principle predictions about
relative prices for these pharmaceuticals across countries. For instance, the level of
competition facing the same me-too pharmaceutical from therapeutic alternatives
may vary across countries. In addition, the same me-too pharmaceuticals may be
subject to differing regulatory constraints.INTERNATIONAL
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Manufacturer prices in Australia for the top selling me-too pharmaceuticals are
lower than those in all comparison countries except NZ, where prices are essentially
equal to Australia (table 3.6 and figure 3.3). For most countries (the US, Canada,
the UK and Sweden), prices are at least 57 per cent higher than those in Australia.
Australian prices are much closer to those in France, Spain and NZ.
Table 3.6 Price ratios for me-too pharmaceuticals, list pricesa
Unit Aust US Canada UK Sweden France Spain NZ
Higher estimate Ratio 1.00 2.99 1.71 1.64 1.65 1.18 1.08 1.01
Lower estimate Ratio 1.00 2.85 1.59 1.57 1.58 1.18 1.02 0.97
No. of matches no. 153 79 73 113 62 66 79 78
Coverageb % 100 64 76 92 55 47 66 75
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. b Coverage shows the percentage of total Australian manufacturer revenue for
me-too molecules accounted for by the matched forms.
Source: PC estimates.




















Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
As discussed later in this section, the available evidence indicates that actual
manufacturer prices are likely to be closer to the lower estimate of prices than the54 PHARMACEUTICAL
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higher estimate. On this basis, it appears that the greatest price gap with Australia
for each comparison country occurs for me-too pharmaceuticals.
For all countries except France, the matches accounted for more than 50 per cent of
Australian revenue for me-too pharmaceuticals. For five countries, the market
coverage equalled or exceeded 64 per cent.
The results of statistical tests align closely with the weighted price ratios in
table 3.6. The tests indicate that price differences with Australia are statistically
significant for all comparison countries (at the one per cent level of significance)
except for NZ and Spain. The weighted price ratios show that prices in NZ and
Spain are nearest to Australian prices for me-too pharmaceuticals.
Generic pharmaceuticals
Generic pharmaceuticals are defined as chemically equivalent items and in this
study include the originator brand. Studies for the US have found that as patents on
originator brands expire, generic copies have been able to capture a significant share
of the market at much lower prices (see, for example, CBO  1998). However,
manufacturers of originator brands may prefer to maintain higher prices when a
pharmaceutical’s patent protection has ended despite a reduction in market share, in
order to reinforce perceptions of higher quality. International trade in generics may
offer less scope for price differentiation than is possible for patented
pharmaceuticals (new innovative and me-too), and therefore may be expected to
result in smaller international price differences.
However, this expectation is not borne out by the results.
Manufacturer prices in Australia for the top selling PBS-listed generic
pharmaceuticals are lower than those in several countries (the US, Canada, the UK,
Sweden and France) but higher compared to Spain and NZ (table  3.7 and
figure 3.4).
The results indicate significant price differences between Australia and most
comparison countries. Based on the lower estimate, manufacturer prices in the US
are more than double Australian prices. Prices in Canada, the UK, Sweden and
France are higher by 10 to 51 per cent. Prices in Spain and NZ are less than those in




Table 3.7 Price ratios for generic pharmaceuticals, list pricesa
Unit Aust US Canada UK Sweden France Spain NZ
Higher estimate ratio 1.00 4.63 2.15 1.77 1.65 1.28 0.97 0.92
Lower estimate ratio 1.00 2.53 1.51 1.41 1.49 1.10 0.89 0.83
No. of matches no. 352 157 140 174 86 85 106 161
Coverageb % 100 62 56 67 41 29 48 62
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. b Coverage shows the percentage of total Australian manufacturer revenue for
generic molecules accounted for by the matched forms.
Source: PC estimates.
























Higher estimate Lower estimate
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Data source: PC estimates.
As noted earlier, the reliability of the price ratios depends in part on the number of
matches and the market coverage of matched pharmaceuticals. The number of
matches achieved for Sweden and France, and to some extent Spain, are relatively
low.9 But while the market coverage for Spain and Sweden was less than
                                             
9 The difficulty experienced in matching generics in Sweden, France and Spain may reflect the
relatively small market share of generics in these countries relative to countries such as the US
and the UK (appendix B).56 PHARMACEUTICAL
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50 per cent, in the case of France, the coverage was very low (only 29 per cent of
Australian revenue).
Statistical tests for this category indicate that price differences with Australia are
significant for most comparison countries. However, based on the lower estimate of
prices, the tests found that generic prices in NZ and France are not statistically
different from Australian prices (at the one and five per cent levels of significance),
even though the weighted price ratios for NZ and France show a 17 per cent and
ten per cent difference respectively.
Prices paid by larger/institutional buyers
As discussed in section 3.1, the manufacturer prices obtained from IMS Health can
be considered to be the maximum potential prices received by manufacturers.
However, in some countries (such as the US), larger/institutional buyers are able to
obtain discounts off these published list prices. In order to assess the significance of
discounts for the price comparisons using IMS Health data, information was sought
on the prevalence of discounting in Australia and the comparator countries.
In discussions with pharmaceutical companies, it was stated that discounting by
manufacturers does occur in Australia. Discounts (usually in the form of free stock)
are offered by some manufacturers to pharmacists in order to encourage them to
stock and dispense generic pharmaceuticals. Such manufacturer discounts usually
are available only on direct sales of generic pharmaceuticals to pharmacists.
As the manufacturer prices for Australia do not account for these discounts, there is
likely to be some upward bias in the Australian manufacturer prices. However,
since most pharmaceuticals are distributed through wholesalers in Australia, the net
impact of failing to account for discounts on companies’ direct sales to pharmacists
is likely to be minimal.10
Evidence indicates that larger/institutional buyers in the US can negotiate
substantial discounts off IMS Health list prices for Australia’s top selling PBS-listed
molecules (table 3.8). For all categories, the estimated discount using FSS prices is
around 24  per  cent based on the higher estimate of prices and even greater at
31 per cent based on the lower estimate (appendix E).
                                             
10 According to IMS Health (pers. comm., April 2001), direct sales from manufacturers to retail
pharmacies account for only three per cent (by value) of their total sales. Around 86 per cent of
manufacturers’ sales are to wholesalers. The remainder are to hospitals (nine per cent) and
governments and others (two per cent).INTERNATIONAL
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However, the level of discounts varies considerably across categories. The largest
discounts occur for me-too pharmaceuticals, at between 34 to 39  per  cent. In
contrast, for new innovative pharmaceuticals, estimated discounts are only around
three to six per cent.
Table 3.8 Estimated discounts for larger/institutional buyers in the US
Higher estimate Lower estimate




All 2.49 24 1.84 31
New innovative 1.94 6 1.86 3
Me-too 1.94 34 1.70 39
Generics 4.00 14 2.08 24
Source: PC estimates.
The use of FSS prices provides a more accurate indication of the price differences
between Australia and the US than the IMS list prices. However, FSS prices are
likely to provide a conservative estimate of the discounts available in the US. The
General Accounting Office (GAO 1997, 2000a) noted that FSS prices may not be
the lowest available in the US market (appendix C). For instance, buyers such as
Health Maintenance Organisations (HMO) may be able to negotiate larger discounts
due to their ability to shift volumes towards lower-priced pharmaceuticals.
However, as information on HMO prices is confidential, the FSS is currently the
best source of public information on discounts in the US. If HMO discounts were
taken into account, it is likely that the price differences would be further narrowed
but not eliminated entirely.
The Commission also received qualitative information on discounts from the
pharmaceutical industry in Canada and Sweden.
Canada’s Research-based Pharmaceutical Companies11 (Rx&D, pers.  comm.,
11 April 2001) considers that some discounting of prescription products does occur
in the form of offers of free goods to pharmacists but that the practice is confined to
generic companies. Rx&D considered that any offers of discounts to selected
customers on patented pharmaceuticals would likely lead to complaints to the
Patented Medicines Prices Review Board (PMPRB) which has the power to
investigate instances of excessive pricing (appendix  B). As a result, discounting
practices are deterred by the possible intervention of the federal regulator.
                                             
11 Canada’s Research-based Pharmaceutical Companies (Rx&D) is the national industry
association representing research-based pharmaceutical companies in Canada. It was previously
known as the Pharmaceutical Manufacturers Association of Canada.58 PHARMACEUTICAL
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The Swedish Association of the Pharmaceutical Industry (LIF) also indicated that
there are no significant discounts for pharmaceuticals in Sweden (LIF, pers. comm.,
3 March 2001). This view is supported by the Swedish National Social Insurance
Board which noted that, while discounts could be negotiated for reimbursed
products, the pharmaceutical companies rarely accept discounts (RFV 2000b).
There is some evidence that significant discounts may be available in the UK
market. For instance, a discount inquiry conducted by the UK Department of Health
in 1998 examined the difference between reimbursement prices and prices paid by
pharmacists for generic pharmaceuticals. The inquiry suggested a discount of over
eight per cent for branded (originator) off-patent molecules and around 24 per cent
for generic molecules (UK Department of Health, pers. comm., 28 February 2001).
The Commission was unable to obtain information on discounts in the UK market
for June 2000. However, the evidence from the earlier discount inquiry for generic
pharmaceuticals suggests that actual prices for some pharmaceuticals in the UK
may be well below those reported by IMS Health.
The Commission was unable to obtain information on the availability of discounts
in France, Spain and NZ.
Difference between higher and lower price estimates
As discussed in the previous section, higher and lower estimates of prices were
reported due to the issues of different pack sizes and multiple manufacturer prices.
The difference between the higher and lower estimates of prices (price range) tends
to be greater for those countries with the largest price gap with Australia (tables 3.4
and 3.7). Based on the results for all categories of pharmaceuticals, the US has both
the largest price ratio (3.48) and the greatest price range (25 per cent). In France,
where prices for all categories are some 12 to 17 per cent higher than Australia, the
price range is around four per cent (table 3.9).
Table 3.9 Price range between higher and lower estimates, per centa 
Category US Canada UK Sweden France Spain NZ
A l l 2 5 1 79646 5
N e w  i n n o v a t i v e 610600 0
M e - t o o 574406 4
Generics 45 30 21 10 15 8 10
a The price range is measured as the difference between the higher and lower estimates, expressed as a




In all seven countries, generic pharmaceuticals account for the largest share of the
price range observed for all categories of pharmaceuticals. For new innovative
pharmaceuticals, there is a price range of six per cent or less. In contrast, the price
range for generics in the US, Canada and the UK varies from 21 to 45 per cent.
For the US, Canada and the UK, somewhere between 40 and over 80 per cent of the
price range is explained by the availability of multiple manufacturer prices for the
same form (appendix E). The contribution of multiple manufacturer prices to the
price range in the US, Canada and the UK highlights the variety of prices available
for generic pharmaceuticals in these countries. In a small number of instances, the
highest price for a generic pharmaceutical was more than ten times the price of the
cheapest.
In a number of cases, it was found that the highest-priced generic pharmaceutical is
more expensive for Australia while the lowest-priced is cheaper. Table 3.10 shows
that for those generic forms that were matched with the US (157 in total), prices in
the US were higher than those in Australia for 147 forms, and ten were lower, based
on the higher estimate of prices. But for the lower estimate of price comparisons, it
was found that US prices were higher than Australia’s for 99 forms, whereas for
58 forms, US prices were actually below Australia’s.
Table 3.10 Higher and lower prices for generic pharmaceuticals
US Canada UK
no. no. no.
Prices higher than Australia
  Higher estimate 147 113 133
  Lower estimate 99 84 109
Prices lower than Australia
  Higher estimate 10 27 41
  Lower estimate 58 56 65
Source: PC estimates.
If overseas volume information were available in instances where the Commission
found multiple manufacturer prices in the comparison country, it would be possible
to provide more precise estimates of price comparisons. This is because the
overseas volume information could be used to calculate a weighted average price.
Overseas volume information was obtained for a sample of pharmaceuticals and
used to assess whether the actual price gap is likely to be closer to the lower range
of prices than to the higher estimate (box  3.1). Based on a small sample of
pharmaceuticals, the evidence suggests that the higher-priced forms of generics
capture only a small share of the market in the US, Canada and the UK. In turn, this60 PHARMACEUTICAL
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suggests that the average prices paid by buyers (and hence average revenue to
companies) in these countries are likely to be closer to the lower estimates.
Box 3.1 Highest and lowest prices for generics in the US, Canada and
the UK
Many of the generic pharmaceuticals in the US, Canada and the UK are characterised
by a wide variety of manufacturers and prices. The Commission obtained overseas
volume data from IMS Health for some of the generic molecules included in the price
comparisons. When possible, volume data were used to weight the range of prices.
These provide a more accurate measure of the average prices that companies receive.
To examine the issue of where actual prices lie within each range, higher and lower
estimates of prices were calculated for those forms for which prices were weighted by
volume data (see table).









US 8 3.81 1.93 2.19
Canada 7 3.93 1.47 1.82
UK 12 3.36 1.80 2.16
Based on this small sample, the actual prices and revenues received by manufacturers
are likely to be closer to the lower estimate of prices than the higher estimate. For
example, in Canada, the volume weighted price ratio of 1.82 is 24 per cent greater
than the lower estimate of prices and 54 per cent below the higher estimate.
Source: PC estimates.
3.3 Price comparisons by therapeutic group
All pharmaceuticals are classified under an internationally recognised system of
Anatomical Therapeutic Chemical (ATC) codes (box  3.2). The ATC system
provides a method of grouping certain pharmaceutical products according to criteria
such as anatomical site of action, indications, therapeutic use, chemical composition
and mode of action.
Each matching form of Australia’s 150 top-selling PBS items can be allocated to its
anatomical site of action (hereafter ATC group) and price comparisons undertaken.
The results assist in identifying which types of pharmaceuticals account for the
observed price differences reported in section 3.2.INTERNATIONAL
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Box 3.2 Anatomical classifications
The major ATC groups identified by their anatomical site of action (with examples of
their therapeutic uses) are:
•   alimentary tract and metabolism (digestive system disorders, ulcers and diabetes);
•   antineoplastic and immunomodulating agents (various cancers, leukemia and
multiple sclerosis);
•   blood and blood forming organs (blood clots, angina, and stroke and heart attack
prevention);
•   cardiovascular system (heart disease and hypertension);
•   dermatologicals (anti-fungals, psoriasis, treatment of burns, dermatosis and severe
acne);
•   general anti-infectives for systemic use (bronchitis, bacterial infections, tuberculosis,
AIDS, sexually transmitted diseases and influenza vaccine);
•   genito urinary system and sex organs (pituitary and testicular disorders, menopause
and infertility);
•   musculo-skeletal system (arthritis and osteoarthritis);
•   nervous system (pain relief, migraine, epilepsy, mental disease and depression);
•   respiratory system (asthma and pulmonary disease);
•   sensory organs (eye infections and glaucoma);
•   systemic hormonal preparations, excluding sex hormones (various pituitary and
thyroid disorders, and endometriosis); and
•   various (includes drug dependence, diagnostic tests and lactose intolerance).
Source: DHAC (2000).
For each ATC group, table 3.11 shows whether Australian manufacturer prices for
the top-selling PBS-listed pharmaceuticals are higher or lower than those in the
comparison countries.12 The table also shows the results for all categories (from
table 3.4) to enable comparisons across ATC groups for each comparison country.
Differences in manufacturer prices between Australia and each of the comparison
countries can vary significantly, depending on the ATC grouping of the matched
pharmaceuticals (table  3.11).13 For example, based on the lower estimates for
Canada, price differences for different ATC groups ranged from 0.5 (for systemic
                                             
12 The results cannot be used to draw conclusions about differences in manufacturer prices for all
pharmaceuticals in an ATC group because the sample of items used may not be representative
of the entire PBS market for that group.
13 The full results showing higher estimates are contained in appendix E (table E.38).62 PHARMACEUTICAL
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hormonal preparations) to 2.0 (for items in the respiratory system group). Prices in
Sweden, the UK and the US were the same or higher than Australian prices for all
ATC groups. Other countries have a mix of higher and lower priced ATC groups.
Table 3.11 Price ratios for ATC groups, list prices, lower estimatesa
ATC group US Canada UK Sweden France Spain NZ
All categories (from table 3.4) 2.6 1.5 1.5 1.5 1.1 1.0 0.9
Alimentary tract and metabolism 3.7 1.6 1.7 1.9 1.3 1.1 0.7
Antineoplastic and
immunomodulating agents
1.5 1.0 1.0 1.0 0.8 0.5 0.7
Blood and blood forming organs 1.8 1.4 1.1 1.2 1.2 1.0 1.4
Cardiovascular system 2.5 1.6 1.5 1.3 1.2 1.0 0.9
Dermatologicals 4.0 1.5 1.0 1.0 0.9 0.7 0.7
General anti-infectives for systemic
use
2.0 0.9 1.4 1.3 1.0 0.8 0.9
Genito urinary system and sex
organs
4.2 1.3 1.5 1.4 0.9 1.0 1.4
Musculo-skeletal system 2.1 1.6 1.6 1.9 1.0 0.8 0.8
Nervous system 2.3 1.3 1.4 1.4 1.0 1.1 1.2
Respiratory system 4.1 2.0 1.7 2.8 1.4 1.1 1.2
Sensory organs 1.8 1.1 1.2 1.1 0.8 0.7 0.9
Systemic hormonal preparations,
excluding sex hormones
2.4 0.5 1.0 1.0 0.8 0.5 0.7
Various 1.4 1.4 2.2 nm 1.2 0.4 1.3
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. Figures in this table are based on lower estimates of prices. The price ratios
reported with a value greater (lower) than one indicates that manufacturer prices for the matched forms in the
comparison country are greater (lower) than the prices of those in Australia. nm No matches were identified in
this category.
Source: PC estimates.
It also is possible to estimate the contribution of particular ATC groups to the
overall results reported in section 3.2. Table 3.12 shows the percentage contributionINTERNATIONAL
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that pharmaceuticals in specific ATC groups make to the overall results for each
comparison country.14
Table 3.12 Contributors to price gap with Australia, ATC groups, lower
estimatesa
ATC group US Canada UK Sweden France Spain NZ
%%%%%%%
All categories (from table 3.4) 162.3 50.7 48.1 47.7 11.9 -3.6 -7.6
Alimentary tract and metabolism 44.4 8.6 12.2 16.3 4.7 1.4 -4.7
Antineoplastic and
immunomodulating agents
2.6 -0.1 0.2 0.3 -1.8 -2.3 -1.5
Blood and blood forming organs 0.9 1.4 0.2 0.9 0.2 0.0 0.1
Cardiovascular system 59.7 24.0 19.3 12.8 7.8 -1.5 -4.3
Dermatologicals 7.4 0.5 0.1 0.0 -0.1 -0.5 -0.5
General anti-infectives for
systemic use
8.0 -1.0 2.6 2.1 0.2 -1.3 -0.7
Genito urinary system and sex
organs
6.0 0.4 0.4 0.6 -0.1 0.0 0.3
Musculo-skeletal system 4.0 2.5 2.1 2.6 0.0 -0.6 -0.6
Nervous system 22.9 3.2 6.2 6.1 -0.4 1.4 3.0
Respiratory system 4.2 10.7 4.0 5.9 2.0 0.6 1.4
Sensory organs 1.6 0.1 0.2 0.2 -0.5 -0.5 -0.2
Systemic hormonal preparations,
excluding sex hormones
0.4 -0.1 0.0 0.0 -0.2 -0.1 0.0
Various 0.3 0.4 0.7 0.0 0.2 -0.3 0.2
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. Figures in this table are based on lower estimates of prices. A positive (negative)
value indicates that the relevant group of pharmaceuticals made a positive (negative) contribution to price
differences; that is, Australian prices were lower (higher) than those in the comparison country.
Source: PC estimates.
                                             
14 The contribution of an ATC group is equal to the share of price differences for that particular























where:  Oij P  = price of pharmaceutical i, within ATC group j, in the comparator country;
Aij P  = price of pharmaceutical i, within ATC group j, in Australia; and  Aij Q  = quantity of
pharmaceutical i, within ATC group j, in Australia.64 PHARMACEUTICAL
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Positive (negative) figures within table 3.12 indicate the relevant ATC group made
a positive (negative) contribution to aggregate price differences — that is,
Australian prices were lower (higher) than those in the comparison country. For
instance, table 3.12 shows that prices in the US for all categories (based on the
lower estimate) were about 162 per cent above Australian prices. Three ATC groups
accounted for a large share of this difference. One group (cardiovascular system)
accounted for around 60 percentage points (or 37 per cent) of the overall difference.
From these results, it appears that a relatively small number of ATC groups have a
large influence on the overall results (driven by both their large share of Australian
expenditure and the size of observed price differences). Four ATC groups
accounted for over 70  per  cent of the total expenditure on Australia’s
150 top-selling PBS molecules. These influential ATC groups are:
•   cardiovascular (which accounted for 34 per cent of Australian expenditure);
•   alimentary tract and metabolism (14 per cent of Australian expenditure);
•   nervous system (15 per cent of Australian expenditure); and
•   respiratory system (nine per cent of Australian expenditure) (appendix E).
Australian manufacturer prices for these four groups were found to be below those
in the comparison countries in nearly all cases. The exceptions are for
cardiovascular items (Spain and NZ), alimentary tract and metabolism items (NZ),
and nervous system pharmaceuticals (France).
In most cases, the results for cardiovascular pharmaceuticals seem to have the
largest effect on the results for all categories. Moreover, Australian manufacturer
prices for this group appear to be well below those for all countries, with the
exception of Spain and NZ (table 3.11).
It is possible to examine the contribution that different categories of
pharmaceuticals make to the estimated price differences for the four key ATC
groupings.
The contribution of different pharmaceutical categories to the aggregate price
differences for each of the four influential ATC groups is shown in table 3.13. As
noted earlier, cardiovascular system pharmaceuticals accounted for around
60 percentage points of the overall price difference for the US. The table shows that




Table 3.13 Contributors to price gap with Australia, influential ATC groups,
lower estimatesa
ATC group US Canada UK Sweden France Spain NZ
%% %% % % %
Generics 7.8 6.9 2.8 1.8 -0.6 -0.7 -0.9
Me-too 51.8 17.2 16.5 11.1 8.5 -0.7 -3.4
New nm nm 0.0 nm -0.1 nm nm
Cardiovascular
system
  All 59.7 24.0 19.3 12.8 7.8 -1.5 -4.3
Generics 27.5 6.1 6.0 8.4 3.8 1.9 -3.3
Me-too 13.7 2.4 5.2 7.3 0.9 -0.4 -1.5
New 3.2 0.1 1.0 0.5 0.0 -0.1 0.0
Alimentary tract and
metabolism
  All 44.4 8.6 12.2 16.3 4.7 1.4 -4.7
Nervous system Generics 3.7 -0.4 0.0 0.6 0.0 -0.8 -0.3
Me-too 14.0 2.7 4.7 5.8 0.4 2.9 3.1
New 5.2 0.9 1.5 -0.3 -0.9 -0.7 0.3
  All 22.9 3.2 6.2 6.1 -0.4 1.4 3.0
Respiratory system Generics 0.1 3.5 0.2 0.5 0.8 -0.3 0.1
Me-too 4.1 7.3 3.8 5.4 1.2 0.9 1.3
New nm nm nm nm nm nm nm
  All 4.2 10.7 4.0 5.9 2.0 0.6 1.4
a  As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn. Figures in this table are based on lower estimates of prices. A positive (negative)
value indicates that the relevant group of pharmaceuticals made a positive (negative) contribution to price
differences (that is, Australian prices were lower (higher) than those in the comparison country). nm No
matches were identified in this category.
Source: PC estimates.
The general pattern emerging from these results is that price differences for me-too
pharmaceuticals in the cardiovascular, nervous and respiratory systems account for
the largest share of the observed price differences with Australia for most
comparison countries.
For the cardiovascular group, me-too pharmaceuticals account for the largest share
of price differences between Australia and all comparison countries, with the
exception of Spain. This reflects the large share of me-too cardiovascular
pharmaceuticals in total Australian expenditure on the top 150 molecules (around66 PHARMACEUTICAL
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27 per cent). Generic pharmaceuticals also make a significant contribution to the
comparisons for the US and Canada.
The contribution of me-too pharmaceuticals also outweighs that of other categories
for pharmaceuticals acting on the nervous system (except for France) and the
respiratory system.
Generic pharmaceuticals make the largest contribution to the results for alimentary
tract and metabolism pharmaceuticals (with a significant contribution from me-too
pharmaceuticals in Sweden, the UK and the US).
The influence of new innovative pharmaceuticals is low overall, reflecting their
relatively small share of total expenditure in Australia. However, the contribution of
new innovative pharmaceuticals is most pronounced for pharmaceuticals acting on
the nervous system.
3.4 Sensitivity of results
The number of methodological choices associated with pharmaceutical price
comparisons means that a wide variety of results (and interpretations) can be
obtained depending on the approach taken to each issue. The methodological
choices made in this study were guided by the purpose of the study, the
requirements of the terms of reference, and data and time limitations.
However, two areas where different values could be used for a given
methodological issue are the choice of exchange rate and classification of
molecules, as discussed below.
Exchange rates
Due to fluctuations in exchange rates through time, the price ratios could be
sensitive to the choice of time period over which the exchange rate is obtained.
In response to the preliminary results, the Commission received a number of
comments regarding the choice of exchange rate period. One respondent asked
whether fluctuations in exchange rates over time had influenced the price
comparisons. Another respondent contended that the use of recent point estimates of
exchange rates was not appropriate, arguing that the relevant exchange rates were
those which applied when listing decisions were made.
Apart from the logistical difficulties in matching exchange rates that applied when
listing decisions were made, the purpose of the study is to compare the prices thatINTERNATIONAL
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manufacturers receive at a particular point in time. Given this purpose, it is
appropriate to use an average exchange rate for the month of June 2000 to estimate
the price ratios reported in section 3.2 because they closely matched the time period
over which the pharmaceutical prices were collected.
To assess the sensitivity of the results, the price ratios for all categories were
recalculated using a number of different exchange rate periods (table 3.14). This
analysis showed that, while the variation in price ratios increased as the exchange
rate period was lengthened, the choice of exchange rate period did not significantly
affect the price comparison results. This is because the average exchange rates for
different periods were relatively stable over the 24 months to June 2000.
Table 3.14 Sensitivity of price ratios to different exchange ratesa
Time period US Canada UK Sweden France Spain NZ
%%%%%%%
30 June 2000 -1.4 -1.7 -0.8 -2.3 -1.1 -1.2 -1.6
Three months to June 2000 0.6 0.5 2.2 -0.4 -0.9 -1.0 2.6
1999-2000 -5.6 -5.3 -0.4 -2.9 -0.4 -0.4 1.1
1998-99 to 1999-2000 -5.3 -6.2 1.4 -0.2 5.2 5.2 3.9
a A negative (positive) value indicates that the price ratio would decrease (increase) by that percentage if that
exchange rate was used instead of the average for June 2000.
Source: PC estimates.
Using the average exchange rate for the three months to June  2000 and as at
30 June 2000, prices in all countries differ by less than three per cent.
Applying the average exchange rate for 1999-2000, prices differ by less than
three per cent in the UK, Sweden, France, Spain and NZ compared to the average
exchange rate for June  2000. In the US and Canada, prices were around five to
six per cent lower with the average exchange rate for the 1999-2000 financial year.
This reflects the general depreciation of the Australian dollar against these
currencies during 1999-2000.
Using the average exchange rate over the years 1998-99 and 1999-2000, prices in
Canada and the US were about five to six per cent lower whereas prices in France,
Spain and NZ were around four  to five  per  cent higher. While the use of this
exchange rate period reduces the price differences between Australia and the North
American countries, the price differences remain significant for all categories. For
Spain and NZ, there were some reversals in relative price levels with Australia, but
these changes were small. For example, in the case of Spain, the price ratio for all
categories (lower estimate) is 1.01 using this exchange rate period compared with
0.96 using the exchange rate for June 2000.68 PHARMACEUTICAL
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Classification of molecules
The Commission sought the assistance of DHAC to classify the 150 molecules
included in the price comparisons. The molecules were classified according to their
status as at 30 June 2000. Their status since June 2000 may have changed as new
molecules may have been listed or as patents have expired.
The price comparisons for all categories would not be altered if molecules were
transferred between the three sub-categories. However, given that the price ratios
within each country differed across the sub-categories, the results obtained for each
country could be sensitive to the classification of individual molecules at the
sub-category level.
Several participants at the round-table disagreed with the categorisation of some
molecules used in the preliminary price comparisons. According to one participant,
many patented molecules in the me-too category could have been included in the
new innovative category. Conversely, another participant argued that a molecule in
the new innovative category should have been classified as a me-too
pharmaceutical.
It should be noted that the terms of reference set out the definitions of
pharmaceuticals to be used in this study. DHAC categorised the 150 molecules
according to these definitions which are consistent with those used under PBS
pricing arrangements; that is, the categories (new innovative, me-too and generic)
also are used for price-setting purposes.
In response to specific comments and as part of the data validation process, the
classification of the 150 molecules was re-examined by the Commission with the
assistance of DHAC. This resulted in four molecules being reclassified (table 3.15).
The final classification is contained in appendix D.
Table 3.15 Reclassified molecules
Molecule Preliminary category Final category
Calcitriol New innovative Generic
Interferon beta–1b New innovative Me-too
Leuprorelin acetate New innovative Me-too
Salmeterol xinafoate New innovative Me-too
Source: DHAC (pers. comm., 20 May 2001).
The price ratios were recalculated using the final classification. Compared to the
preliminary results, the reclassification had no effect on the price ratios for all
categories. There were only minor changes in the price ratios for the me-too andINTERNATIONAL
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generic categories. However, for some countries, the final results for new
innovative pharmaceuticals (table 3.5) differed significantly from the preliminary
results. While the final price ratios were lower for all comparison countries except
NZ, the changes were substantial for the US and Canada in particular.
3.5 Conclusion
This chapter has reported the results of a comparison of manufacturer prices in
Australia for 150 top-selling PBS-listed pharmaceuticals. The principal finding is
that manufacturer prices in Australia for these top-selling products are low
compared to those in the US, Canada, the UK and Sweden. Australian prices are
close to those in France, Spain and NZ.
Accounting for discounts has a significant impact on the size of the observed price
difference between Australia and the US. However, prices in Australia are still well
below those in the US when discounts are taken into account. Significant discounts
also may be available in the UK for generic items but there is insufficient
information to enable an assessment of the effect of discounts on the price
comparisons. There is no evidence of significant discounts being offered in Canada
and Sweden. Information on discounts in NZ, Spain and France is unavailable.
Prices in Australia for new innovative pharmaceuticals are much closer to those in
other countries. Although there is still a significant gap in new innovative prices for
the US and the UK, the gaps are less than for the other categories. Australian prices
for new innovative pharmaceuticals are close to those in Canada and Sweden, the
same as those in NZ, and above those in France and Spain.
The largest price differences were observed for me-too pharmaceuticals. Australian
prices are below those in all comparator countries, except for NZ on the lower
estimate of prices.
Significant price differences also were observed for generic pharmaceuticals.
Generic prices were found to be much higher than Australia for the US, Canada, the
UK and Sweden. Generic prices in Australia are close to those in France and
slightly above those in Spain and NZ.
Finally, an analysis of the price comparisons by therapeutic group shows that four
groups have a large influence on the overall results. These influential groups include
pharmaceuticals acting on the cardiovascular system, alimentary tract and
metabolism, the nervous system and the respiratory system. For these groups, me-
too pharmaceuticals account for a significant share of the observed price differences
between Australia and most comparison countries.REASONS FOR PRICE
DIFFERENCES
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4 Reasons for price differences
The primary purpose of this study is to estimate, for selected countries, differences
in the prices received by manufacturers for pharmaceuticals listed on the
Pharmaceutical Benefits Scheme (PBS) (chapter  3). The terms of reference also
require the Commission to identify, as far as possible, the reasons for any observed
differences.
A number of potential reasons for the observed price differences were identified at a
roundtable meeting of industry experts held to discuss the preliminary results. They
included inter-country differences in:
•   pharmaceutical subsidy arrangements;
•   cost-containment policies (especially the effects of price reviews, economic
evaluations and reference pricing); and
•   the speed of introduction of new pharmaceuticals to the market.
In addition, roundtable participants identified particular factors that may have
contributed to the results for the individual categories.
This chapter examines whether the factors identified by participants are likely to
have contributed to the reported results.
4.1 Subsidy arrangements
Some roundtable participants considered that differences in the pharmaceutical
subsidy arrangements prevailing in the comparison countries may have contributed
to the observed price differences. It was also considered that price differences may
depend on how subsidy arrangements are administered, including the willingness of
governments to exploit any bargaining power they possess.
Systemic differences in subsidy arrangements
Chapter  2 noted that countries can be classified by aspects of their subsidy
arrangements, including:72 PHARMACEUTICAL
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•   whether public pharmaceutical subsidy or private insurance arrangements
dominate; and
•   whether governments have a positive or negative subsidy list.
Based on these characteristics, Australia’s subsidy arrangements differ most from
those applying in the United States (US), Canada, and the United Kingdom (UK).
The results in chapter 3 showed that prices in these countries were significantly
higher than those in Australia.
In the US and Canada, private insurers cover pharmaceutical costs for a significant
proportion of the population. The coverage of government subsidy schemes is
generally limited to specific groups in society, such as the aged, people with
disabilities and the poor (appendix B). Reflecting this, the public sector share of
total pharmaceutical expenditure in the US and Canada (around 15 and 32 per cent
respectively) is the lowest amongst the comparison countries. In contrast, the public
sector accounts for around 53  per  cent of total pharmaceutical spending in
Australia.1
The lower population coverage of the government subsidy schemes and the
existence of multiple private insurers competing against each other may have
diluted the buying power of government agencies and private sector insurers.
However, many of the individual entities operating in the US and Canada are likely
to spend more on pharmaceuticals each year than the Australian Government spends
on the PBS. Also, competition among private insurers may strengthen incentives to
reduce pharmaceutical prices.
Significant price differences also were observed between Australia and the UK,
even though both provide universal subsidies. Whereas companies operating in
Australia apply for a listing on the PBS (a positive subsidy list), the UK
Government decides which products will not be eligible for subsidies (that is,
placed on a negative list). A positive subsidy list may provide governments with
somewhat more power in negotiating reimbursement prices, especially for me-too
pharmaceuticals (chapter 2).
Of the remaining comparison countries, Sweden had significantly higher prices than
Australia whereas prices in France, Spain and New Zealand (NZ) were broadly
similar. All four of these countries are similar to Australia in that they offer
universal subsidies covering a large number of products on positive subsidy lists.
The difficulties in finding associations between price differences and subsidy
arrangements suggest that the price differences reflect additional factors such as
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differences in demand conditions, the subsidy status of pharmaceuticals, volume
restrictions, delays due to marketing approval requirements, patent arrangements,
the level of competition amongst pharmaceuticals within therapeutic groups, and
production and marketing costs.
One further possibility is that the results reflect differences in the contribution of the
pharmaceutical industry to the economies of the comparison countries. For instance,
a possible argument is that Governments may be more sensitive to using their
negotiating power to lower prices for subsidised pharmaceuticals, when the
pharmaceutical industry is a relatively large contributor to the economy.
The evidence for this hypothesis is mixed. Prices were higher than in Australia in
four countries that are major producers and exporters of pharmaceuticals. In the US,
the UK, Sweden and France the pharmaceutical industry accounts for between 1.1
and 1.7 per cent of gross domestic product (GDP). The UK, France and Sweden
also are net exporters of pharmaceuticals (imports and exports are about equal in the
US) (appendix B).
Comparatively low prices were observed in Australia and NZ, whose
pharmaceutical industries are relatively small, accounting for around 0.6 per cent of
GDP in Australia and 0.4  per  cent of GDP in NZ. Like  Australia, NZ also is a
significant net importer (appendix B).
However, the high prices observed for Canada do not fit in with the view that the
largest price differences are observed in countries with the largest pharmaceutical
industries. Canada’s industry accounts for around 0.8 per cent of GDP.
In addition, while prices in Spain were about the same as Australia’s, it has a
relatively significant industry (accounting for 1.4 per cent of GDP) (appendix B).
However, the low prices in Spain may reflect the fact that it has only recognised
pharmaceutical patents since 1992. According to Kanavos (1999b), this has meant
that a large number of copy products exist on the Spanish pharmaceutical market,
which are significantly cheaper than the originator products.
Overall, it is difficult to find a clear association between the broad features of the
subsidy arrangements in the comparison countries and the price differences with
Australia.
Differences in the administration of subsidy arrangements
Some of the overall results may be due to differences in the way that subsidy
arrangements were applied to the pharmaceuticals in the sample. Specific factors
affecting the price comparisons may include differences in:74 PHARMACEUTICAL
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•   the level of subsidy; and
•   volume controls (such as restrictions on the subsidised uses of pharmaceuticals).
The following discussion therefore focuses on how inter-country differences in the
application of subsidy arrangements may influence the results.
Level of pharmaceutical subsidies
In principle, price differences for some matched pharmaceuticals may be due to
differences in the effective rate of subsidy. Suppliers may be more willing to accept
lower prices in exchange for obtaining subsidy status, depending upon the rate of
subsidy (chapter 2).
As all comparison countries require consumers to make a contribution (copayment)
towards the cost of subsidised pharmaceuticals, the effective subsidy rate depends,
in part, on the level and type of copayment. There are significant differences across
the comparison countries in the type of copayment system and levels of copayment
for matched pharmaceuticals.2 Some of the comparison countries have proportional
copayment systems (France, Sweden and Spain), while others have a fixed
copayment system (Australia, the UK and NZ).3
Statistics on the private contributions to expenditure on pharmaceuticals do not
distinguish between private expenditure by patients or by third-parties (such as
private insurers). Nevertheless, this information shows considerable variation across
countries in the proportion of expenditure funded by governments (table 2.1).
Ideally, comparisons of effective subsidy rates would occur for individual
pharmaceuticals. While subsidy information for all of the pharmaceuticals in the
sample was unavailable, there is some evidence that subsidy levels do differ across
the comparison countries. For example, in Australia, the Government pays around
75 per cent of the total cost of ranitidine.4 In comparison, governments in France
and Spain pay 65 and 60 per cent of the total cost respectively.
                                             
2 Comparisons of subsidy levels are further complicated by the safety net arrangements that exist
in most comparison countries. These may involve annual limits on the out of pocket
expenditure on pharmaceuticals or provide for reduced copayments when a certain level of
annual expenditure is exceeded.
3 A mixture of proportional and fixed copayment systems are used in the US and Canada.
4 The subsidy rate was calculated by dividing the total cost to the Government of subsidies for
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Due to the lack of information on subsidy rates for the pharmaceuticals in the
sample, it is not possible to assess the contribution of this factor to the results.
Volume controls
Roundtable participants considered that Australia’s use of volume controls for items
listed on the PBS should be taken into account when interpreting the results.
Volume controls include restrictions on indications (the circumstances in which
subsidised pharmaceuticals may be used), requirements on physicians to seek
authorisation prior to prescribing a medicine, and price-volume agreements).5
In principle, volume controls affect the level of sales and hence manufacturer
revenues, giving rise to a trade-off between the prices and use of volume controls. If
governments consider that the subsidy cost of a pharmaceutical is excessive, at the
price offered by the supplier, they may attempt to reduce the budgetary cost by
imposing volume restrictions (chapter 2).
However, it is difficult to predict how volume controls placed on pharmaceuticals
will affect manufacturer prices, as this may depend on the characteristics of demand
and supply. For example, imposing volume controls could cause manufacturer
prices to rise if unit costs fall with the quantity produced. Also, imposing volume
controls may not affect manufacturer prices if they are easily circumvented by
doctors and/or patients.
Roundtable participants considered that volume controls are used more often in
Australia than the comparison countries. It was considered that the results for new
innovative pharmaceuticals could therefore mask differences in the way the
matched pharmaceuticals are used.
While it was not possible to obtain information on volume controls for all countries,
some information for Canada (Ontario) and  NZ supports participants’ views
(box 4.1).
Overall, there is some evidence that volume restrictions are more likely to be used
in Australia than in some comparison countries. However, it is not clear how the
use of volume controls in Australia may have influenced the price differences.
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Box 4.1 Use of volume controls in Australia, NZ and Ontario
The prevalence of volume controls for the new innovative and me-too pharmaceuticals
in the sample was examined for Australia, NZ and Ontario.
In Australia, 20 out of the 21 new innovative molecules in the sample were subject to
some form of restriction on their use (at 30 June 2000). Most of these molecules (17)
were listed with the highest level of restriction (Authority Required). Of the 49 me-too
molecules in the sample, 37 (or 76 per cent) were subject to some form of restriction
on their use at 30 June 2000.
NZ also imposed volume controls on many of the new innovative and me-too
molecules in the sample. Information was available for only 12 of the new innovative
molecules in the sample. All of these items were covered by a restriction (that they
could be prescribed by medical specialists only). For the 36 me-too molecules listed in
the NZ schedule that were also available in Australia, it was found that 21 (or
58 per cent) had some form of restriction.
Slightly fewer molecules were subject to some form of restriction in the Canadian
province of Ontario. Information was available for 11 new innovative molecules in the
sample, nine (82 per  cent) of which, required authorisation of some form and were
reimbursed only if specified clinical conditions for use had been met. For me-too
molecules, 14 out of the 35 me-too (40  per  cent) molecules listed on the Ontario
formulary required some form of authorisation.
Sources: DHAC (2000); Ministry of Health and Long–Term Care (2001) ; Pharmac (2000b).
4.2 Cost-containment mechanisms
Roundtable participants considered that the strong emphasis on cost-containment
within Australia’s subsidy arrangements had an important influence on the results.
In particular, participants identified a number of influential elements of Australia’s
cost-containment systems, including:
•   differences in cost-containment policies;
•   the use of economic evaluations; and
•   the use of reference pricing to establish reimbursement prices for specific groups
of pharmaceuticals.
The influence of these elements is discussed separately and in the context of case




Cost-containment policies include product-by-product price controls, reference
pricing, economic evaluations and mandatory price cuts (chapter 2). The US,
Canada and the UK are most different to Australia and the other comparison
countries in their use of cost-containment policies because companies are relatively
free to set prices for pharmaceuticals (box 4.2). Prices in these countries were
considerably higher than in Australia, based on the overall results.
The other comparison countries, like Australia, employed more stringent
cost-containment mechanisms, although there is considerable variation in the types
of mechanisms that they use (box 4.2).
Within this sub-group, it was found that price differences with Australia were
smallest for NZ and Spain even though these countries have very different
cost-containment policies.
NZ may have the most stringent cost-containment measures of the comparison
countries. Like Australia, it requires companies to submit economic evaluations
with applications for listing new pharmaceuticals or for increasing the price or
widening the clinical uses of pharmaceuticals already listed. It also has
implemented a reference pricing system that covers sub-groups of therapeutically
equivalent on- and off-patent pharmaceuticals, and sets benchmark reimbursement
prices for these sub-groups at the level of the lowest-cost item. But it has gone
further than Australia, by using competitive tendering and tender protection
agreements to put additional downward pressure on prices (appendix B).
The cost-containment measures used in Spain may be less stringent. Companies are
not required to submit economic evaluations. Also, while Spain has a reference
pricing system, it extends to chemically equivalent (generic) pharmaceuticals only.
Furthermore, benchmark reimbursement prices may be set above the level of the
lowest-cost item within sub-groups.
The difficulty in finding a clear link between the price differences with Australia
and the type of cost-containment policies may reflect differences in the way that
cost-containment measures are applied. The results also may reflect particular
factors in the comparison countries. Both Sweden and France are major producers
and exporters of pharmaceuticals. And as noted above, Spain did not recognise
pharmaceutical patents until relatively recently.
Overall, it is difficult to find a clear association between the price differences with
Australia and the type of cost-containment policies employed by different countries.78 PHARMACEUTICAL
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Box 4.2 Pharmaceutical cost-containment arrangements in
comparison countries
US: Companies are generally free to price pharmaceuticals. Managed care plans
directly negotiate rebates from manufacturers based on their ability to steer members
toward the cheapest pharmaceutical.
Canada: Companies are free to price new pharmaceuticals subject to Federal
regulations which provide that launch prices of patented products should not be higher
than the median price in seven other developed countries (including the UK and the
US). Also, price rises cannot exceed the rate of change in the consumer price index.
UK: All new prescription products approved for marketing are automatically
reimbursed. Companies are free to set prices for new products subject to an overall
cap on their rate of return but must seek approval before they can increase the prices
of existing products.
Sweden: Products are reimbursed once a price is agreed with the Government.
Negotiations may have regard to international price comparisons — the aim is to award
a ‘European price’. Reference pricing is only applied to off-patent products. Pricing of
new innovative pharmaceuticals are usually accompanied by a price-volume
agreement.
France: Prices are negotiated via ‘conventions’ (five-year contracts). Reimbursed
prices are based on several factors including: prices of local comparators; prices of the
product in other European markets; and the degree of ‘innovativeness’ of the product
(the therapeutic improvement over existing products).
NZ: Economic evaluations are mandatory for all new products. Reference pricing is
widely used and groups may include patented and off-patent products. Additional cost-
containment methods are used such as competitive tendering and tender protection
agreements.
Spain: The Government controls prices of all prescribed pharmaceuticals. Factors
considered in price negotiations include the prices of the product in other European
markets, prices of therapeutically-equivalent products and the innovativeness of the
product. Price-volume agreements are used frequently for more expensive products.
Reference pricing is used for some generic products.
Source: Appendix B.
Role of economic evaluation
Roundtable participants considered that Australia’s mandatory economic evaluation
requirements, combined with the rigorous evidence-based approach to assessing
reimbursement decisions, were major factors explaining the price differences,
especially for me-too items.REASONS FOR PRICE
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Some participants considered that me-too products offer no measurable advantage
over existing products. According to this view, a new me-too product is likely to
receive the same price as comparable items (which may include another me-too or
low-cost generic) under Australia’s evidence-based system. It was therefore
expected that prices for me-too products would be somewhat higher in countries
that do not undertake evidence-based economic evaluations.6
Australia, NZ and the Canadian provinces of Ontario and British Columbia are the
only jurisdictions to require companies to submit an economic evaluation with
applications for listing new pharmaceuticals or for increasing the price or widening
the clinical uses of pharmaceuticals already listed (chapter 2). Prices in Australia
were close to those in NZ but not to Canada.
In Sweden, France and Spain, companies may elect to provide an economic
evaluation of benefits over alternative treatments in arguing for higher
reimbursement prices, but it is not compulsory to do so. Australian prices were
closer to those in France and Spain but not to those in Sweden.
No information was available on the application of economic evaluations in the US
managed care sector, but they are not used to determine reimbursement prices for
items listed on the Federal Supply Schedule (FSS) (appendix B). In the US, large
buyers also are able to obtain significant discounts off the list prices of me-too
pharmaceuticals. The largest discounts were obtained on Australia’s top-selling
me-toos (ranging from 34  to 39  per  cent). This could suggest that the ability to
control admission to the list of subsidised products will be just as, if not more,
important in influencing negotiated prices, as any requirement to undertake
economic evaluations.
It is difficult to assess the impact of economic evaluations on price differences using
the results of this study.
Role of reference pricing arrangements
Australia’s reference pricing arrangements also were identified as a potential cause
of the price differences. Roundtable participants suggested that price differences be
computed for me-too pharmaceuticals subject to formal reference pricing, and the
results compared with those for me-too products not covered by this policy.
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Differences between the two results were expected to provide an indication of the
extent to which Australia’s reference pricing system has suppressed me-too prices.
The Commission identified 24 me-too pharmaceuticals within the sample of 49 that
were covered at some point under reference pricing arrangements. These molecules
accounted for approximately 76 per cent of the estimated revenue for all me-toos in
the sample.7
These pharmaceuticals were chosen because their prices were reviewed by the
Pharmaceutical Benefits Pricing Authority during 1999-2000 using the weighted
average monthly treatment cost (WAMTC) methodology.8 In essence, WAMTC is
a mechanism used to price patented and off-patent (generic) pharmaceuticals that
are considered by the Pharmaceutical Benefits Advisory Committee (PBAC) to be
therapeutically-interchangeable. The method is used to compare the monthly
treatment cost of pharmaceuticals which are available in different dosage types,
strengths and pack sizes (box 4.3).
Price differences between Australia and the comparator countries were calculated
for the WAMTC me-too pharmaceuticals. These results were then compared with
those obtained for 25 me-too pharmaceuticals that were not under WAMTC pricing
reviews at 30 June 2000 (table 4.1).
Table 4.1 Price ratios for WAMTC and non-WAMTC me-too
pharmaceuticals, list prices, as at 30 June 2000a
US Canada UK Sweden France Spain NZ
Higher
WAMTC 3.1 1.7 1.6 1.7 1.2 1.1 1.0
Non-WAMTC 2.1 1.7 1.2 1.3 0.9 0.9 1.1
Difference 1.0 0 0.4 0.4 0.3 0.2 -0.1
Lower
WAMTC 3.0 1.6 1.6 1.6 1.2 1.1 1.0
Non-WAMTC 2.1 1.4 1.1 1.3 0.9 0.9 1.1
Difference 0.9 0.2 0.5 0.3 0.3 0.2 -0.1
a As the bilateral comparisons are based on Australian consumption patterns and different bundles of
pharmaceuticals for each country comparison with Australia, conclusions about relative price levels across
countries cannot be drawn.
Source: PC estimates.
                                             
7 The individual molecules are identified in table D.2 in appendix D.
8 Recently, use of the methodology to review prices for these groups was suspended.REASONS FOR PRICE
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The results indicate that for all comparison countries except NZ, greater price
differences were observed for those me-too items subject to reference pricing in
Australia, than for products that were not.
Box 4.3 Weighted average monthly treatment cost (WAMTC)
WAMTC is a mechanism used to price patented and non-patented (generic)
pharmaceuticals considered by the PBAC to be therapeutically-interchangeable.
The method involves estimating the annual cost of treatment using each
pharmaceutical (based on daily dosage and script data):
provided   treatment   months   of   number   Total
 year a   over   provided   drug   the   of   cost   Total
= WAMTC
The WAMTC is calculated for all pharmaceuticals in a particular sub-group. The
pharmaceutical with the lowest average monthly treatment cost is selected as the
benchmark for the therapeutic group. The reimbursement price for other
pharmaceuticals within the group are adjusted (lowered) to the point where their
WAMTC is equal to the benchmark level. For those pharmaceuticals covered under the
Therapeutic Group Premium policy, manufacturers may charge a premium above the
reimbursement price which the patient (rather than the Government) must pay.
Five therapeutic sub-groups are currently subject to WAMTC pricing reviews. These
are:
•   H2 receptor antagonists (within the alimentary tract and metabolism ATC group);
•   Proton pump inhibitors (alimentary tract and metabolism);
•   ACE inhibitors (cardiovascular system);
•   Calcium channel blockers (cardiovascular system); and
•   HMG CoA reductase inhibitors (cardiovascular system).
Within these five sub-groups, a total of 20 me-too PBS molecules in 64 forms, were
subject to price reviews using the WAMTC method as at 30 June 2000. A further five
generic pharmaceuticals within the sample were subject to WAMTC pricing reviews.
A sixth sub-group (comprising four molecules), Selective Serotonin Re-uptake
Inhibitors (SSRIs), was covered by the WAMTC arrangements prior to July 1999. At
that time, price adjustments using the WAMTC mechanism were suspended, pending a
review of the methodology. However, pharmaceuticals in this group have been
included in the study of price differences for pharmaceuticals subject to WAMTC
pricing reviews because the manufacturer price of these items at 30 June 2000 would
have been influenced by the pricing reviews that occurred prior to mid-1999.
Sources: PBPA (2001; 2000).
However, these results should be interpreted with caution as the study was not
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in each group may not be representative of all me-too pharmaceuticals listed on the
PBS. Differences in consumer preferences (relating to the form, dosage and strength
of a medicine) may mean that the price ratios for the matched sub-samples are not
representative of the true price ratios for all me-too WAMTC and non-WAMTC
pharmaceuticals.
Another concern about the representativeness of this analysis relates to the group of
non-WAMTC pharmaceuticals. Table 4.2 shows that the Commission was able to
match many of the important me-too pharmaceuticals covered under WAMTC
pricing arrangements. For instance, 50 per cent of the potential Australian revenue
for WAMTC me-too pharmaceuticals in the sample was covered by matches for
France and up to 99 per cent for the UK.
However, the Commission was unable to achieve a consistently high level of
coverage for non-WAMTC me-too pharmaceuticals. Table  4.2 shows that only
34  per  cent of the potential Australian revenue for non-WAMTC me-too
pharmaceuticals was covered by matches for France and 38  per  cent for Spain.
Therefore, the price ratios for the non-WAMTC pharmaceuticals for France and
Spain must be interpreted with caution.
Table 4.2 WAMTC and non-WAMTC coverage of me-too pharmaceuticals,
as at 30 June 2000
Unit US Canada UK Sweden France Spain NZ
WAMTC
Coveragea %6 65 79 95 55 07 27 8
No. of matches no. 41 31 60 26 31 41 44
Non-WAMTC
Coverageb %5 76 56 15 53 43 86 2
No. of matches no. 38 42 47 36 33 34 34
a Coverage shows the percentage of total Australian manufacturer revenue for me-too WAMTC molecules
accounted for by the matched forms. b  Coverage shows the percentage of total Australian manufacturer
revenue for me-too non-WAMTC molecules accounted for by the matched forms.
Source: PC estimates.
Overall, the results provide some support for the contention that Australia’s
reference pricing system has contributed to the reported price differences for
me-too pharmaceuticals but due to the concerns about the representativeness of the
sample, the extent of the contribution remains unclear.REASONS FOR PRICE
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Case studies of price differences over time
Roundtable participants considered that a better understanding of the reasons for
price differences could be obtained by looking at price differences between
Australia and the comparison countries over time. It was considered that a
longitudinal study could be used to link changes in price differences to the
application of particular cost-containment policies.
The principal purpose of this study was to obtain a snapshot of price differences
between Australia and the comparison countries. Thus, prices over time were not
obtained for the pharmaceuticals in the sample. However, additional pricing
information was provided by GlaxoSmithKline Australia Limited (GSK) and the
Department of Health and Aged Care (DHAC) for three pharmaceuticals ranitidine
(Zantac), paroxetine (Aropax) and salmeterol (Serevent) (appendix F).
For all three products, the gap between prices in Australia and the comparison
countries was larger at 30 June 2000 than at the earlier time periods. The increases
in price gaps were due to a combination of nominal price reductions in Australia,
price changes in the comparison countries, and changes in exchange rates.
The prices of all three products in Australia declined in nominal terms over the
relevant periods. The price of ranitidine declined by 61 per cent (between May
1983 and June 2000), paroxetine declined by 45 per cent (between May 1993 and
June 2000), and salmeterol declined by 36 per cent (between December 1994 and
June 2000).
According to GSK, several factors contributed to the price reductions in Australia,
including:
•   competition from the entry of new producers (of generic equivalents and
therapeutically-interchangeable products). For example, between May 1983 and
June 2000 the patent on ranitidine in Australia expired and several competitors
entered the market;
•   price reductions at the time of listing (for two out of the three products, prices
declined significantly in the period between the market launch and listing on the
PBS). For ranitidine, the price reduction on listing occurred before the
requirement for economic evaluations was introduced in Australia;
•   reference pricing (two of the products are in therapeutic groups that were subject
to WAMTC pricing reviews). For example, paroxetine is one of a number of
Selective Serotonin Re-uptake Inhibitors (SSRIs) that were subject to reference
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•   changes in volume controls. According to GSK, a significant portion of the price
reduction for salmeterol occurred when volume controls on the product were
eased.
Movements in the price gaps for these products also were influenced by changes in
nominal prices in the comparison countries. According to GSK, the price reductions
that occurred in some countries were due to:
•   competition from generics and therapeutically-interchangeable pharmaceuticals.
For example, the price of paroxetine in the UK fell by 48 per cent due, in part, to
the launch of new therapeutic competitors and price reductions by them; and
•   government decisions such as mandatory price cuts. For example, the price of
salmeterol in France fell due to several compulsory price cuts under a
price-volume agreement with the Government.
Prices in the US for all three products increased significantly over the period (by
between 19 and 45 per cent). However, there is considerable doubt about the prices
and changes in them. While GSK provided list prices for the US, the comparable
FSS prices for all three were consistently lower. For example, the FSS price for
salmeterol was around 26 per cent below the list price reported by GSK.
Some of the change in the Australian dollar denominated prices of the products in
the comparison countries were due to changes in exchange rates. The Australian
dollar depreciated against most of the currencies over the different time periods
examined.
In summary, for the three products examined, price differences with Australia
generally increased over time due to a combination of factors influencing
Australian prices and prices in comparison countries. The case studies suggest that
price differences at a point in time are likely to be influenced by a combination of
inter-country differences in competition and government regulation of prices and
volumes.
4.3 Market launch of new pharmaceuticals
At the roundtable, it was suggested that pharmaceuticals available in Australia are
‘older’ than those in the comparison countries. It was considered that the price of a
pharmaceutical is related to its global age (the time that has elapsed since the
product was first launched anywhere in the world), such that older molecules obtain




To examine this issue, the Commission used information from IMS Health on
global and the local market launch dates, to estimate the average time between the
global launch of a pharmaceutical and the launch of the product in each of the
comparison countries.
The Commission focused on those molecules where it was possible to match at least
one form (not necessarily the same one in all countries) with Australia across the
seven countries. This yielded a sample of 39 molecules.9 In order to undertake the
comparison, the first date of marketing of any form of the molecule was used as the
relevant basis for comparison.
Figure 4.1 shows the estimated median delay (measured in years) between the first
launch of a sample of products anywhere in the world (the global launch date), and
the local launch date, for Australia and six countries where data were available. This
delay is likely to reflect many factors, including local demand conditions, marketing
approval processes and the time taken to obtain a listing for reimbursement
purposes.10
For most countries, there is no significant difference in the delay between the global
launch and the local launch. For example, the delay between the global and
Australian launch dates is an average of 2.6 years for all categories. This is similar
to the results for France, the US, Spain, Canada and NZ.
The exception is the UK, where the average delay between the global and local
launch is just over 6  months. This could be due to the high number of new
molecules launched in the UK (giving a delay of zero). Of the 39  molecules
included in the sample, it was found that the global launch occurred in the UK in
12 cases. This compares with three molecules launched initially in the US, and none
in Australia. The UK may be a relatively attractive market in which to launch new
products because, once approved for marketing, new pharmaceuticals are
automatically reimbursed under the UK’s subsidy arrangements (appendix B).
The results suggest the ages of the molecules in the sample do not differ
significantly. However, the results should be interpreted with caution. The major
limitation is that the measured delay does not take into account the amount of time
it takes to obtain a PBS listing. Another limitation is the small number of molecules
(39) included in the sample.
                                             
9 The analysis was also undertaken for all 150 molecules (appendix E). The results did not differ
significantly between the analyses.
10 According to Merck Sharp and Dohme (pers. comm., 22 June 2001), the time between seeking
and obtaining reimbursement in Australia is considerably longer than in countries such as
Sweden, France and Spain.86 PHARMACEUTICAL
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a  Comparisons are for 39  matched molecules (within the top 150  PBS molecules) with at least one form
matched with Australia, excluding molecules with local launch dates prior to global launch dates. The molecule
launch delay is calculated as the median value of the time difference between the global launch date and the
date of launch of the first form in a country, for all molecules.
Data source: PC estimates.
4.4 Price differences for individual categories
A number of factors, apart from those already identified, may have had a specific
influence upon the price differences for the separate categories of pharmaceuticals.
New innovative pharmaceuticals
For patented new innovative pharmaceuticals, it could be expected that
manufacturers will be able to differentiate their prices across countries, reflecting
differences in the price sensitivity of demand (chapter 2).
However, it was found that prices in Australia for the top-selling new innovative
pharmaceuticals are close to those in most other comparison countries, except the
US and the UK. International price benchmarking is employed to different extents
in Canada, Sweden, France, Spain and NZ (chapter 2). The US and the UK do not
use benchmarking. Prices in the US and the UK were higher than in Australia.REASONS FOR PRICE
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This finding may indicate that the use of international price benchmarking by
governments may be discouraging manufacturers from differentiating their prices
across countries according to market conditions.
Me-too pharmaceuticals
For me-too pharmaceuticals, there is some evidence that Australia’s
cost-containment arrangements may have contributed to the observed price
differences. The finding, reported earlier in this chapter, that the size of the gaps
between Australian and overseas prices was mostly larger for items under reference
pricing, suggests that Australia’s cost-containment systems explain some of the
observed price differences for me-toos. Several other features of Australia’s system
may have been influential, including the requirement for economic evaluations and
competition between therapeutic alternatives.
Generic pharmaceuticals
It is more difficult to determine the reasons for the finding that significant price
differences exist for Australia’s top-selling generic pharmaceuticals. Potential
reasons include variations in:
•   the costs of marketing and distributing generics;
•   impediments to generic competition;
•   the patent status of particular pharmaceuticals; and
•   cost-containment policies affecting the pricing of generics (such as reference
pricing and generic substitution).
In the absence of major barriers to international trade in generics, international price
differences could be expected to reflect differences in transport, distribution and
marketing costs in each country (arising, for example, from differences in product
liability costs, labelling requirements and pharmaceutical registration and evaluation
processes).
The results for generic pharmaceuticals may suggest that these costs differ across
the comparison countries. For instance, previous studies have found that product
liability and marketing costs are higher in the US compared to some other countries.
Unlike most of the other comparison countries, direct to consumer advertising is
permitted in the US and there is some evidence that advertising expenditure has
been growing rapidly.11
                                             
11 For example, see Harris (2000).   88 PHARMACEUTICAL
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Generic price differences also may be explained by the protection of some overseas
markets through explicit or implicit trade barriers.
In most countries, national regulations permit new producers of a pharmaceutical to
enter the market once the patent on a pharmaceutical has expired. Indeed, many
countries such as Australia, the US and Canada, have adopted an abbreviated
marketing approval procedure designed to facilitate the entry of generic
producers.12
However, patent arrangements also can work to delay the entry of generic
competitors. For example, in the US, under the Drug Price Competition and Patent
Term Restoration Act 1984 (also known as Hatch-Waxman Act) the first generic
producer to obtain a marketing approval receives a period of six months exclusivity
from the date it commences marketing its pharmaceutical.
However, if the producer of the originator product seeks to challenge a prospective
generic producer on the grounds that it has infringed a patent that is still in force,
then, under the Hatch-Waxman Act, the US Federal Drug Administration
automatically suspends the approval process for the new generic product for 30
months. There have been several cases where these US legal provisions have been
used by pharmaceutical companies to deter or delay generic competition.13 Indeed,
the existence of these provisions may encourage pharmaceutical companies to
obtain new patents on an existing product (by changing some aspects of the
formulation or dispensing method) in order to deter generic competitors.
According to the OECD (2001), pharmaceutical companies in Europe also have
attempted to deter generic entry through exploiting provisions of European Union
(EU) law that allow producers of generics to obtain rapid approval for their
products. Under EU law, generic producers need not conduct extensive clinical
trials to demonstrate the efficacy, safety and quality of their products if it can be
demonstrated that their products are bioequivalent with the reference product.
However, the reference product must be ‘marketed in the member state for which
the application is made’. Some manufacturers of reference products have reputedly
removed their product from the market shortly before patent expiration and replaced
it with a slightly modified version. In this event, the generic producer faces the risk
that its application for marketing approval will be rejected on the grounds that there
is no longer a marketed reference product available (OECD 2001, p. 38).
                                             
12 Under pharmaceutical approval processes, companies seeking permission to market new
pharmaceuticals usually must conduct trials to establish the safety, efficacy and quality of their
products. Under an abbreviated marketing approval process, companies are usually only
required to establish that their products are bio-equivalent to the originator pharmaceuticals.
13 See, for example, OECD (2001, p. 38) and The Economist (2001, p. 68).REASONS FOR PRICE
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Price differences for some of the generic molecules covered in this study also could
exist because the relevant molecule is still covered by a patent in the comparison
country (and therefore subject to little competition from chemically identical
substitutes). For example, six different brands of the off-patent pharmaceutical
metformin hydrochloride in 500 mg tablets (used to treat diabetes) are available in
Australia. However, the Commission understands that in the US, it is covered by an
extended patent and therefore the supplier may face less competition from
alternative producers.
There is also evidence that pharmaceutical manufacturers of generics in some
countries are able to obtain significantly higher prices compared to generic
competitors. For instance, chapter 3 reported that US manufacturers of originator
brands are able to sustain prices that are well above those of their generic
competitors. The manufacturers of these high-priced originator brands may prefer to
maintain higher prices at the cost of some reduction in market share, possibly in
order to maintain perceptions of higher quality. This suggests some advantages exist
in being the first to market.
In addition, companies in the US and NZ, and to some extent in Canada, are
permitted to advertise products to consumers directly. The use of direct to consumer
advertising may reinforce consumer perceptions of quality and enable
manufacturers of the originators to maintain relatively high prices.14
Differences in cost-containment mechanisms also may explain some of the generic
price differences. In Australia, the pricing arrangements for generics may limit the
ability of suppliers of originator brands to charge higher prices than competing
generic suppliers. Australia sets the reimbursement price for generics at the level of
the lowest priced generic (chapter 2). Under the brand premium policy, suppliers
may set a higher price but the patient pays the difference between the
manufacturer’s price and the reimbursement price. Other countries such as NZ,
Sweden and Spain employ similar methods for setting generic reimbursement
prices. However, Sweden and Spain do not set the benchmark price at the level of
the lowest priced generic.
Another factor potentially contributing to price differences for generics is
differences in the prescribing behaviour and price sensitivity of doctors. According
to Jacobzone (2000, p. 16), there is some evidence that doctors in most countries are
insensitive to prices, and that there is significant inertia in prescribing behaviour.
This could reinforce any potential advantage to suppliers that are first to market a
new pharmaceutical.
                                             
14 In countries which do not permit direct to consumer advertising, marketing to prescribers
(doctors) may serve a similar purpose.90 PHARMACEUTICAL
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Generic substitution policies are designed, in part, to overcome prescribing inertia
(chapter  2). For example, in Australia, pharmacists are allowed to substitute a
generic item for a more expensive branded product if the doctor has indicated that
generic substitution is permitted and the patient agrees. The brand premium policy
complements generic substitution by helping to heighten awareness of prices for
generics. The policy allows suppliers of bioequivalent generics to set a price above
that of the lowest-priced brand. The patient can then decide whether to buy the
cheaper alternative or pay more for a particular brand.
In summary, a number of factors may have contributed towards the price
differences for generics, including variations in:
•   the costs of marketing and distributing generic pharmaceuticals;
•   impediments to generic competition;
•   the patent status of particular pharmaceuticals; and
•   cost-containment policies affecting the pricing of generics (such as reference
pricing and generic substitution).
4.5 Conclusions
The large number of factors potentially influencing pharmaceutical prices in
Australia and the comparison countries, and the nature of the results, precludes
definitive conclusions about the causes of the reported bilateral price differences.
The price differences are probably due to a combination of influences, including
systematic differences in health systems, pharmaceutical subsidy and
cost-containment systems, and production costs (including marketing and liability
costs). They also may be due to a variety of factors affecting the prices of particular
matched pharmaceuticals, such as inter-country differences in demand conditions,
patent expiration and the level of competition from other me-too or generic
products.
There is nevertheless some evidence to support the views of roundtable participants
that Australia’s subsidy and cost-containment arrangements have assisted in
keeping prices relatively low. The size of the gaps between Australian and overseas
prices were mostly larger for me-too items under reference pricing. Other features
of Australia’s cost-containment policies, such as the use of economic evaluations to
assist in establishing and reviewing reimbursement prices, also may have
contributed to the price differences. The case studies lend some support to the view
that Australia has been successful in reducing the prices of products listed on the
PBS over time through a combination of cost-containment measures.REASONS FOR PRICE
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A number of particular factors may have influenced the price differences for the
separate categories of pharmaceuticals.
For new innovative pharmaceuticals, the use of international price benchmarking by
governments may be reducing the scope for manufacturers to differentiate their
prices across countries according to market conditions.
There is some evidence that cost-containment measures have contributed to the
comparatively low prices for me-too pharmaceuticals in Australia. The size of the
gaps between Australian and overseas prices was mostly larger for me-too items
under reference pricing.
Price differences for generic pharmaceuticals may be due to a combination of
differences in: cost-containment policies (such as reference pricing and generic
substitution); the costs of producing, distributing and marketing generics; and
competitive conditions.CONSULTATION A.1
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B International subsidy arrangements
This appendix summarises the subsidy and cost-containment arrangements
employed in the following OECD countries:
•   Canada;
•   France;
•   New Zealand (NZ);
•   Spain;
•   Sweden;
•   United Kingdom (UK); and
•   United States (US).
The discussion for each country is accompanied by a short description of the health
care system in which the pharmaceutical subsidy arrangements are embedded.
Table B.1 summarises key socio-economic characteristics of the countries included
in this appendix.B.2



































1999 1997 1999 1997 1998 1998 1997 1997 1997
Australia  18 967   12  21 248 9.9 (’98)  1 696 69.3 213 52.5 8.7
Canada  30 491   12  19 967 16.1 (’92) 1 893 (’99) 69.9 287 (’99) 31.9 (’99) 7.0 (’99)
France  59 099   16  24 292   51.0  2 358 76.4 506 (’98) 58.2 (’98) 16.4 (’98)
NZ  3 811   11  14 297 8.8 (’89)  1 127 77.1 188 70.8 13.1
Spain  39 418   16  15 126 26.5 (’96)  1 044 76.9 207 72.6 19.6
Sweden  8 868   17  25 753 6.4 (’96)  2 146 83.8 282 71.2 10.9
UK  59 333   16  23 908   9.8 1 685 (’99) 84.2 (’99) 244 64.2 12.5
US  272 878   13  31 935 6.5 (’84) 4 390 (’99) 44.2 (’99) 451 (’98) 15.4 (’98) 3.7 (’98)
a Figures in parentheses indicate the latest year available. b Percentage of the population aged 65 and over. c Pharmaceutical expenditure comprises prescription
medicines, over-the-counter products and expenditure on other medical non-durables (such as bandages, elasticised stockings, incontinence articles, condoms and






Overview of Canada’s health care system
Canada has a predominantly publicly financed and privately delivered health care
system. The public system comprises an interlocking network of ten provincial and
three territorial health insurance plans. Through adherence to principles set at the
national level (under the Canada Health Act), the system is referred to as a
‘national’ health insurance system (Medicare). Medicare provides universal and
comprehensive coverage for medically necessary hospital, in-patient and out-patient
physician services but does not subsidise the cost of pharmaceuticals (HC 2000).
The Federal Government’s role in the health system is to: develop and administer
national standards or principles; assist in financing provincial health care services;
and meet other constitutional requirements — such as direct health service delivery
to specific groups, such as native Canadians.
Each province or territory is responsible for: managing and delivering health
services; planning, financing and evaluating the provision of hospital care,
physician and allied health care services; and some aspects of public health and
prescription pharmaceutical care (HC 2000).
Main features of the pharmaceutical system
Like Australia, pharmaceutical expenditure in Canada has increased considerably
since the 1980s. Health Canada (HC  1997) estimates that during the 1980s and
1990s, provincial pharmaceutical program expenditures increased at rates of
between 11  to 20  per  cent, per annum. In 1999, pharmaceutical expenditure was
around 15 per cent of total health care expenditure, at US$287 per person (totalling
around US$9  billion) (table  B.1). According to the Patented Medicine Prices
Review Board (PMPRB 2001), total sales of pharmaceuticals in 2000 was around
US$10 billion.
Canada is a small producer of pharmaceuticals, with production of only
US$4.6 billion in 1996 (or around 0.8 per cent of gross domestic product (GDP)),
compared with the US of US$82.5  billion (or around 1.1  per  cent of GDP)
(OECD  2000). Like Australia, Canada is a net importer1 of pharmaceuticals (in
1996 imports exceeded exports by US$1.3 billion) (OECD 2000).
                                             
1 Pharmaceutical imports in Canada are ordinarily by manufacturers for purposes of repackaging
and resale (PMPRB, Canada, pers. comm., 2 May 2001).PHARMACEUTICAL
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Per capita expenditure on pharmaceuticals and other medical non-durables is higher
in Canada compared with all other comparison countries except France and the US.
However, the percentage of public expenditure on pharmaceuticals and other
medical non-durables is lower in Canada than all other countries except the US
(OECD 2000).
Subsidy arrangements
Canada’s pharmaceutical subsidy arrangements differ considerably from
Australia’s. Unlike Australia, which offers universal coverage, pharmaceuticals in
Canada are subsidised for specific segments of the population. For example, the
Federal Government is responsible for subsidising the cost of pharmaceuticals to a
small segment of the population, including the ‘First Nations’ and Inuit living on
reserves, war veterans, the Royal Canadian Mounted Police, military personnel and
inmates of federal penitentiaries. Further, each Canadian province or territory
administers its own publicly-funded prescription pharmaceutical program, with
varying coverage and administrative arrangements (PMPRB, Canada,
pers. comm., 2 May 2001). The provinces and territories account for approximately
80  per  cent of public expenditures on pharmaceuticals (Willison,  D., Canada,
pers. comm., 16 May 2001).
Multiple payers finance prescription medicine expenditure in Canada. The
provinces subsidise the costs for some sectors — for instance, seniors and social
welfare recipients. Those pharmaceutical costs not covered by the public sector are
paid for by the private sector — and mostly by insurance companies and by
employers as employee benefits. It is estimated that around 22 per cent of elderly
Canadians have some form of private pharmaceutical insurance, usually as retiree
benefits from their former employers (Freund et al. 2000). In 1995, it was estimated
that 62 per cent of prescription medicines were paid for by private plans, 19 per cent
by provincial plans, seven per cent by both, while 12 per cent of Canadians were not
covered (HC  2000). The elderly and social welfare recipients are estimated to
account for approximately 33  per  cent of total spending on pharmaceuticals in
Canada (PMPRB, Canada, pers. comm., 2 May 2001).
A variety of different subsidy arrangements exist in the provinces. All elderly
citizens in Canada with financial need have some form of insurance coverage for
out-patient prescription pharmaceuticals  — two provinces restrict pharmaceutical
coverage to low income elderly; three other provinces provide the same levels of
coverage to all elderly residents; and the remainder have coverage for all elderly but
means-based variation in cost sharing (Freund et al. 2000). Rather than outline each
scheme, those for Ontario and British Columbia are outlined below. These two




(Statistics  Canada  2000) and they have had a significant influence upon the
development of reimbursement schemes in the other provinces.
Ontario
The Ontario Drug Benefit (ODB) program covered approximately
3100 pharmaceuticals in 1999. The ODB covers approximately 45 per cent of all
claims (Ontario Drug Programs Branch, Canada, pers. comm., 23 May 2001). From
1990 to 1996, 38 per cent of new innovative pharmaceuticals approved by HC and
introduced in Ontario were fully covered by the ODB program (Rx&D 1999). The
ODB accounts for 40  per  cent of all prescription spending in Ontario
(Brogan Inc 2001).
Manufacturers seeking to have a product included on the ODB formulary must
complete a submission to the Ontario Ministry of Health and Long–Term Care’s
Drug Programs Branch — the Drug Quality and Therapeutics Committee (DQTC)
reviews the submissions. DQTC bases its recommendation on various criteria
including evidence on safety and efficacy, and the availability of suitable alternative
agents.
Eligibility for reimbursement under the ODB is limited to:
•   persons aged 65 years or over;
•   persons receiving professional services under the Home Care Program; and
•   residents of long-term care facilities or homes for special care (and who are
eligible for welfare assistance).
Pharmaceuticals listed on the ODB formulary are reimbursed at the listed drug
benefit price (DBP).2 Most products listed on the formulary are reimbursed at the
DBP, plus a ten  per  cent mark-up and applicable fees (dispensing and
compounding). The mark-up is intended to cover distribution costs. Often the
acquisition charges are the same as the ODB cost (Ontario Drug Programs Branch,
Canada, pers. comm., 23 May 2001).
Copayments were introduced under the ODB program in July 1996. As at 1999,
those eligible for coverage under the ODB pay a maximum of
Can$2 per prescription, provided they meet certain criteria (for instance, a senior
single person with an annual net income of less than Can$16  018). Otherwise,
patients pay for pharmaceuticals up to an adjustable threshold (for example, $100
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deductible)3 and then a maximum of Can$6.11  per  prescription
(Ministry of Health and Long-Term Care 2001).
British Columbia
British Columbia’s (BC) pharmaceutical insurance program is called Pharmacare
(BCP). The program began in January 1974. Every BC resident is eligible for
coverage under one of seven benefit plans (Ministry of Health and Ministry
responsible for Seniors 2001a).
Residents aged 65 and over pay the first Can$200 in dispensing fees. All other
eligible drug costs for these people are fully reimbursed. The drug costs for persons
residing in long-term care facilities and people receiving social income assistance
are reimbursed at 100 per cent.
Three plans also provide specific coverage for cystic fibrosis and some mental
health drugs, as well as families qualifying for at home assistance for special needs
children.
All residents not covered by one of the other plans belong to BCP’s universal plan.
Under this plan, residents must pay for pharmaceuticals up to an annual deductible
of between Can$600 or Can$800, depending on their income. Families qualifying
for a Can$600 deductible receive 100 per cent of BCP reimbursement on
expenditure exceeding the deductible. Families qualifying for a Can$800 deductible
must pay a 30  per  cent copayment of eligible drug and dispensing costs up to
Can$2000 per year, past which BCP pays 100 per cent of eligible costs.
Pricing of pharmaceuticals
The pricing arrangements in Canada vary according to the province and the type of
pharmaceutical. Each provincial pharmaceutical plan establishes its own
reimbursement price and a variety of pricing mechanisms are used. However,
according to the PMPRB (Canada, pers.  comm.,  2  May  2001), there is little
variation in pharmaceutical prices across Canada.
Patented pharmaceuticals
All patented prescription and non-prescription pharmaceuticals sold in Canada,
including those reimbursed by provinces, must comply with a set of pricing
                                             





guidelines set out in the Patent Act 1985 and administered by the PMPRB. These
arrangements apply to a large portion of the market in Canada. In 2000, 63 per cent
of the US$10  billion in pharmaceutical sales were accounted for by patented
medicines (PMPRB 2001).
The PMPRB is responsible for ensuring patented pharmaceutical prices in Canada
are not excessive. To ensure this, patentees are required to file comprehensive price
and sales information on a regular basis (PMPRB, Canada, pers.  comm.,
2  May  2001). The PMPRB can investigate allegations of excessive pricing and
order patentees to reduce the price and take measures to offset any excess revenues
they may have received (PMPRB 1999).
The guiding principles behind the PMPRB’s pricing guidelines are:
•   the prices of most new patented pharmaceuticals cannot exceed the price of the
most expensive pharmaceuticals in a therapeutic class;
•   for breakthrough pharmaceuticals, the prices cannot exceed the median of the
price of the same pharmaceuticals in seven specified countries (France,
Germany, Italy, Sweden, Switzerland, the UK, and the US);
•   the prices of existing patented pharmaceuticals cannot increase by more than
annual changes in the Consumer Price Index (CPI); and
•   the price of a patented pharmaceutical in Canada can, at no time, exceed the
highest price for the same pharmaceutical in the comparator countries (PMPRB,
Canada, pers. comm., 2 May 2001).
Although the PMPRB monitors pharmaceutical industry research and development
(R&D), it does not take industry development considerations (such as levels of local
investment and R&D expenditure) into account in determining whether a price is
excessive (PMPRB, Canada, pers. comm., 2 May 2001).
Provincial schemes
In the province of Ontario, economic evaluation plays a critical role in decisions on
whether to include a pharmaceutical on the ODB formulary. The Ministry of Health
and Long-Term Care (2000b, pp. IIIA–14) will only list a pharmaceutical that is
priced higher than the alternative, if an economic evaluation has been conducted on
the pharmaceutical and it is shown to offer a significant therapeutic advantage.
Consequently, the Ministry has published broad guidelines for economic analysis of
pharmaceuticals (Ministry of Health and Long-Term Care 1994).PHARMACEUTICAL
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The independent review committee responsible for evaluating pharmaceuticals (the
DQTC) continually monitors and revises the list of pharmaceuticals available on the
ODB.
Economic evaluation also plays a critical role in decisions on whether to include
new pharmaceuticals on the BCP formulary. According to the Ministry of Health
(pers. comm., 7 June 2001),  decisions  to  include  a  new  pharmaceutical  on
Pharmacare take into account:
•   an evidence-based assessment of the therapeutic advantage of the
pharmaceutical;
•   economic evaluation;
•   the financial impact on Pharmacare; and
•   other relevant information as specified by experts.
In seeking to have a new pharmaceutical listed on the BCP formulary, companies
must submit an economic evaluation that, among other things, identifies appropriate
comparators and provides quantitative evidence of claimed improvements or greater
efficacy relative to these comparators.
The province of BC uses a low cost alternative (LCA) system and a reference
pricing system to determine reimbursement prices for items already listed on the
BCP formulary. The LCA program pays the lowest price for pharmaceuticals that
contain the same active ingredient(s). Patients eligible for Pharmacare benefits will
receive full coverage for the preferred ‘reference’ pharmaceutical. They may choose
a more expensive pharmaceutical and pay only the difference in price.
BCP also uses a reference pricing system called the Reference Drug Program
(RDP), that appears to be similar to Australia’s Therapeutic Group Premium Policy,
to determine reimbursement prices for certain items.
The RDP was introduced in October 1995 and now covers several categories of
drugs, including: H2 antagonists (used to treat certain stomach complaints); nitrates
for treating angina; NSAIDs (anti-inflammatory drugs for treating arthritis); drugs
used to treat high blood pressure (excluding diuretics and beta blockers); ACE
Inhibitors and some calcium channel blockers (Ministry of Health and Ministry
responsible for Seniors 2001c).
Under RDP, Pharmacare designates a reference pharmaceutical — defined as the
most cost-effective pharmaceutical within a therapeutic category (which can be a
combination of therapeutic categories). Patients who are eligible for Pharmacare
have the option of being fully covered for the reference pharmaceutical or, as in




According to the Ministry of Health (pers. comm., 7 June 2001), the RDP seeks to
promote the coverage of pharmaceuticals based on the best scientific evidence and
economic information available. For specific therapeutic categories of drugs, BCP
limits the maximum level of coverage, consistent with each of its benefit plans, to
the cost of a product or products within that category. BCP recognises other drugs
in the category up to the level of the ‘reference product(s)’.
For products not subject to RDP or LCA, or for which special exemptions to RDP
or LCA have been granted, BCP pays a maximum price no greater than the
manufacturer’s price plus seven per cent.
Discounts
Pharmaceutical discounts may be offered in Canada. However, the PMPRB argues
there is ‘no extensive discounting’ on patented pharmaceuticals in Canada:
It is the PMPRB’s experience that the selling price of a patented [pharmaceutical] to all
classes of customers across the country is close to the price listed in the Ontario Drug
Benefit Formulary. That conclusion suggests that there is no extensive discounting on
these products.
The PMPRB also stated that:
Analysis … of provincial [pharmaceutical] expenditures in six provinces has also found
no considerable differences in the prices charged to the provincial [pharmaceutical]
plans. This result would be predicted given that provincial formulary prices are public
and at least one province, Quebec, has a policy that it will not list a [pharmaceutical] at
a price higher than the best price available to another publicly-funded [pharmaceutical]
program. (pers. comm., 2 May 2001)
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
Attempts are made in Canada to influence prescribing behaviour via prescribing
guidelines. Even though there are no Federal prescribing guidelines, most provinces
and territories have clinical practice guidelines. There appear to be no sanctions for
doctors who fail to follow them (Kanavos 1999b).
Policies to encourage generic substitution
The price mechanisms used by the provinces in Canada tend to favour, when
available, generic substitution (HC  2000). For example, the province of OntarioPHARMACEUTICAL
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encourages generic pharmaceuticals by only reimbursing pharmacists for the lowest
cost interchangeable generic pharmaceutical product on the ODB formulary. The
interchangeability between two pharmaceuticals is met when both products have the
same active ingredient(s) in the same strength and dosage form (Ministry of Health
and Long-Term  Care  1999). Pharmacists usually dispense the lowest priced
interchangeable product unless ‘no substitution’ is written on the prescription and
the no substitute order meets prescribed conditions (Ministry of Health and
Long-Term Care 2000a).
These policies may have contributed to the relatively large share of the Canadian
pharmaceutical market which is accounted for by generics. According to HC
(1997), in 1996-97, 40 per cent of prescriptions written in Canada were for generics
(representing 12  per  cent of total pharmaceutical sales). As noted above, the
PMPRB estimated that patented items accounted for 67 per cent of the Canadian
market, implying that the market share of generics (including originator brands) is
around 23 per cent of total sales.
B.2 France
Overview of the French health care system
Table B.1 shows that, after the US, France spends the most per capita on health
(US$2358  per  person). Public expenditure on health as a proportion of total
expenditure is around 76 per cent — which is greater than Australia, Canada and the
US.
The French health care system covers virtually the entire population (99 per cent)
(Kanavos  1999b). The system is funded by an employee/employer contribution,
patient copayments and taxes. According to the French Ministry of Social Affairs,
in 1999, taxes represented nearly 40 per cent of health insurance resources (France,
pers. comm., 16 May 2001).
There are different health care schemes available, determined by the individual’s
social and/or professional category. The main scheme covers employees and
pensioners (and their families), and covers 80  per  cent of the population. It is
funded mainly by employer contributions (a levy of 12.8 per cent of gross salaries)
and employee contributions (a levy of 6.8 per cent of gross salaries). In addition,
87  per  cent of the population also are members of voluntary, supplementary
sickness funds, or private health insurance, which cover out-of-pocket expenses on




Main features of the pharmaceutical system
Pharmaceutical production in France increased from around US$1.4 billion in 1970
to over US$21 billion in 1995, in nominal terms, or around 1.4 per cent of GDP
(OECD  2000). In 1996, France was a net exporter of pharmaceutical products
(exports were approximately US$7.2  billion and imports US$5.7  billion)
(Jacobzone 2000, pp. 67–68).
Per capita expenditure on pharmaceuticals and other medical non-durables is higher
in France (US$506) than in many other developed countries (table B.1). The public
share of total expenditure per capita is also relatively high at US$295 per person.
Reimbursed pharmaceuticals account for around 90 per cent of the French market
(Levy 1997).
Pharmaceutical consumption per capita in France is the highest within the OECD
countries, reaching 51 medicines per person in 1997 (OECD 2000). According to
Kanavos (1999b, p. 68) a major contributor to France’s high per capita consumption
of medicines is the fact that patients can either see a general practitioner (GP) or
have direct access to specialists (without first seeing a GP). Kanavos considers that
the prescribing levels of specialists are usually higher than those of GPs and, in
addition, a GP may not know which pharmaceuticals a specialist has prescribed for
the same patient, and vice versa. However, according to the French Ministry of
Social Affairs, in 1999, 84  per  cent of pharmaceuticals in ambulatory care were
prescribed by GPs (who represent around 50 per cent of physicians in ambulatory
care) (France, pers. comm., 16 May 2001).
Between 1990 and 1997, the average annual rate of growth of total pharmaceutical
expenditure4 was 4.3 per cent, while public expenditure grew on average at around
4.5 per cent a year (OECD 2000).
Subsidy arrangements
The national health insurance fund (Caisse Nationale d’Assurance Maladie
(CNAM)) subsidises prices of pharmaceuticals to all citizens.
The Transparency Committee grants reimbursement status for subsidised
pharmaceuticals where medical efficacy has been proven. The decision to grant a
product reimbursement status is based on an assessment of the product’s medical
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benefit or therapeutic value and is determined by evaluating the risk/benefit ratio of
the product, taking into account the current treatment alternatives and their
characteristics (Friedeberg-Steward 2000, p. 1203). Although it is not mandatory, a
company can present an economic evaluation of its product when seeking a listing
with the national health insurance fund (Ministry of Social Affairs, France,
pers. comm., 16 May 2001).
Comparisons between new products and currently available treatment alternatives
are determined by the Amelioration du Service Medical Rendu (ASMR). Unless the
product is the first in a new class, the evaluation is done in comparison with
products of the same pharmaco-therapeutic class.
Pharmaceuticals granted reimbursement status are placed in one of three classes on
a ‘positive list’, which determines the level of reimbursement. These are:
•   100 per cent reimbursement for life-saving medicines. Products in this category
include agents against diabetes, AIDS, cancer and chronic diseases;
•   65 per cent for reimbursed pharmaceuticals not included in one of the other two
groups (for example, pharmaceuticals for certain infectious diseases); and
•   35  per  cent for pharmaceuticals mainly used for non-serious conditions and
disorders.
The majority of reimbursable products (72 per cent) lie in the 65 per cent category
(Ministry of Social Affairs, France, pers. comm., 16 May 2001).
Reimbursement rates also depend on the type of beneficiary. For example, patients
suffering from a specified long-term illness are exempt from copayments for all
medicines relevant to that condition (Kanavos 1999b, p. 70).
Pricing of pharmaceuticals
Once a pharmaceutical has been approved on the grounds of its safety, efficacy and
quality, manufacturers are free to set the price of their pharmaceuticals in the
market. However, if they want their pharmaceuticals to be subsidised by the
national health insurance fund, reimbursement status firstly has to be granted by the
Transparency Committee. Once reimbursement status is granted, through
negotiations, the Pricing Committee (Comite Economique) sets the actual price.
Manufacturers cannot price reimbursable pharmaceuticals above the price set by the
Pricing Committee (Ministry of Social Affairs, France, pers. comm., 16 May 2001).
In January 1999, the Government approved two new methods by which prices for




•   a company can subscribe to a five-year contract (‘convention’) in which prices
of products are agreed upon. The convention is the main method by which prices
of reimbursed pharmaceuticals are set. Negotiations are based on sales forecasts,
made at the therapeutic class level. If actual sales exceed the targets, firms are
required to pay rebates. Companies also may reduce prices for older products in
order to receive higher prices on new products (Ministry of Social Affairs,
France, pers. comm., 16 May 2001); or
•   a company can agree to negotiate prices on a ‘product-by-product’ basis.
According to the Ministry of Social Affairs (France, pers. comm., 16 May 2001)
only one per cent of firms have opted for the ‘product-by-product’ pricing.
The reimbursement price of a pharmaceutical is based on discussions surrounding
the pricing rationale of companies5 and the degree of innovativeness of the product
as indicated by the ASMR level (table B.2) granted by the Transparency Committee
(Friedeberg-Steward 2000, p. 1204).
Table B.2 ASMR levels
Level I A major therapeutic improvement over existing therapy
Level II An important improvement over existing products
Level III A moderate improvement over existing products
Level IV A minor improvement over existing products
Level V No improvement over existing products, only economic benefits
Level VI Rejection
Source: Friedeberg-Steward (2000).
A  ‘convention’ is negotiated between the company and the Pricing Committee
which links a certain price to a fixed volume of sales, by therapeutic classes. The
price for a new product is usually highest for ASMR Levels I and II. For products
that exhibit no improvement over existing products, prices usually will be set at the
level of (or lower than) those of existing pharmaceuticals.
The convention is valid for five years, after which, pharmaceuticals are again
subjected to the Transparency Committee and the Pricing Committee for evaluation
of their therapeutic value and price. The prices may change before the convention
expires if the company exceeds the agreed maximum sales volume.
For innovative products, pricing is based on evidence that the products have clear
clinical improvements over existing similar products which, according to Willison,
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(Canada, pers. comm., 16 May 2001) may include patent and off-patent products.
Pricing of innovative products also may take into account the prices of similar
products in other European countries.
In the past, the French Government also has implemented across-the-board price
reductions for certain items. For example, in July 1998, companies marketing
generics had to reduce prices to 30 per cent below those of the originator brands.
However, many companies failed to do so. Therefore, in November 1998, the
Government issued a ruling reducing prices of 37  generic products by up to
50 per cent on some products (Kanavos 1999b).
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
Until relatively recently, the French Government had a system of prescribing
guidelines, mainly in the form of negative recommendations for doctors (Kanavos
1999b). Under this system, random checks on doctors occurred and financial
penalties could be imposed if the guidelines were breached. However, no penalties
have been imposed from 1999 onwards because the Conceils d’Etat rejected the
way these penalties were calculated (Ministry of Social Affairs, France,
pers. comm., 16 May 2001). According to Willison, (Canada, pers. comm., 16 May
2001), these guidelines have recently been abolished.
Policies encouraging generic substitution
Compared to many other countries, the generic pharmaceutical market in France is
relatively small.
Originator off-patent pharmaceuticals and generic copies account for around
16 per cent of total prescriptions in France — as of January 2000, generic copies
accounted for 5.6 per cent of all pharmaceutical packs prescribed. The volume of
generic dispensing is growing, although at a slow rate (EGA France 2001).
There have been recent attempts to encourage the generic market. For instance, in
1998, pharmacists signed an agreement with the Government allowing generic
substitution where the product shares the same active ingredient, dosage and
pharmaceutical form. Companies marketing generics also have launched campaigns






Overview of New Zealand’s health care system
NZ has a comprehensive, publicly-funded health care system supplemented by
private health insurance. The National Advisory Committee on Health and
Disabilities advises the Government on which services should be publicly funded,
and on funding priorities. The Government, through the Ministry for Health,
allocates money to the District Health Boards (DHBs) to purchase health services
and issues broad guidelines on what services must be provided. The DHBs run
public hospitals and provide other services (for example, public health nursing
services).
Health services are provided in both public and private settings. Primary care (first
contact, self-referral health care) is mostly provided by publicly-subsidised,
privately-owned general practices. Secondary medical care is mostly provided in
publicly-owned hospitals (MOH 2000).
The NZ health system is in a process of reform. For example, beginning in 2000-01,
increasing responsibility for funding health care has been transferred from the
federal level (Ministry of Health) to the regional level DHBs. Further, the Ministry
for Health has initiated a strategy document to provide a unified nationwide
framework for the development of the NZ health sector (MOH 2000).
Main features of the pharmaceutical system
Since 1998, pharmaceutical expenditure growth in NZ has been relatively low. For
example, between April 1998 and July 1999, total expenditure declined and, since
July 1999, it has remained relatively stable (Pharmac 2000a).
According to the Pharmaceutical Management Agency Limited (Pharmac),
pharmaceutical prices are the main factor explaining the recent decline and stability
of pharmaceutical expenditure. This is due to a strong downward trend in prices
over the past decade. For example, prices declined 35 per cent between April 1993
and April 2000 (Pharmac 2000a).
Consequently, per capita expenditure on pharmaceuticals and other medical
non-durables is low in NZ (US$188) compared to many other countries. Like a
number of these countries, the public sector accounts for a large share of total
expenditure (US$133  per  person). Further, NZ spends less per capita on health
expenditure than Australia (OECD 2000).PHARMACEUTICAL
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NZ has a small pharmaceutical industry. In 1987, pharmaceutical production was
US$150 million which represented about 0.4 per cent of GDP. NZ is a net importer
of pharmaceuticals, importing US$312 million net in 1996 (OECD 2000).
Subsidy arrangements
The pharmaceutical subsidy arrangements in NZ provide universal coverage for the
cost of many pharmaceuticals. Like Australia, the resident’s level of subsidy
depends upon his or her economic and health status. Residents holding a
Community Service Card (based on family income and size) or High Use Health
Card (based on 12 or more visits to a doctor in a year) obtain a larger subsidy. There
are currently around 3000 pharmaceuticals subsidised by the NZ Government.
Pharmaceuticals granted reimbursement status are placed on a ‘positive list’.
Pharmac advises the Government on which pharmaceuticals to include on the
schedule and the ex-manufacturer reimbursement level. The schedule is published
three times a year and updated monthly (Pharmac 2000b).
Decisions on listing, subsidy levels, and prescribing guidelines and conditions, are
made by the Pharmac Board with input from independent medical experts on the
Pharmacology and Therapeutics Advisory Committee (PTAC) and its specialist
sub-committees, and Pharmac’s managers and analysts (Pharmac 2000c).
The Government also seeks to influence patients’ demand for pharmaceuticals
through a system of copayments. The amount of copayment depends upon the
economic and health status of the patient. Residents with a Community Services
Card or High Use Health Card pay NZ$3 per item for medicines. Adult patients,
without the above cards, pay NZ$15 (children NZ$10) for subsidised medicines up
to 20 items per year. Brand premiums also may be paid. Children under six are
generally free (Pharmac 2000b).
NZ also has safety net arrangements. After 20 prescriptions in a year, family
members’ charges are NZ$2 per item for the rest of the year or free for concessional
cardholders (Pharmac 2000b).
Pricing of pharmaceuticals
Like Australia and the Canadian provinces of Ontario and British Columbia,




comparator products that are already listed on the schedule and be accompanied by
evidence of any claimed benefits compared to these comparators (Pharmac 2001).6
In deciding whether to list a new pharmaceutical, resource allocation and budgetary
constraints are two major issues influencing Pharmac’s deliberations
(Phamac  1999b,  p.  1). Consequently, economic evaluations (specifically, cost–
utility analysis (CUA)) play an important role in listing and pricing decisions.
Using CUA, Pharmac compares the cost-effectiveness of introducing different
pharmaceuticals, in different therapeutic groups. This means, for example, that
Pharmac attempts to compare the cost-effectiveness of a new pharmaceutical to
prevent heart attack with another that cures gastric ulcers (Pharmac 1999b, p. 3). To
do this, Pharmac ranks each new pharmaceutical according to value for money in
terms of Quality-Adjusted Life Years (QALY) saved (Pharmac 1999b, p.  4).7
Pharmac then uses other criteria when making its listing and pricing decisions,
including:
•   the community’s health needs;
•   the availability and suitability of existing medicines;
•   the clinical benefits, costs and risks of a product;
•   the direct cost to health service users; and
•   other criteria as Pharmac sees fit (Pharmac 2000b).
Reference pricing is widely employed by Pharmac in setting reimbursement prices.
Pharmac classifies all pharmaceuticals into therapeutic groups and further into
sub-groups. Reimbursement prices are then set with reference to the lowest-priced
pharmaceutical in the relevant sub-group — which may include both generic and
patented pharmaceuticals. This system is similar to that applied for certain groups of
pharmaceuticals in Australia and British Columbia.
Since 1997, Pharmac has introduced several additional measures designed to reduce
the prices of off-patent pharmaceuticals. These are:
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marketed (in local currencies (excluding taxes), NZ dollar equivalents and exchange rates
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p. 16).
7 QALY measures the years gained through premature death prevention; quality-adjusted years
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•   sole supply tenders (whereby pharmaceutical manufacturers compete against
one another for the sole right to supply a pharmaceutical in a therapeutic
sub-group);
•   tender protection contracts (suppliers on the schedule agree to reduce the price
of certain products, in exchange for a commitment from Pharmac not to tender
the products); and
•   cross-subsidisation of products.
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
The Government seeks to influence the behaviour of prescribers through a number
of strategies, including:
•   budget-holding. Most GPs have entered into budget-holding arrangements to
encourage cost-effective use of medicines;
•   treatment restrictions. For some pharmaceuticals, patients need to meet specified
criteria in order to be eligible for subsidy;
•   prescriber guidelines. Physicians use these guidelines for more appropriately
targeting pharmaceutical use. However, no sanctions are in place if physicians
do not adhere to the guidelines (Jacobzone 2000, p. 75); and
•   restricted prescribing rights. Pharmac’s Pharmaceutical Schedule has restrictions
that also extend to the type of prescriber, which aim to improve targeting.
Examples include:
-  hospital pharmacy-specialist prescription. Prescriptions may only be written
by a medical practitioner in the specialist category defined by the Schedule,
and only hospital pharmacies may dispense; and
-  specialist authority. These are only subsidised after approval is obtained from
Health Benefits Limited (patient must meet the specific criteria)
(OECD 2001, p. 271).
Policies to encourage generic substitution
The Commission was unable to find any information on the size of generic markets
in NZ.
Under a preferred brand arrangement, pharmacists are required to dispense only the




doctor’s approval to substitute the preferred pharmaceutical (if the prescription
specifies a non-preferred brand).
B.4 Spain
Overview of the Spanish health care system
Health services in Spain are provided predominantly by the public sector, with
approximately 77 per cent of total health expenditure funded by the public sector
(table B.1). A mix of central and regional health authorities provide public health
care services. Health services in ten regions are administered by the central
Government through the Instituto Nacional de la Salud (the National Health
Institute). Services in a further seven autonomous regions are provided by regional
health authorities. Private sector expenditure on health care is funded via direct
patient payments and insurance schemes.
Under Spain’s health care system, most forms of medical treatment are provided
free of charge. However, the consumer’s freedom to chose his or her doctor or
hospital is limited and patients must make a contribution towards the cost of
prescription pharmaceuticals.
Compared to many other European countries, the share of GDP devoted to
health care spending in Spain is low. Total public health care expenditure in Spain
was US$39.5 billion in 1997, representing approximately 7.4 per cent of GDP.
Main features of the pharmaceutical system
The proportion of total and public health care spending devoted to pharmaceuticals
rose throughout the 1990s. In 1996, the Ministry of Health reported that
pharmaceutical expenditure had risen by 130 per cent over the previous seven years.
In 1997, total spending on pharmaceuticals accounted for around 20.7 per cent of
total health care costs — which is high compared with many other European
countries. A relatively large share of pharmaceutical expenditure is financed
through the public sector (around 73  per  cent in 1997)  —  higher than all other
countries listed in table B.1.
Pharmaceutical production in Spain was around US$7.0  billion in 1994,
representing about 1.4 per cent of GDP (OECD 2000). In 1996, Spain was a net
importer of pharmaceuticals (exports were valued at US$1.4 billion and imports at
US$2.4 billion) (Jacobzone 2000, p. 68).PHARMACEUTICAL
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Until 1992, Spain did not recognise the patent protection of pharmaceutical
products, although process patents were recognised (Medicos sin Fronteras,
pers. comm., 18 May 2001). Therefore, a large number of copy products exist on
the Spanish pharmaceutical market, which are significantly cheaper than the
originator product (Kanavos 1999b).
Subsidy arrangements
Like Australia, the pharmaceutical subsidy arrangements in Spain provide for
universal coverage of the population and cover a wide range of prescription items.
Prescription pharmaceuticals in Spain are subsidised under a national scheme with
universal coverage. The Spanish Agency of Medicines grants the marketing
authorisation. All matters regarding pricing and reimbursement of pharmaceuticals
are the responsibility of the central Government (Medicos sin Fronteras,
pers. comm.,  18 May 2001).  The  Dirección General de Farmacia y Productos
Sanitarios (Directorate General of Pharmacy and Health Products (DGFPS)) within
the Ministry of Health is responsible for pharmaceutical affairs.
According to Kanavos (1999b,  pp.  154–155), Spain has both a negative and a
positive list. Prior to 1993, all prescription pharmaceuticals were automatically
granted reimbursement status. In 1993, approximately 800 products were excluded
from reimbursement and placed on a negative list (Kanavos 1999b, p. 155). In 1998,
more products were added to this negative list (OECD 2001, p. 291).
In deciding whether to list a product on the reimbursement formulary, the
Subdirección General de Planificación Farmacéutica (Pharmaceutical Planning
area) within the DGFPS takes into account a number of factors, such as:
•   the severity of the medical condition that the pharmaceutical is designed to treat;
•   the usefulness of the pharmaceutical; and
•   the efficacy and cost of the pharmaceutical compared to products that are
already listed.
A product may be refused listing if the Government considers that the price
proposed by the company is too high.
Most patients must make a contribution (copayment) towards the cost of
prescription pharmaceuticals, which is based on a proportion of the pharmaceutical
price. The disabled, people over 65 years of age, hospital patients and people being
treated for work-related injuries are exempt from paying copayments. The




pharmaceutical (Medicos sin Fronteras, pers.  comm., 18  May  2001).8 A reduced
copayment of ten per cent applies to those suffering from chronic or life-threatening
illnesses (up to a maximum of Pst439, around A$4.20, per prescription).
Pricing of pharmaceuticals
The Government controls the prices of all pharmaceuticals launched in the Spanish
market (Kanavos 1999b,  p.  151). Spain uses a mix of measures to influence
pharmaceutical prices. As well as direct price controls for prescription
pharmaceuticals, the Spanish Government has negotiated a set of profit controls
with the pharmaceutical industry.
The Subdirección General de Estudios Económicos (Economic Affairs area), within
the DGFPS, is responsible for price setting and price reviews. Prices of
pharmaceuticals are determined taking into account several factors including:
•   European price comparisons;
•   therapeutic equivalents available locally and their local prices;
•   innovativeness;
•   profits;
•   R&D in Spain;
•   volume and value of sales;
•   manufacturing and marketing costs (including distribution and
promotion/advertising costs); and
•   general administrative expenses (Medicos sin Fronteras, pers. comm., 18 May
2001).
According to Medicos sin Fronteras (pers. comm., 18 May 2001), the main factors
used when determining prices of pharmaceuticals subsidised by the national scheme
are the first two factors listed above, and, if the product is not manufactured in
Spain, the transfer price established by the company. Although economic
evaluations are currently used for hospital negotiations, they are not generally used
in price negotiations or in determining reimbursement conditions (Medicos sin
Fronteras, pers. comm., 18 May 2001).
A reference pricing system was proposed in 1996, and approved in 1999. At the
beginning of 1999, around 50 bioequivalent generic pharmaceuticals, already on the
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market, were to be included in the reference price list. It was expected that
approximately 200 generic pharmaceuticals were to be included on the list by the
end of 1999 (Kanavos 1999b, p. 152). However, the reference pricing system was
only fully implemented at the end of 2000. Currently, it applies to 74 active
ingredients available as generics, marketed in 753 different presentations (that is,
different pharmaceutical forms, dosage, and pack sizes) (Medicos sin Fronteras,
pers. comm., 18 May 2001).
The reference price is set in the range 10–50 per cent below the most expensive
medicines in each group of products. During the first trimester of 2001, the
introduction of this system, besides other mechanisms, resulted in the first decrease
in nominal pharmaceutical expenditure in 12  years (a five  per  cent decrease)
(Medicos sin Fronteras, pers. comm., 18 May 2001).
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
In 1998 the National Health Institute started monitoring the prescribing behaviour
of physicians. The objective of the Institute is to monitor pharmaceutical
expenditure by the physician’s patients, rewarding those physicians with patient
spending below a certain level but who still meet a number of good clinical practice
and patient satisfaction criteria. Physicians may be awarded roughly 20 per cent of
the savings made.
The Institute offers financial incentives to physicians in primary care, by giving
bonuses of up to Pst125 000 to each physician who prescribes generics for at least
six per cent of all prescriptions. In December 1999, generic prescribing accounted
for only 3.5 per cent of the total prescribing in primary care (EGA Spain 2001).9
Policies to encourage generic substitution
The Ministry of Health has conducted several information campaigns promoting the
use of generics and emphasising their safety, efficacy, and quality to physicians and
the public.
Generic substitution is compulsory for the pharmacist. Further, the Spanish
Government recently announced that the mark-up to pharmacists on generic
                                             




products would increase to 33  per  cent compared to 29  per  cent for non-generic
products (Medicos sin Fronteras, pers. comm., 18 May 2001).
B.5 Sweden
Overview of the Swedish health care system
Sweden has a decentralised health care system. The Minister for Health and Social
Affairs is responsible for overall health policy and proposing legislation. The
23  County Councils are responsible for the overall planning and allocation of
resources towards health services. County Councils also run and own hospitals,
health centres and other institutions. Municipalities, the lowest tier of government,
are responsible for long-term care, domiciliary care and nursing homes.
Main features of the pharmaceutical system
Sweden’s expenditure on out-patient pharmaceuticals increased substantially in the
1990s, as it did in Australia. For example, between 1990 and 1998, expenditure on
pharmaceuticals almost doubled, rising from approximately SKr7  billion to
SKr13  billion (RFV  2000a). According to Willison (Canada, pers.  comm.,
16 May 2001), this increase in expenditure may be linked with Sweden joining the
European Union (EU) in 1995 and the subsequent influx of many more
pharmaceuticals into the Swedish market.
Sweden has higher per capita expenditure on pharmaceuticals and health care than
Australia. Further, the public sector share of expenditure is also higher than
Australia (OECD 2000).
Like the UK, pharmaceutical production in Sweden accounts for a large percentage
of its GDP. For example, pharmaceutical production was US$4.4  billion or
approximately 1.7 per cent of GDP in 1996 (OECD 2000).
Sweden, like France and the UK, is a net exporter of pharmaceuticals. Sweden’s net
exports totalled US$1.6 billion in 1996.
Subsidy arrangements
Like many European countries, Sweden has a universal social insurance scheme.
The scheme is available to all residents, including emergency patients from the
EU/EEA countries and seven other countries. The scheme is administered by thePHARMACEUTICAL
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National Social Insurance Board (the Riksförsäkringsverket, RFV) and the social
insurance offices. The social insurance scheme is financed primarily through payroll
taxes, with County Council grants and patient copayments providing the remainder
of funding. Special County Council grants and patient copayments cover out-patient
costs for pharmaceuticals (RFV, pers. comm., 23 May 2001).
All prescription pharmaceuticals are automatically placed on a positive subsidy list
once approval for marketing and a retail price are obtained. The positive list is
called the Drug Benefit Scheme (DBS) and covers most prescription
pharmaceuticals plus some over-the-counter (OTC) products. Sweden also has a
negative list for pharmaceuticals. The negative list includes cough remedies,
nicotine substitutes and hair restorers. In 2001, pharmaceuticals for the treatment of
obesity and erectile dysfunction were added to this negative list (RFV, pers. comm.,
23 May 2001).
Before a pharmaceutical can be included on the DBS, companies must apply for a
reimbursement price from the RFV. It typically takes between three and six weeks
to obtain a reimbursement price, but price negotiations may begin prior to market
authorisation (RFV 2000b).
In seeking a reimbursement price for a new product from the RFV, companies must
provide information on:
•   its safety and efficacy (as determined by the Medical Agency);
•   the requested pharmacy purchase price of the product;
•   prices of competing products in the domestic market and abroad;
•   the health and economic value of the product; and
•   projected sales volumes for the first three years (RFV, pers.  comm.,
23 May 2001).
There are no formal economic evaluation guidelines in Sweden, but if a
manufacturer of a new innovative pharmaceutical seeks to obtain a premium price,
some form of economic evaluation is always requested. The RFV (2000b) argues it
prefers cost-benefit documentation on a macro level, though it does accept cost-
minimisation, cost-effectiveness and cost-utility analysis, when they address a
particular issue at hand. There are no immediate plans to introduce economic
evaluation guidelines in Sweden (RFV 2000b).
Patient copayments were introduced in Sweden in 1990, with all patient groups,
with the exception of insulin users, making copayments. In 1997, a new system for
patient copayment was introduced (RFV, pers. comm., 23 May 2001). It also was




be transferred to the County Councils (RFV  2000a). However, currently (and
probably for the next few years at least) it will be a shared responsibility between
the Government and the County Councils.
Consumers bear the full cost of their pharmaceutical consumption expenditure up to
the point where their total pharmaceutical purchases, over a twelve-month period,
exceed SKr900 (A$173). When the total purchases exceed this amount, the cost of
pharmaceuticals will be subsidised. The reimbursement rate progressively increases
with consumer purchases, until the ceiling of SKr1800  (A$346)  per  annum is
reached. Once pharmaceutical expenditure has reached this level, the
reimbursement rate is 100  per  cent (OECD 2001,  p.  302; RFV, pers. comm.,
23 May 2001).
Pricing of pharmaceuticals
The RFV uses a reference pricing system (introduced on 1 January 1993) to set the
reimbursement price of multi-sourced off-patent pharmaceuticals and prescribed
OTC pharmaceuticals — the system excludes patented pharmaceuticals. By
definition, the system covers only about ten per cent of market volume and the RFV
has no plans for its extension (RFV 2000b).
The reimbursement price is set by reference to the price of the cheapest product
available with the same active ingredient, pack size, dosage and route of
administration (Kanavos 1999b), plus a ten per cent margin above the price of the
cheapest generic (Drummond et al. 1997). If a pharmaceutical on the list had a price
above the reference price level, the patient would pay the difference
(Nilsson et al. 2000).
The reimbursement price of pharmaceuticals on the DBS cannot increase within two
years of the product’s launch. Further, the RFV restricts price negotiations to once
per year. Pharmaceutical companies are allowed, however, to reduce the price of
their product at any time. The RFV regularly reviews the reimbursement prices
(RFV, pers. comm., 23 May 2001).
The RFV often includes a price-volume agreement when setting the price of new
innovative pharmaceuticals on the DBS. This enables the RFV to limit the expected
costs to the DBS by lowering the pharmaceutical price if sale forecasts, submitted
by the manufacturer to the RFV, are exceeded.
The RFV also uses cross-country price comparisons when fixing the price of a
product. Pharmaceutical manufacturers must provide information on prices in other
EU countries where the product is marketed. The RFV aims to award a ‘EuropeanPHARMACEUTICAL
PRICES STUDY
B.26
price’ (RFV, pers. comm., 23 May 2001). According to Kanavos (1999b, p. 246),
the RFV seeks to ensure that the ‘Swedish price should be similar to that in Finland
and Norway, but lower than that in Denmark, the Netherlands, Germany and
Switzerland’.
More recently, proposals were developed to create a new pricing authority and to
change the method of setting prices for pharmacists (RFV, pers. comm.,
23 May 2001).
Prescribing guidelines, limitations and budgets
There are no national prescribing guidelines in Sweden but regional pharmaceutical
and therapeutic committees have been established to provide doctors with
information on more cost-effective treatments. The guidelines suggested by these
committees are not policed and no sanctions are imposed upon doctors breaking the
suggested guidelines. However, the County Councils’ increased economic
responsibility will most probably lead to increased control of prescribing costs
(RFV, pers. comm., 23 May 2001).
Policies to encourage generic substitution
In 1994, generic substitution and parallel imports were allowed (RFV, pers. comm.,
23 May 2001). In 1999, sales of generics (excluding originators) accounted for little
more than five per cent of the Swedish pharmaceutical market (Kanavos  1999b).
Kanavos (1999b) also indicated that this percentage remained stable for the few
years leading up to 1999.
A study by Nilsson et al. (2000) found that the share of generic pharmaceuticals
(including originator brands) available as a proportion of the total number of
pharmaceuticals available in Sweden decreased from 44  per  cent in 1980 to
30 per cent in 1997.
Nilsson et al. (2000) also argued that a large share of generic pharmaceuticals fail
on the market within a few years of their introduction. Examining individual
products over time, the study found that between 1991 and 1996, of the group of
generic pharmaceuticals approved by the Swedish Medical Products Agency, 30 out
of the 32 originator pharmaceuticals were still in the market compared to 17 out of
the 31 generic copies. The originator pharmaceuticals had 70 per cent of the sales
volume and 88 per cent of the sales value.
Nilsson et al. (2000) speculate that the Swedish reference pricing system may be




According to this study, the main advantage most generic copies have over the
branded originator is the fact that the copies can compete on the basis of lowering
their prices well below the originator’s price to gain market share. With reference
pricing, the prices of most pharmaceuticals (including high-priced branded
generics) are lowered to the reference price level. This mechanism reduces the
ability of generic producers to compete with the branded originator on the basis of
price setting. Further, in Sweden, generics are advertised much less than the original
products and there are no strong incentives for physicians to prescribe inexpensive
medicines.
The low level of generic sales has persisted despite the 1994 reforms allowing
pharmacists to substitute a generic pharmaceutical for a prescribed pharmaceutical,
if they receive approval from the doctor. Like many other countries, approval is not
required if the name of the manufacturer or importer is absent from the prescription
and the product is available under the same name from different sources.
The 1994 reforms also required the Medical Products Agency to provide doctors
with generic information and for doctors to pass this information on to patients.
B.6 United Kingdom
Overview of the UK health care system
Per capita health expenditure in the UK (at US$1685) is similar to that in Australia,
while the proportion of public expenditure on health is around 84 per cent — the
highest of all the other countries listed in table B.1. The UK also has a relatively
older population, with 16 per cent aged 65 and over (table B.1).
The National Health Service (NHS) provides universal health care coverage. It is
funded by general taxation (96  per  cent) and patient copayments (four  per  cent)
(Warner-Lambert 1999). Patients have to register with GPs, who control access to
specialists.
In addition, approximately 11  per  cent of the population are covered by private
health insurance. Private health insurance is not an alternative to the NHS, nor does
it complement the NHS. It only provides a superior level of comfort and quicker
access to treatment. Of those within the private schemes, employers pay around
60 per cent of contributions (Kanavos 1999b).PHARMACEUTICAL
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Main features of the pharmaceutical system
Pharmaceutical production in the UK was US$16.2 billion in 1994 (accounting for
1.6 per cent of GDP), compared to US$1.3 billion in 1970 (OECD 2000). In 1996,
pharmaceutical exports were valued at around US$7.8  billion and imports at
US$4.5 billion (Jacobzone 2000, p. 68).
In 1997, public expenditure on pharmaceuticals and other medical non-durables
accounted for 12.5  per  cent of total public expenditure on health in the UK
(table  B.1). This was considerably higher than Australia (8.7  per  cent), Canada
(7.0 per cent), Sweden (10.9 per cent) and the US (3.7 per cent).
Between 1990 and 1997, the average rate of growth of pharmaceutical expenditure
was 8.5 per cent per annum, while public expenditure on pharmaceuticals grew on
average at around 8.0 per cent per annum (OECD 2000).10
Subsidy arrangements
The UK Government subsidises pharmaceuticals for the whole population, through
the NHS. This scheme is similar to Australia — it is a national scheme with
universal coverage.
All prescription pharmaceuticals approved for marketing in the UK, except for
those included on the pharmaceutical negative list, are automatically reimbursed in
full (Kanavos 1999b). There are approximately 10 000 products prescribed in the
community (DoH, pers.  comm., 22  May  2001). The NHS (General Medical
Services) Regulations 1992 lists a large range of pharmaceuticals (known as
Schedule ten or the ‘Black List’) which are not subsidised under the NHS.
Approximately 3000 pharmaceuticals are listed in Schedule ten (Lockharts
Solicitors 1999). The pharmaceuticals included in the Black List are mostly OTC
pharmaceuticals, including analgesics for mild to moderate pain, indigestion
remedies, laxatives, cough and cold remedies, vitamins, tonics, benzodiazepine,
sedatives and tranquillisers, anti-diarrhoeals, drugs for allergic disorders, hypnotics
and anxiolytics, appetite suppressants, drugs for vaginal and vulval conditions,
contraceptives, drugs used in anaemia, topical anti-rheumatics, drugs acting on the
ear and nose, and drugs acting on the skin (excluding the generic forms) (DoH,
pers. comm., 22 May 2001).
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In addition, 11 pharmaceuticals (four relate to treatment of erectile dysfunction) are
listed in a second schedule (Schedule 11) which may only be used for the treatment
of certain specified conditions (DoH, pers. comm., 22 May 2001).
The Advisory Committee on NHS Drugs determines the Black List. In assessing
whether a product is black-listed, the Committee determines whether the product is
necessary to provide either therapeutic or preventative treatment within the general
medical services of the NHS. If there is a clinical need for this product, the
Committee will then consider if the need is being met by another product already
available under the NHS. If a product meets the same clinical need effectively and
is at a lower price than listed products, the Committee recommends that the product
in question be available under the NHS. If not, the product will be black-listed. The
Committee periodically updates the Black List (Stanbridge 1997).
The National Institute for Clinical Excellence (NICE) was set up on 1 April 1999
(as part of the NHS). The role of NICE is different to that of the Pharmaceutical
Benefits Advisory Committee (PBAC) in Australia.
The role of NICE is to offer guidance and advice rather than to recommend which
products should be eligible for subsidy. NICE aims to provide patients, health
professionals and the public with robust, reliable national guidance on current ‘best
practice’. The guidance will cover both individual health technologies (including
pharmaceuticals, medical devices, diagnostic techniques, and procedures) and the
clinical management of specific conditions (NICE 1999).
NICE will provide NHS health professionals with three types of guidance:
•   the results of appraisals of new and existing health technologies. For new
technologies, the focus will largely be on those expected to have significant
clinical or resource impact on the NHS. Existing technologies will be those for
which there are unexplained or unacceptable variations in use, or controversy
about their clinical and/or cost-effectiveness. The results of the appraisal process
will provide patients and health professionals with a single, authoritative source
of advice;
•   clinical guidelines developed to assist practitioner and patient decisions about
appropriate health care for specific clinical circumstances; and
•   simple methods of clinical audit to monitor the use of particular interventions, or
the care received by patients, against agreed standards (NICE 1999).
For subsidised pharmaceuticals, individuals pay a fixed amount per prescription.
The standard prescription charge is currently £6.10, irrespective of the actual cost of
the pharmaceutical. In practice, only a small percentage of prescriptions attract a
copayment fee. For instance, in 1999, over 85 per cent of all prescriptions filled inPHARMACEUTICAL
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England did not incur a copayment fee (DoH, pers.  comm., 22  May  2001). The
elderly, pregnant women, students and people on low incomes are exempt from this
copayment (Stanbridge  1997). Patients also can opt to purchase pre-payment
certificates, which effectively cap total copayments (Jazobzone 2000).
Pricing of pharmaceuticals
The UK is one of the few countries in the OECD where the Government does not
control the manufacturer prices of new subsidised pharmaceuticals directly.
However, it does intervene in price setting indirectly through regulating the
profitability of pharmaceutical companies supplying certain products to the NHS
under the Pharmaceutical Price Regulation Scheme (PPRS).
The PPRS is a voluntary agreement made between the Department of Health (DoH)
and the pharmaceutical industry represented by the Association of the British
Pharmaceutical Industry (ABPI). It has operated in various forms since 1957. A
new scheme commenced on 1 October 1999 and will apply until 2004. The scheme
applies to branded pharmaceuticals (whether covered by a patent or not), but does
not apply to non-branded generic pharmaceuticals, exports, medicines sold under
private prescriptions, and non-subsidised OTC medicines sold to the public
(Kanavos 1999b).
The objectives of the PPRS include:
•   to secure the provision of safe and effective medicines for the NHS at reasonable
prices;
•   to promote a strong and profitable pharmaceutical industry capable of sustained
R&D expenditure to ensure the future availability of new and improved
medicines; and
•   to encourage the efficient and competitive development and supply of medicines
to pharmaceutical markets in the UK and other countries (DoH 1999a, p. 4).
The PPRS provides a framework for determining reasonable limits to profits made
from the supply of medicines to the NHS. Under the PPRS, all pharmaceutical
companies must submit an annual financial return (AFR) presenting the sales,
costs11 and capital employed for sales to the NHS.
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There are two levels of return on capital (ROC) targets:12
•   level  1, used to decide price increase applications, has a ROC target of
17 per cent per annum; and
•   level 2, used to analyse companies’ AFRs, has a ROC target of 21 per cent per
annum (DoH 1999a).
These allowable returns will be associated with an upper margin of tolerance
(MOT). Companies will be able to retain profits of up to 140  per  cent of the
level two ROC target.13 The MOT will not be available to a company for any year
in which it has had a price increase agreed by the DoH.
If the DoH’s assessment of an AFR shows profits in excess of the MOT, it will
negotiate one or more of the following:
•   price reductions, during the following year sufficient to bring prospective profits
down to an acceptable level, on the basis of available forecasts;
•   repayments of that amount of past profits which are agreed to exceed the MOT;
and/or
•   a delay and/or restriction of price increases agreed for the company.
New pharmaceuticals introduced following the granting of an EU or UK new active
substance marketing authorisation may be priced at the discretion of the company,
subject to its total profit constraint (DoH 1999a, p. 16).14
Firms in the PPRS wishing to raise the prices of existing pharmaceuticals must seek
approval from the DoH. Price increases will only be approved if the DoH’s
assessment shows that the forecast profits in the current and following financial
year of a company are below 50 per cent of their level one ROC target. No price
increase is allowed within 12 months of a previous increase, and no price increase is
allowed to compensate for loss of revenue as a result of other government initiatives
(for example, price reductions under the Selected List Scheme) (DoH, pers. comm.,
22 May 2001).
                                             
12 The allowable ROC which may be earned by companies from home sales of NHS medicines
will be based on the historical value of average capital employed.
13 Taking the MOT into account, companies have an effective ROC of nearly 30 per cent.
14 The constraint is defined as a rate of return on manufacturers’ total NHS capital stock (DoH,
pers. comm., 22 May 2001). A company must provide costs and capital included in its AFR
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As part of the 1999 agreement between the Government and industry there was a
4.5  per  cent decrease in prices of branded pharmaceuticals listed on the
reimbursement list from 1 October 1999 (DoH, pers. comm., 22 May 2001).
In August 2000, a statutory maximum price scheme was put in place covering the
main unbranded generic medicines supplied for NHS use in the community (DoH,
pers. comm., 22 May 2001). Up to the end of 1998, competition in the market and
incentives on community pharmacists to buy more cheaply than the headline price
at which they were reimbursed had produced a gradual decline in the prices of
generics over a period of years. In 1999, this trend was reversed and prices rose
steeply. The maximum price scheme was introduced in response.
The scheme prohibits supply of certain generic medicines to community pharmacies
and dispensing doctors, for NHS use, for more than a stated maximum price. The
scheme applies mainly to 500 or so presentations of the preparations with the
highest net ingredient cost. The maximum prices have been set primarily by
reference to the historic prices that were reimbursed to community pharmacies and
dispensing doctors, with some adjustment following consultation with interested
parties.
Changes to the supply and reimbursement of generic medicines, including pricing
arrangements, may result from a long-term review of the generics supply chain
which is currently under way (DoH, pers. comm., 22 May 2001).
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
Most doctors have access to a computerised prescribing advice system offering
recommended treatment options on a range of clinical conditions (called
PRODIGY). Under this system, a prescription also can be generated with the
generic product as the default (Kanavos 1999b).
In the UK, from April 1999, all GPs have pharmaceutical budgets within Primary
Care Groups (Kanavos 1999b). Spending by physicians is tracked monthly by the
Prescription Analysis and Cost system (BCG  1999). The system is designed to
provide an incentive for physicians to reduce the cost of their prescribing.
According to the DoH (pers.  comm., 22  May  2001) individual GP practices can
earn incentive payments (modest sums to be spent for the benefit of patients) if they
meet budgetary criteria and improve their prescribing to meet other specified




Policies to encourage generic substitutions
For generic products, the main measures in place are the default prescription on the
prescribing system and financial incentives available to doctors. At present over
65 per cent of all scripts are written generically, although these account for less than
a quarter of total pharmaceutical expenditure (Kanavos  1999b). As well,
pharmacists can substitute a generic product on a script where the product’s patent
has expired.
B.7 United States
Overview of the US health care system
The health care system in the US is mainly privately funded and provided. The
public sector share of total expenditure on health is around 44 per cent in the US —
the lowest compared to the seven other OECD countries listed in table B.1. Public
health care is a shared federal and state government responsibility. Public
health care arrangements are targeted at:
•   the elderly (through Medicare), which reimburses many medical benefits but
generally does not include coverage for out-patient pharmaceutical prescriptions;
•   the poor (via the Medicaid program) which includes comprehensive
pharmaceutical coverage; and
•   veterans of military service (via the Veterans Administration), which includes
comprehensive pharmaceutical coverage (GAO, pers. comm., 22 May 2001).
Within the private health insurance sector, there has been a shift to managed care
plans15 because they can generally charge lower prices than conventional insurance
plans. The proportion of full-time workers with health insurance who were enrolled
in such plans increased from around 26  per  cent in 1988 to 61  per  cent in 1995
(CBO 1998).
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Managed care organisations are financed primarily through employer/employee and
individual contributions, and beneficiaries are encouraged to use the services
provided by health care providers who are part of the organisation.
Main features of the pharmaceutical system
The US is the main producer of pharmaceuticals, with its production increasing
from US$6.6 billion in 1970 to US$82.5 billion in 1996 (OECD 2000). However,
the US is not the largest exporter of pharmaceuticals amongst the OECD countries.
The UK, for example, has higher exports. In 1996, the US exported US$6.84 billion
and imported US$6.99 billion of pharmaceuticals (Jacobzone 2000, p. 68).
The majority of expenditure on pharmaceuticals and other medical non-durables is
funded by the private sector. Most individuals have to obtain health benefits,
including prescription pharmaceutical coverage, through employers who purchase
health insurance or contract with a managed care plan (GAO,
pers. comm., 23 May 2001).  Table B.1  shows  that  although  per  capita  total
expenditure on pharmaceuticals and other medical non-durables is US$451 in the
US (higher than all countries except France), public expenditure only accounts for a
small part of this (US$70 per capita).
Between 1990 and 1997, the average rate of growth of total pharmaceutical
expenditure16 was 8.9  per  cent per annum, while public expenditure grew on
average at around 13.5 per cent per annum (OECD 2000).
Subsidy arrangements
The US Government generally subsidises the cost of a limited number of
pharmaceuticals to particular segments of the population, namely the poor (through
Medicaid), and defence personnel and veterans of military service (through the
Department of Veterans Affairs).
Generally, the Medicare benefit package (covering people aged 65 and over, some
disabled people under 65 years of age, and people with permanent kidney failure
treated with dialysis or a transplant) does not provide subsidies for out-patient
pharmaceuticals (GAO  2000a). However, Medicare beneficiaries can choose to
have prescription pharmaceutical coverage by choosing to receive their Medicare
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bandages, elasticised stockings, incontinence articles, condoms and other mechanical
contraceptive devices). It also includes spending on prescription medicines and OTC products,




coverage from a Medicare+Choice plan that offers this benefit (GAO, pers. comm.,
23 May 2001). Services provided to Medicare+Choice plans are through a managed
care organisation (GAO 2000a).
Medicare beneficiaries also can purchase Medigap policies, or supplemental
insurance, but only three of the policies offer pharmaceutical coverage (GAO,
pers. comm.,  23 May 2001).  Eight per cent  of  Medicare  beneficiaries  have
prescription pharmaceutical coverage through Medigap. However, these packages
have a 50  per  cent copayment, a US$250 deductible, and a cap at either
US$1250 or US$3000 (Mathematica Policy Research 2000).
Medicaid is a jointly funded federal/state health insurance program.17 Although
federal government guidelines exist, each of the States is responsible for:
establishing eligibility standards; determining the type, amount, duration, and scope
of services; setting the rate of payment for services; and administering the program.
Most state Medicaid programs pay for prescribed pharmaceuticals. States may
impose nominal deductibles or copayments for Medicaid coverage, but in practice
this is rare (Hood 1997, p. 6).18
The Veterans Administration is a separate government scheme that provides
subsidised out-patient pharmaceutical services to veterans of military service.
Veterans who receive medications for treatment of service-related conditions, or
who have incomes that do not exceed the maximum Veterans Administration
pension, receive free out-patient pharmaceutical services. Other veterans who have
prescriptions filled by the Veterans Administration may be charged US$2 for each
30-day supply of medication (Department of Veterans Affairs 2001).
Most people in the US are either enrolled in private health insurance schemes —
which provide subsidised pharmaceuticals to their enrollees — or are uninsured
(18.4 per cent of the non-elderly population in the US had no health insurance in
1998 (The  Economist  2000)), in which case pharmaceuticals are purchased at
market (that is, unsubsidised) prices.
The private health insurance schemes are generally provided by managed care
plans, and include Health Maintenance Organisations (HMOs), Preferred Provider
                                             
17 Medicaid is for certain low-income and needy people. It covers approximately 36  million
individuals including children, the aged, blind, and/or disabled, and people who are eligible to
receive federally assisted income maintenance payments (HCFA 2001).
18 According to the GAO (pers. comm., 23 May 2001), most State Medicaid programs require
participants to pay nominal copayments, but allow pharmacies to waive the copayments if
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Organisations (PPOs) and Point-of-Service (POS) plans.19 Copayments are usually
required for prescription pharmaceuticals. Most types of managed health care plans
have moved to ‘managing’ their out-patient prescription pharmaceutical benefits
through pharmaceutical benefit management (PBM) companies.
Within the privately-run managed health care sector, most schemes will have some
form of pharmaceutical formulary (reimbursement list), which lists pharmaceuticals
that are preferred for use and are subsidised by the plan. The lists are reviewed
periodically and modified by the respective plans. The list may be:
•   an ‘open or voluntary’ formulary, allowing coverage for both formulary and
non-formulary medications, with beneficiaries paying no more for using
non-formulary pharmaceuticals; or
•   an ‘incentive-based’ formulary which offers enrollees lower copayments for the
preferred product and generic pharmaceuticals, and partly subsidises
non-formulary products, but the copayments are higher; or
•   a  ‘closed, select or mandatory’ formulary which limits coverage to selected
pharmaceuticals and requires enrollees to pay the full cost of non-formulary
pharmaceuticals (GAO 2000b).
PBM companies negotiate to pay lower prices for pharmaceuticals to both the
manufacturers and the pharmacists. With a pharmacist, a PBM company channels
their patients to use a particular pharmacy in return for lower retail prices. With
manufacturers, the PBM companies negotiate lower prices based on their ability to
influence their physicians and members to prescribe and consume particular
brand-name products listed on their formulary. If there is a choice of
pharmaceuticals, the least costly products are listed on the plan’s formulary
(Health Net 2001).
For private sector managed care plans (such as HMOs), fixed or variable
copayments are required for prescriptions. Deductibles also usually apply
(CBO 1998, p. 10). Currently, around 30 per cent of pharmaceutical costs are borne
by cash paying patients (BCG 1999). However, this share is declining with the rise
of HMOs and government programs.
                                             
19 Enrollees in a HMO generally must seek services from those physicians and hospitals
associated with the HMO. Those enrolled in PPOs can receive services from any provider, but
pay higher deductibles and copayments if they choose service providers outside the PPO’s
network. POS plans (also known as open-ended HMOs) allow their enrollees to receive
services from providers outside the plan’s network. When enrollees use the network providers,
a POS plan functions in a similar manner to HMOs. When other providers are used, the





Most private insurance plans have copayment requirements. For example,
60 per cent of retail sales are paid by a third party to some extent (BCG 1999). A
1993 survey by the Bureau of Labor Statistics found that HMOs generally charged
US$3 to US$5 for a prescription pharmaceutical purchase (CBO  1998,  p.  10).
Under government plans, the copayments (if any) required for prescriptions are
small.
Pricing of pharmaceuticals
In general, pharmaceutical companies and suppliers are free to price their products
as they see fit for the majority of the US pharmaceutical market. However,
depending on the subsidy program (private or government) various measures are
used to contain the prices of subsidised pharmaceuticals.
Most government programs that cover prescription pharmaceuticals mandate some
form of price control such as a mandatory rebate, discount, price cap or limit on
price increases. The Medicaid Drug Rebate Program, in particular, requires that
companies which sell to Medicaid provide rebates equal to the greater of
15.1 per cent of the average manufacturers price (AMP)20 or the difference between
the AMP and the manufacturers ‘best price’ to any other purchaser. Additional
rebates are required for any products where price increases exceed the CPI
(GAO 2000c).
In the private sector, managed care plans also adopt a variety of techniques to
control manufacturer prices of pharmaceuticals on their reimbursement lists. Direct
negotiations with pharmaceutical manufacturers often result in rebates (discounts)
being offered by manufacturers to plans, thereby reducing the actual cost of
pharmaceuticals. Cost-containment measures also extend to the distribution
network, with plans negotiating reimbursement rates and dispensing fees with
pharmacies (GAO 2000b).
Other cost-containment mechanisms
Prescribing guidelines, limitations and budgets
Prescribing guidelines for doctors are set by managed care organisations. The extent
of recommendations and use of sanctions depends on the type of managed care
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setting involved (Jacobzone  2000). Formularies, usually listing generics where
possible, also are used to encourage doctors to prescribe more cost-effectively.
Policies to encourage generic substitutions
Some government health programs, such as Medicaid, and many private health
insurance plans have actively promoted generic substitution (CBO 1998). As well,
by 1980, most States had passed laws allowing pharmacists to dispense a generic
pharmaceutical even if the prescription called for a branded product.
The Drug Price Competition and Patent Term Restoration Act 1984 (also known as
Hatch-Waxman Act) made it easier and less costly for generic pharmaceutical
manufacturers to enter the market. Manufacturers needed only to demonstrate
‘bioequivalence’ to an already approved innovator pharmaceutical (that is, that the
active ingredient is absorbed at the same rate and to the same extent in the generic
as in the innovator pharmaceutical). Manufacturers are not required to prove
independently the safety and efficacy of their products in the same way as new
chemical entities.
There are, however, provisions in the Hatch-Waxman Act that also can work to
delay the entry of generic competitors. For example, when the Hatch-Waxman Act
reduced the testing requirements for generic pharmaceuticals, it also extended
patent protection for new innovative pharmaceuticals (CBO 1998).
In addition, although the Hatch-Waxman Act provides the first generic producer (to
obtain a marketing approval) a period of six months exclusivity from the date it
commences marketing its pharmaceutical, it also allows for the US Federal Drug
Administration to automatically suspend the approval process of this new generic
product for 30 months if the producer of the originator product challenges the
prospective generic producer on the grounds that it has infringed a patent that is still
in force (OECD 2001).METHODOLOGY C.1
C Methodology
This appendix describes in detail the methodology used to undertake the price
comparison of Pharmaceutical Benefit Scheme (PBS)-listed molecules.
C.1 Introduction
Elements of the methodology that are explored in more detail in this appendix are:
•   choosing the basket of molecules for comparison;
•   choosing molecules within the basket;
•   matching molecules;
•   prices used;
•   converting prices to a common currency; and
•   weighting manufacturer prices.
C.2 Choosing the basket of molecules for comparison
The terms of reference for the study require the Commission to examine differences
between the prices of PBS-listed molecules and the prices received overseas, and to
explain, as far as possible, the reasons for any differences. In undertaking this task
one issue to be addressed is whether molecules not subsidised under the PBS should
be included as part of the price comparisons.
Defining the potential basket of molecules to include all prescription and
over-the-counter molecules irrespective of whether they are listed on the PBS would
provide the most comprehensive data set for this study. Also, including some non-
PBS-listed molecules could provide a ‘control group’ that could provide
information on the extent to which the PBS influences the prices of PBS-listed
molecules. However, the list of PBS molecules is extensive and covers a large share
of the Australian pharmaceutical market. Hence, there is likely to be a high degreeC.2 PHARMACEUTICAL
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of substitutability between many PBS and non-PBS molecules, limiting the size and
usefulness of a control group of non-PBS molecules.1
Cost and time constraints also precluded such a wide comparison of pharmaceutical
prices. Therefore, the study focuses on PBS-listed molecules. In doing so,
conclusions cannot be drawn about the impact of the PBS on overall pharmaceutical
prices in Australia. Inferences can only be drawn about those molecules listed on
the PBS.
C.3 Choosing molecules within the basket
There are approximately 820 molecules listed on the PBS. The practicalities of data
availability preclude including all these molecules in the price comparison. Hence,
it was necessary to identify a sample of PBS-listed molecules for comparison.
One possible approach is to select a pre-determined number of molecules from
those listed on the PBS at random. The aim of random sampling is to ensure that the
group of molecules chosen for the study is representative of all of those listed on the
PBS. It also allows for conclusions to be drawn about the general level of
pharmaceutical prices between Australia and overseas countries.
An alternative approach to choosing the sample of molecules is to select key
molecules based on their share of total expenditure (defined as the sum of patient
contribution and government subsidy), or the volume of consumption. Most
previous studies have chosen the molecules for comparison on the basis of total
expenditure (IC 1996).
Examination of PBS expenditure data shows that a small number of molecules
accounts for a large share of total expenditure under the scheme (figure C.1). The
top 250 pharmaceutical molecules account for over 90 per cent of total expenditure.
The top 150 molecules account for over 80 per cent.
                                             
1 A high rate of substitutability between PBS and non-PBS pharmaceuticals implies that
government interventions affecting the prices of PBS items also will affect the prices of
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a PBS expenditure data were adjusted using survey data collected by the Department of Health and Aged
Care for non-subsidised PBS medicines for the year 1998. b Expenditure on molecules listed part-way during
1999-2000 was annualised (appendix D).c Pharmaceuticals are ranked by total annualised expenditure.
Data source: DHAC.
The characteristics of the PBS expenditure data indicate that choosing molecules
based on total expenditure is the most appropriate approach for this study. The
approach ensures that the prices of those molecules that have the most influence on
pharmaceutical company revenues and Government subsidy payments are included
in the study. The ability to match Australian molecules with those in overseas
countries also is increased by focusing on those molecules that dominate
expenditure in Australia.
However, in taking this approach to choosing the molecules for price comparisons,
conclusions cannot be drawn about the general level of prices for PBS-listed
molecules between Australia and overseas countries. The sample of molecules is
not necessarily representative of the entire PBS market. Instead, inferences can only
be drawn for those molecules selected.
Categorisation of molecules
The terms of reference require that the basket of PBS molecules examined includes
three categories of molecules: new innovative; new chemical entities (me-too); andC.4 PHARMACEUTICAL
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molecules subject to generic competition (generics). The terms of reference also
specified that there be at least ten forms in each of these groups.
The Commission sought the assistance of the Department of Health and Aged Care
(DHAC) to categorise the top  150 molecules included in the price comparison.
DHAC categorised the sample of 150 molecules into one of the three categories
based on their status at (or as close as possible to) 30 June 2000. The number of
new innovative, me-too and generic molecules in the sample is 21, 49 and 80,
respectively (appendix D).
C.4 Matching molecules
Molecules are marketed to consumers in a wide variety of forms. A particular
molecule can be marketed in forms that can differ by the dosage type (for example,
tablets, syrups and injections), by strength (the amount of active ingredient) and by
pack size. In Australia, 584 different forms for the top 150 PBS-listed molecules
were identified for 1999-2000. It is important to note that the status of these
molecules will change over time as patents expire and new items are listed.
The variety of ways in which molecules are sold complicates international price
comparisons because the forms available for each molecule often differ between
countries. Two approaches have been developed to account for different forms of
molecules:
•   aggregation across forms; and
•   form matching.
Aggregation across forms
Aggregation across forms involves converting all dosage types, strengths and pack
sizes to a standard unit for comparison.2 One approach is to calculate a price per
gram of active ingredient. This is done by weighting the price per gram of active
ingredient for each form by its share of total sales revenue for all forms of the
molecule. An alternative approach is to calculate a price per standard dosage for
each molecule. This is done by converting different dosage types to a standard
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dosage for comparison. A standard dosage can be defined as one tablet, capsule or a
certain amount of liquid or cream.3
The aggregation across forms approach is comprehensive — it can include the price
and quantity for all forms in each country in the price comparison. In doing so, it
allows for global comparisons (all countries) to be undertaken because of the large
sample sizes involved. It also allows for a more rapid calculation of price indexes
compared to the form matching approach. This feature can be particularly important
if the prices of many hundreds of molecules (with each available molecule in many
different forms) are being compared across countries.
However, the approach also has some important disadvantages.
First, it is necessary to exclude molecules that contain multiple active ingredients
from the sample. This is because of difficulties in determining the weight of each
active ingredient in the molecule. For the top 150 molecules chosen for this study,
10 contain multiple ingredients.
Second, using this approach could show that a price differential exists even if the
forms and prices of all molecules are identical across countries. This is because the
price per gram of active ingredient or standard dosage may differ depending on the
dosage type.4 As the price of each form is weighted by its share in the total
expenditure on the molecule, the resulting index can indicate a price differential if
shares of the identical forms vary across countries.
Third, aggregation across forms is data intensive, as prices and quantities are
required for each form and for each country under comparison. In countries such as
the United States (US), there are many thousands of forms available (including
different pack sizes) for Australia’s top selling 150 PBS-listed molecules.
Form matching
The approach adopted by this study was to seek direct matches for each of the 584
forms of Australia’s 150 top-selling molecules in each comparison country
                                             
3 Another possible standard dosage is a defined daily dosage (DDD). DDDs are an international
unit of pharmaceutical utilisation. They are established by the Nordic Council on Medicines
and the World Health Organization Drug Utilisation Research Group. There is a level of
subjectivity associated with the development of DDD. DHAC also has noted that on some
occasions it is difficult to assign a DDD for a molecule with multiple active ingredients
(DHAC 1999b).
4 The price per standard dosage, such as price per tablet, also usually differs across forms. For
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(hereafter referred to as form matching).5 The form matching approach is designed
to achieve meaningful results through ensuring that, where possible, ‘like with like’
price comparisons are undertaken. Compared to alternative approaches used in
some previous studies (section  1.3), under a form matching approach prices
associated with injections and inhalers are not directly compared with those of
tablets and syrups. Also, the relevant comparison is usually between a price per
pack rather than per tablet or other measurement unit.
That said, the practicalities of matching many hundreds of forms necessitated
making some assumptions. While an attempt was made to match identical dosage
types, there often are many different forms within a particular dosage type. For
example, many types of tablets and capsules may be available in slightly different
forms, such as standard, slow-releasing or film-coated. In such cases, prices for
slightly different forms within a given dosage type were considered comparable for
this study.
Even by assuming comparability within a dosage type, in a number of instances a
direct match on the form available in Australia still could not be obtained in the
overseas country. Also, in some countries multiple prices exist for the same form of
molecule. The approach adopted for these instances was as follows:
•   if a match could not be obtained on dosage type or exact strength, the form was
removed from the sample (coded as no match molecule (NMM), form (NMF) or
strength (NMS));
•   if Australia’s pack size was unavailable in the overseas country, an estimate of
the price of this pack size was created in some instances; and
•   where multiple prices of the same form were encountered, a weighted average
price was calculated if overseas volume data were available. Otherwise, the
highest and lowest prices for the form were included in the price comparison.
In order to avoid making assumptions about the relationship between prices and
pack sizes or the link between price per unit of active ingredient and different
dosage types and strengths, higher and lower estimates of prices were reported for
each comparison country.6
                                             
5 A direct match on form requires a match on dosage type, strength and pack size in the
comparison country.
6 If a comparison country’s pack size was within 20 per cent of the Australian pack size, a linear
adjustment was made to the overseas price to calculate an equivalent Australian pack size price.
The 20 per cent threshold was chosen in order to limit any bias arising from inter-country
differences in the relationship between prices and pack sizes.METHODOLOGY C.7
The procedure used to match pharmaceuticals is outlined in figure C.2 (the codes
are explained in table C.1). The number of no-matches and matches obtained for the
comparison countries using this procedure is examined in appendix E.
While form matching seeks to provide the most meaningful results, its use has some
important implications for interpreting the price comparisons. In particular, the
number of matches with the comparison countries is reduced (compared to the
aggregation across forms approach). This is because the number and type of forms
for which prices could be obtained differ across countries. Only 18 out of 584 forms
were available in all of the comparison countries. As such, it was not possible to
undertake a ‘global’ price comparison, with the prices of all forms compared across
all comparison countries.7 Instead, the study was restricted to bilateral price
comparisons between Australia and each overseas country.
Importantly, using this approach, conclusions about the prices of the top selling
PBS-listed molecules cannot be drawn across the comparison countries. For
example, the price ratios produced for the US relative to Australia, and the United
Kingdom (UK) relative to Australia cannot be used to draw inferences about the
level of prices between the US and the UK. Such comparisons are problematic for
two reasons:
•   the price ratios are based on different samples of molecules; and
•   simple comparisons between two foreign countries (by dividing one price ratio
by another) alters the underlying price ratio formula creating interpretational
difficulties.
Even if the sample of molecules were the same across all comparison countries, it
still would not be valid to compare the price ratios. Dividing the price ratio for the
US relative to Australia by that for the UK relative to Australia would produce a
price ratio which weights US and UK prices by Australian quantities. Price ratios
derived in this way are not relevant for the purpose of this study. They also are
problematic as measures of relative prices between two foreign countries because
the sample of molecules is drawn from the Australian PBS and Australian quantities
are used as weights.
                                             
7 Another difficulty in comparing prices across countries based on top selling PBS-listed
molecules is that the sample of molecules may be unrepresentative of the top selling molecules
in each of the comparison countries. The results, therefore, cannot be used to draw inferences
about whether manufacturer prices in the comparison country are, on average, higher or lower
than Australia’s.C.8 PHARMACEUTICAL
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a See table C.1 for a full explanation of the matching codes. b This refers to dosage type. c Pack sizes within
or equal to ±20 per cent of the Australian pack size.METHODOLOGY C.9
Table C.1 Matching codes
Code Short description Full description
NMM No match molecule No match was found for the molecule.
NMS No match strength For a matched molecule, no match was found for strength.
NMF No match form For a matched molecule and strength, no match was found
for dosage type.
DM Direct match There is a direct match for molecule, strength, dosage type
and pack size. As there is only one manufacturer, the price
is used for both higher and lower estimates.
DMWAP Direct match weighted
average price
There is a direct match for molecule, strength, dosage type
and pack size. As there are multiple manufacturers,
volume data are used to calculate a weighted average
price. This price is used for both higher and lower
estimates.
DMUL Direct match upper
lower
There is a direct match for molecule, strength, dosage type
and pack size. There are multiple manufacturers but, as
there is no volume data, higher and lower prices are used.
PSL Pack size linear There are matches for molecule, strength, dosage type but
not for pack size. For pack sizes within or equal to ±20% of
the Australian pack size, the price is calculated using the
linear method.a As there is only one manufacturer, the
price is used for both higher and lower estimates.
PSLWAP Pack size linear
weighted average
price
There are matches for molecule, strength, dosage type but
not for pack size. Pack sizes are within or equal to ±20%
of the Australian pack size. As there are multiple
manufacturers, volume data are used to calculate a
weighted average price. This price is then recalculated
using the linear method and is used for both higher and
lower estimates.
PSLUL Pack size linear upper
lower
There are matches for molecule, strength, dosage type but
not for pack size. For pack sizes within or equal to ±20% of
the Australian pack size, the price is calculated using the
linear method. There are multiple manufacturers but, as
there is no volume data, higher and lower prices are used.
NMPS No match pack size There are matches for molecule, strength, dosage type but
not for pack size. Pack size exceeds ±20% of the
Australian pack size. There is one or more manufacturers
producing one different pack size.
PSUL Pack size upper lower There are matches for molecule, strength, dosage type but
not for pack size. Pack sizes exceed ±20% of the
Australian pack size. There is one manufacturer producing
multiple pack sizes. If the Australian pack size lies
between the overseas pack sizes, the closest pack size on
each side of the Australian pack size are selected. If the
Australian pack size is not in-between, the closest two
pack sizes are selected. Prices are calculated using the
linear method and are used as higher and lower estimates.
(Continued on next page)C.10 PHARMACEUTICAL
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Table C.1 (continued)
Code Short description Full description
PSULWAP Pack size upper lower
weighted average
price
There are matches for molecule, strength, dosage type but
not for pack size. Pack sizes exceed ±20% of the
Australian pack size. If the Australian pack size lies
between the overseas pack sizes, the closest pack size on
either side of the Australian pack size are chosen. If the
Australian pack size is not in-between, the closest two
pack sizes are selected. As there are multiple
manufacturers producing different pack sizes, volume data
are used to calculate a weighted average price for each
pack size. The prices are recalculated using the linear
method and used as higher and lower estimates.
PSULMM Pack size upper lower
multiple manufacturer
There are matches for molecule, strength, dosage type but
not for pack size. Pack sizes exceed ±20% of the
Australian pack size. If the Australian pack size lies
between the overseas pack sizes, the closest pack size on
either side of the Australian pack size are selected. If the
Australian pack size is not in-between, the closest two
pack sizes are chosen. As there are multiple
manufacturers producing different pack sizes but no
volume data, the prices are calculated using the linear
method and used as higher and lower estimates.
a The linear method calculates the price per pack by multiplying the price per tablet or capsule (based on the
overseas pack size) by the Australian pack size.
C.5 Prices used
The terms of reference for the study specify that price comparisons should be made
at the ex-factory (manufacturer) level. For all overseas countries except Sweden,
manufacturer prices were obtained from IMS Health (chapter 3 and appendix D).
IMS Health prices can be considered the maximum prices received by
manufacturers, referred to as the ‘list’ or published price. However, in some
countries, the pharmaceutical market may be segmented into buyers of various sizes
and influence. Some larger/institutional buyers within each country may be able to
negotiate lower prices with manufacturers in the form of discounts off published list
prices (chapter 3).
According to Danzon (1996), in the US, substantial discounts often are negotiated
by the managed care plans and mail order sectors, while Medicaid and other Federal
programs receive rebates and other forms of discount from manufacturers that are
not reflected in list prices. There have been a number of attempts to quantify the
discounts across the various segments of the US market (box C.1). The US may not
be the only country that has substantial discounts available for large buyers. The listMETHODOLOGY C.11
prices in the UK also may overstate manufacturer prices because the data do not
reflect discounts to pharmacists (Danzon and Chao 2000).
Box C.1 Studies of discounting of pharmaceuticals in the United States
Boston Consulting Group (BCG), 1993
The BCG study found that although 25 per cent of the market (the ‘traditional retail
pharmacy’) was paying the list price for pharmaceuticals in 1992, an estimated
55 per cent of the market was receiving discounts of up to 30 per cent off the list price,
comprising: 30  per  cent off the list price for mail-order pharmacy (representing
five  per  cent of the market); 30 per cent off the list price for managed hospital
pharmacy (representing 15 per cent of the market); and 25 per cent off the list price for
managed retail (representing 35 per cent of the market).
Congressional Budget Office (CBO), 1998
The CBO conducted an examination of pharmaceutical pricing and found that
consumers without prescription drug insurance coverage pay higher prices for
pharmaceuticals than those with insurance.
US House of Representatives, 1999
This study investigated the pricing of five brand-name prescription pharmaceuticals
that accounted for the largest share of total sales to the elderly. The study attempted to
estimate the differential between the prices charged to the pharmaceutical companies’
most favoured customers (such as the Health Maintenance Organisations (HMOs) and
the Federal Government) and the prices charged to seniors who lack prescription drug
coverage. The study found that older Americans without insurance pay higher prices
for commonly used pharmaceuticals (the average price differential was 134 per cent).
Federal Trade Commission (FTC), 1999
The FTC examined prescription pharmaceutical pricing practices and found that
pharmaceutical companies practise differential pricing whereby companies set lower
prices to large buyers like hospitals, HMOs and pharmaceutical benefit management
companies (PBMs), and charge higher prices to other buyers that include the
uninsured and independent and chain retail pharmacies.
Sources: The Pink Sheet April 5 (1993); US House of Representatives (1999).
Given the commercial nature of transactions between many buyers and sellers of
pharmaceuticals, it is difficult to obtain information on the actual prices paid by
some buyers in the comparison countries (chapter 3).
However, in some countries, government agencies publish the prices they pay for
pharmaceuticals. As discussed in chapter  2, through deciding which
pharmaceuticals are eligible for subsidies, governments often have considerable
bargaining power with manufacturers. This manifests itself in cost-containment
measures directed at both prices paid and total expenditure on pharmaceuticals. AsC.12 PHARMACEUTICAL
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such, published prices by governments may be considered representative of the
prices paid by larger/institutional buyers in each country.
An example of government published prices is the Federal Supply Schedule (FSS),
which is administered by the Department of Veterans Affairs (VA) in the US.
Pharmaceutical companies must make their brand-name pharmaceuticals available
through the FSS in order to receive reimbursements for drugs covered by Medicaid.
The prices negotiated under the FSS are intended to equal or better the prices
manufacturers charge their ‘most-favoured’ non-federal customers under
comparable terms and conditions (GAO 2000a). Danzon notes that ‘manufacturers
face a significant economic penalty for failure to participate in the FSS. This in turn
gives the VA leverage in negotiating prices’ (Danzon 1999, p. 11).
The FSS price may not be the lowest price available in the US market. First, price
negotiations between VA and pharmaceutical suppliers involves both price and the
terms and conditions of supply. Terms and conditions of supply include contract
length and ordering and delivery practices. Because the terms and conditions can
vary by pharmaceutical, the FSS may not be the lowest price in the market
(GAO 1997; 2000a). Second, some buyers may be able to negotiate prices below
those achieved under the FSS. For example, the VA has obtained some
pharmaceutical prices lower than the FSS through the competitive tendering of
national contracts. On average, these contracts have resulted in prices that are about
one-third lower than corresponding FSS prices (GAO 2000a).
A further market segment, and hence a further set of pharmaceutical prices, that also
could be included in the study are prices paid by hospitals. However, the hospital
market appears to be different to the outpatient pharmaceutical market (which the
PBS covers), because pharmaceutical companies adopt different pricing and
marketing strategies. Hence, prices paid by hospitals may not provide useful
information to help explain the influence of the PBS on listed pharmaceuticals.
Also, information on the prices received by manufacturers on their sales to hospitals
is not available for some of the comparison countries (Spain and Sweden).
C.6 Converting prices to a common currency
Manufacturer prices were calculated for each country in the local currency. In order
to compare prices it was necessary to convert local currency prices into a common
currency. The most commonly used approach is to use official exchange rates. An
alternative approach is to use purchasing power parity (PPP) exchange rates.
The appropriate conversion factor depends on the purpose of the price comparison.
The purpose of this study is to estimate, for selected countries, differences in theMETHODOLOGY C.13
prices received by manufacturers for pharmaceutical molecules listed on the PBS.
Given this purpose, official exchange rates are the most appropriate conversion
factor. This is because they provide the most relevant information on the revenue
and cost implications of pricing PBS-listed molecules at international, rather than
Australian, levels. Official exchange rates also are one factor taken into
consideration by the Pharmaceutical Benefits Pricing Authority (PBPA) in
reviewing the price of existing pharmaceuticals and those recommended for listing
under the PBS.8
A limitation of using official exchange rates is that they can fluctuate over time,
reflecting short-term factors. Hence, the results may be sensitive to the time period
on which the exchange rate is based. This problem can be overcome by calculating
‘average’ exchange rates for the comparator countries over a specified time period.
For the results presented in chapter 3, the average exchange rate for the month of
June 2000 was used to convert overseas currencies into Australian dollars. This was
chosen as it is the closest average exchange rate to the time period over which the
pharmaceutical prices were collected.
Recognising that exchange rates fluctuate over time, the sensitivity of the price
comparisons to different exchange rates was tested. Prices were converted using
average exchange rates for:
•   30 June 2000;
•   the three months to June 2000;
•   the 1999-2000 financial year; and
•   the period 1 July 1998 to 30 June 2000 (1998-99 to 1999-2000).
The results for these different exchange rates are summarised in chapter  3 and
presented in more detail in appendix E.
The alternative to using official exchange rates is PPPs, which are designed to
reflect the real purchasing power of a national currency. Some researchers have
suggested PPPs should be used to convert overseas prices on the basis that they
better reflect the resources that a consumer must forgo in order to purchase a basket
of pharmaceuticals. Hence, PPPs may be appropriate to assess whether consumers
or governments are ‘better-off’ under foreign or Australian prices. PPPs also tend to
be less sensitive to short-term speculative movements compared to official
exchange rates.
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However, PPPs are less appropriate than official exchange rates given the purpose
of this study. In particular, they do not accurately reflect the revenue and cost
implications of pricing PBS-listed molecules at international rather than Australian
levels. Official exchange rates, and not PPPs, are used in reviews of new and
existing pharmaceutical prices by the PBPA. While the results reported in chapter 3
are based on official exchange rates, the results for prices converted by PPPs are
included as part of the sensitivity analysis (appendix E).
C.7 Weighting manufacturer prices
The terms of reference require the Commission to calculate some form of weighted
average price. This requirement reflects the fact that unweighted price comparisons
are unduly influenced by higher-priced molecules, as no level of ‘significance’ is
applied to each price.
The choice of an appropriate weight depends on the purpose of the study and the
information sought from the resulting price comparison. Two issues in weighting
prices were identified:
•   the choice of countries from which weights are obtained; and
•   the choice of weights from the countries chosen.
Choice of country
A range of values could be used to weight pharmaceutical prices for each of the
countries included in the study.
If the weights applied are sourced from Australia (as suggested by the terms of
reference), the resulting index is known as a Laspeyres index. Under this approach,
the index can provide information on whether prices in Australia are higher or lower
than those overseas. If weights are sourced from the comparison countries, the
resulting index is known as a Paasche index. This index can provide information on
the revenue and cost implications to a comparison country if it purchased its
pharmaceutical requirements from Australia.
If pharmaceutical consumption patterns differ across countries, the Laspeyres and
Paasche indexes will give different results when applied to the same price data.
Often, a calculated relative price differential (based on the same molecule prices)
will be greater for that of the Laspeyres index compared to that of the PaascheMETHODOLOGY C.15
index. This result is usually attributed to the assumption that consumers will buy
relatively less of those molecules whose prices have become relatively dearer.9
Given the limitations of these two indexes, other indexes have been developed, such
as the Fisher’s ideal index, that represents a combination of home and overseas
country weights.
Past studies have found that pharmaceutical consumption patterns differ
considerably across countries, due to factors such as disease patterns,
pharmaceutical availability and medical practices (see, for example, Danzon and
Chao 2000). This means that different results are likely to be obtained depending on
the country (or combination of countries) from which the price weights are
obtained. As a consequence, some studies have recommended that a range of
indexes be reported (Andersson 1993). In contrast, other studies have argued that it
is probably most appropriate for each country to weight prices by its own
consumption patterns (Danzon and Chao 2000).
The purposes of this study suggest that Australia is the most appropriate country
from which to obtain the price weights (Laspeyres index). The resulting index
provides information on the revenue and cost implications of pricing Australia’s top
selling PBS-listed molecules at international prices. Information on the cost and
revenue implications for overseas countries of purchasing their pharmaceutical
requirements at Australian prices (Paasche index) is of less relevance for this study.
Choice of weight
Having chosen to obtain the price weights from Australia, it is then necessary to
decide what weights will be applied.
From the perspective of pharmaceutical companies, it may be that weighting
pharmaceutical prices by the volume of sales is appropriate. This is because the
resulting index provides an indication of the revenue that pharmaceutical companies
could have received if they obtained the comparison country’s prices on their
Australian sales. The robustness of this interpretation depends on the extent to
which Australian consumption and supply patterns would change in response to the
new (overseas) set of prices.
From the Government’s perspective, it also may be considered useful that the study
provides information on the effect of the PBS on aggregate subsidy payments. In
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this case, the relevant quantity weight is the volume of sales that attracted a subsidy
payment from the Government. This is estimated by the number of PBS scripts.
Prices were weighted by both the volume of sales and the number of PBS scripts.
However, the results differed little between the two different weights. The results in
chapter 3 are presented weighted by the volume of Australian sales. Results with
prices weighted by the number of PBS scripts can be found in appendix E.DATA SOURCES D.1
D Data sources
This appendix describes the data sources used in the international price
comparisons.
D.1 Summary of sources
A number of data sources were used to undertake the international price
comparisons (table D.1).
Table D.1 Sources of data
Country Data sources
Australia IMS Health, Department of Health and Aged Care
United States IMS Health, Federal Supply Schedule
United Kingdom IMS Health, Chemist and Druggist Monthly Price List, Prescription Cost Analysis
Canada IMS Health, Ontario Drug Benefit Formulary and Pharmacare Low Cost
Alternative Reference Drug Program Booklet (British Columbia)
New Zealand IMS Health, Pharmac Pharmaceutical Schedule
France IMS Health, National Health Insurance Fund
Spain IMS Health
Sweden Riksförsäkringsverket (RFV; National Social Insurance Board)
In the following section, data obtained from IMS Health are first described.
Additional data sources obtained from individual countries are then described.
D.2 IMS Health data
IMS Health data for the 150  molecules included in the study was obtained for
Australia, the United States (US), Canada, the United Kingdom (UK), France, Spain
and New Zealand (NZ). The data provided by IMS Health included:
•   the form names and new form codes (NFC) for each molecule;1
                                             
1 NFCs for pharmaceuticals are developed by the European Pharmaceutical Marketing Research
Association. They were first developed in the mid 1960s and are an internationally recognised
system of classifying pharmaceuticals (EPHMRA 2001). They were used to assist in matching
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•   local currency manufacturer prices;
•   volume data for 30 identified molecules in each comparison country and the top
150 molecules in Australia;
•   the global launch date for each molecule;
•   the manufacturer and launch date for each form in the respective country; and
•   reimbursement status.
Discussion on the collection, interpretation, and limitations of IMS Health data can
be found in chapter 3 of the report.
D.3 Australia
Manufacturer prices and expenditure data were obtained from the Department of
Health and Aged Care (DHAC) for 1999-2000. This data included the number of
scripts, Commonwealth Government subsidy payments and total expenditure (sum
of patient contribution and government subsidy) for pharmaceuticals subsidised
under the PBS.
The DHAC data included expenditure on highly specialised (section  100)
pharmaceuticals. The Commonwealth Government negotiates the price and
provides funding to the States and Territories for these pharmaceuticals, which are
medicines for chronic conditions that because of their clinical use or other special
features, are restricted to supply through hospitals (DHAC 2000).
For the purpose of ranking molecules by total expenditure, two adjustments were
made to the DHAC data, namely:
•   an estimate of the volume of PBS pharmaceuticals that did not attract a PBS
subsidy was added. This estimate was obtained from the 1998 Australian
Statistics on Medicines (DHAC 1999b); and
•   for pharmaceuticals that were listed part-way during 1999-2000, total
expenditure was annualised on the basis of average monthly expenditure.2
Brand and therapeutic group premiums
In Australia, government policies permit manufacturers to add either a brand
premium (BP) or a therapeutic group premium (TGP) to the negotiated or
subsidised price of some products. For those products for which a BP or TGP
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applied, a weighted average price was calculated between the premium and non-
premium form based on their volume of sales.
Weighted average monthly treatment cost
The Pharmaceutical Benefits Pricing Authority uses the weighted average monthly
treatment cost (WAMTC) method to determine the reimbursement price for
pharmaceuticals in a number of therapeutic groups. Table  D.2 lists those
pharmaceuticals within the sample that have been subject to WAMTC pricing
reviews, classified by their category (me-too or generic).
Table D.2 Pharmaceuticals covered under TGP/WAMTC arrangements at
30 June 2000a
Me-too Generic
TGP and WAMTC molecules
Amlodipine Besylate Captopril
Atorvastatin Calcium Nifedipine













Candesartan Cilexetilb Diltiazem Hydrochloride









a  Selective Serotonin Reuptake Inhibitors (SSRIs) molecules (citalopram hydrochloride, fluoxetine
hydrochloride, paroxetine hydrochloride, and sertratine hydrochloride) are included within the WAMTC group
because earlier price reviews could have affected their price. b Prices are not directly subject to WAMTC
reviews but are affected indirectly through price links to enalapril maleate. c Price is not directly subject to




The top  150  molecules included in the price comparison were categorised by
DHAC, and are presented in table D.3.
Table D.3 Molecule classification
New innovative Me-too Generic
Alendronate Sodium Amlodipine Besylate Aciclovir
Alprostadil Atorvastatin Calcium Allopurinol
Carvedilol Budesonide Amiodarone Hydrochloride
Ciprofloxacin Candesartan Cilexetil Amoxycillin
Cisapride Ceftriaxone Amoxycillin with Clavulanic Acid
Clopidogrel Hydrogen Sulfate Citalopram Hydrobromide Aspirin
Clozapine Docetaxel Atenolol
Cyclosporin Eformoterol Fumarate Dihydrate Azathioprine
Disodium Pamidronate Enalapril Maleate Beclomethasone Dipropionate
Epoetin Alfa Famciclovir Betamethasone Dipropionate
Filgrastim Famotidine Betamethasone Valerate
Insulin Lispro Felodipine Calcitriol
Interferon Alfa-2b Fluticasone Calcium
Latanoprost Fluticasone Propionate Captopril
Leflunomide Fluvastatin Sodium Carbamazepine
Mycophenolate Mofetil Follitropin Alfa Cefaclor
Olanzapine Follitropin Beta Cephalexin
Ribavirin And Interferon Alfa-2b Fosinopril Sodium Chloramphenicol
Risperidone Gabapentin Codeine Phosphate with Paracetamol
Rituximab Goserelin Acetate Cyproterone Acetate





Lamivudine With Zidovudine Doxycycline
Lamotrigine Erythromycin Ethyl Succinate
Lansoprazole Flucloxacillin






Omeprazole Magnesium Hypromellose with Dextran
Pantoprazole Sodium Sesquihydrate Indapamide Hemihydrate
Paroxetine Hydrochloride Influenza Vaccine
Perindopril Erbumine Insulin Isophane (N.P.H.)
Pravastatin Sodium Insulin Neutral





Sertraline Hydrochloride Levodopa with Carbidopa
Simvastatin Levonorgestrel with Ethinyloestradiol
Stavudine Medroxyprogesterone Acetate
Trandolapril Metformin Hydrochloride
Valaciclovir Hydrochloride Metoprolol Tartrate
Venlafaxine Hydrochloride Minocycline
(Continued on next page)DATA SOURCES D.5
Table D.3 (continued)




































Pharmaceutical prices were obtained from the publicly available Federal Supply
Schedule (FSS) in the US. The FSS is a catalogue of manufacturer prices containing
over 17 000 pharmaceutical products available to federal agencies and institutions.
The FSS is administered by the Department of Veterans Affairs. Prices were
obtained from the FSS in November 2000.
D.5 United Kingdom
Pharmaceutical prices were obtained from the Chemist and Druggist Monthly Price
List. Prices are reported at the manufacturer level. Prices reported are the maximum
(list) price received by manufacturers. Prices obtained are at July 2000 (CD 2000a;
2000b).D.6 PHARMACEUTICAL
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Pharmaceutical prices also were obtained from the Prescription Cost Analysis.
Prices are reported at the wholesale level. Prices are reported before any discounts
and, therefore, can be considered list or the maximum prices received by
manufacturers. Prices are at September 1999 (DoH 2001).
D.6 Canada
Pharmaceutical prices for Ontario were obtained from the Ontario Drug Benefit
Formulary/Comparative Drug Index (no. 36) supplemented with relevant updates
(Ministry of Health and Long–Term Care 1998). Prices are at the manufacturer
level for April 2000.
Prices for British Columbia were obtained from the Pharmacare Low Cost
Alternative Reference Drug Program Booklet. These prices are for March 2001
(Pharmacare 2001b).
D.7 New Zealand
Pharmaceutical prices were obtained from the publicly available New Zealand
Pharmaceutical Schedule, published by Pharmac. Prices are reported at the
manufacturer level, and represent the price negotiated between Pharmac and
pharmaceutical companies. Prices are those effective from April to June  2000
(Pharmac 2000a).
D.8 France
Pharmaceutical prices were obtained from the National Health Insurance Fund
(Caisse Nationale d’Assurance Maladie (CNAM)). Prices are at the manufacturer
level for September 2000.
D.9 Sweden
Pharmaceutical prices were obtained from the Riksförsäkringsverket (RFV;
National Social Insurance Board). The RFV sets a reimbursement price for each
pharmaceutical (based on information supplied by the companies). Prices obtained
were at the wholesale (pharmacy buying) level. A wholesaler margin was deducted
to obtain an estimate of manufacturer prices. Prices are for November 2000.DATA SOURCES D.7
D.10 Case study
Pricing information was provided by GlaxoSmithKline Australia Limited (GSK) for
three particular brands of the following pharmaceuticals: ranitidine (Zantac);
paroxetine (Aropax); and salmeterol (Serevent). The information provided by GSK
is summarised in the following tables.
Table D.4 Ranitidine hydrochloride (Zantac) 150mg tablets, pack of 60a,b
Australia US Canada Sweden Spain
Launch date Apr ’82 na Nov ’82 Aug ’83 Oct ’82
Launch price 42.60 na 37.40 46.01 44.37
Launch ERc 1.00 na 1.25 6.91 111.43
May 1983 price 41.93 75.57d 52.74 49.87 44.37
1982-83 ER 1.00 1.01 1.25 6.37 111.43
June 2000 price 16.42 144.97e 71.35 35.75 35.30
a Prices reported in this table are expressed in Australian Dollars.b The FSS price of rantidine was A$115.25
at November 2000, representing a 21 per cent discount. In contrast, the cheapest generic price for rantidine in
the US was A$3.02. Ranitidine was reimbursed on the PBS in August 1984 at a price of $34. c The market
launch exchange rate (ER) is the average exchange rate for the financial year (ending 30 June) within which
the pharmaceutical was launched. d The January 1993 price was used. e The November 2000 price was
used. na Not available.
Data sources: ABS (2000b); DHAC (pers. comm., 25 June 2001); EconData (1999); GSK (pers. comm.,
20 June 2001).
Table D.5 Paroxetine hydrochloride (Aropax) 20mg tablets, pack of 30a,b
Australia US Canada UK Sweden NZ
Launch date Nov ’93 Jan ’93 May ’93 Feb ’91 May ’93 Aug ’92
Launch price 50.03f 59.54 53.73 77.11 63.43 41.91
Launch ERc 1.00 0.73 0.89 0.44 4.28 1.37
May 1993 price 50.03 59.54d 53.73 81.01 63.43 41.91
1992-93 ER 1.00 0.73 0.89 0.42 4.28 1.37
June 2000 price 27.58 100.48e 51.57 45.03 50.69 28.07
a Prices reported in this table are expressed in Australian Dollars. b The FSS price of paroxetine was A$54 at
November 2000, representing a 46 per cent discount. Paroxetine was reimbursed on the PBS in August 1994
at a price of $49.93. c The market launch exchange rate (ER) is the average exchange rate for the financial
year (ending 30 June) within which the pharmaceutical was launched. d  The May 1993 US price was
unavailable but has been estimated using the launch price. e The November 2000 price was used. f The
launch price at November 1993 was used as the price as for May 1993.
Data sources: ABS (2000b); DHAC (pers. comm., 25 June 2001); EconData (1999); GSK (pers. comm.,
20 June 2001).D.8 PHARMACEUTICAL
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Table D.6 Salmeterol Xinafoate (Serevent) oral pressurised inhaler,
25 mic/dose, 120 dosesa,b
Australia US France Spain
Launch date Jun ’93 Mar ’94 Aug ’94 Sep ’92
Launch price 41.90 58.76 42.88 49.97
Launch ERc 1.00 0.68 4.06 75.19
Dec 1994 price 41.90 57.34 42.88 36.75
1994-95 ER 1.00 0.73 4.06 97.94
June 2000 price 26.94 92.01 36.11 38.47
a Prices reported in this table are expressed in Australian Dollars. b The FSS price of salmeterol was A$68 at
November 2000, representing a 26 per cent discount. Salmeterol was reimbursed on the PBS in February
1995 at a price of $37. c The market launch exchange rate (ER) is the average exchange rate for the financial
year (ending 30 June) within which the pharmaceutical was launched.
Data sources: ABS (2000b); DHAC (pers. comm., 25 June 2001); EconData (1999); GSK (pers. comm.,
20 June 2001).RESULTS IN DETAIL E.1
E Results in detail
This appendix provides further detail on the results presented in chapter 3 of the
report. It includes:
•   an analysis of matching results;
•   list price comparisons;
•   diagnostic tests;
•   price comparisons with the Federal Supply Schedule (FSS);
•   information on the difference between higher and lower estimates;
•   price comparisons by therapeutic group; and
•   data on molecule age and launch delay.
E.1 Analysis of matching results
Table E.1 shows the numbers of no-matches, direct matches and adjusted matches
achieved for each comparison country using the form matching procedure (outlined
in appendix C).
The number of no-matches exceeded the combined number of direct and adjusted
matches for all the comparison countries except the United Kingdom (UK). For
most countries, the form matching approach resulted in a relatively high number of
no-matches for dosage type (NMF). Three Anatomical Therapeutic Chemical
(ATC) groups were responsible, on average, for around half of the no-matches for
dosage type. The largest single contributor was pharmaceuticals acting on the
respiratory system. The other leading groups included the genito urinary system and
sex hormones, and antineoplastic and immunomodulating agents.
Some countries scored a relatively high number of no-matches for pack size
(NMPS) and strength (NMS). The ATC groups relating to the nervous system, the
cardiovascular system, and general anti-infectives for systemic use, on average,
accounted for about half of the no-matches on pack size. The same three groups
accounted for approximately 45  per  cent of the no-matches for strength. All
countries scored a relatively low number of no-matches for molecule (NMM)
except for Sweden.E.2 PHARMACEUTICAL
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Table E.1 Matching results, all categories
Codea US Canada UK Sweden France Spain NZ
No matches
NMM 21 30 22 172 58 55 42
NMS 56 64 103 28 113 96 45
NMF 179 161 86 134 124 115 156
NMPS 55 87 47 63 113 114 75
Total 311 342 258 397 408 380 318
Direct matches
DM 99 107 116 71 70 70 216
D M W A P 1 18 1 70361
DMUL 54 49 64 51 35 49 23
Total 164 164 197 122 108 125 240
Adjusted matches
PSL 14 7 45 19 29 23 12
P S L W A P 00608 1 60
PSLUL 7 8 34 8 10 36 3
PSUL 53 16 20 32 16 1 4
P S U L W A P 3750112
PSULMM 32 40 19 6 4 2 5
Total 109 78 129 65 68 79 26
Total matchesb 273 242 326 187 176 204 266
a Table E.2 contains abbreviated descriptions for these codes. b Sum of direct and adjusted matches.
Source: PC estimates.
The level of matching varied between the comparison countries, with the UK
achieving the highest number of matches (326) whereas France achieved the lowest
(176). For all countries, the number of direct matches exceeded the number of
adjusted matches. Direct matches using the same price (DM) and direct matches
using two prices for upper and lower estimates (DMUL) accounted for most of the
direct matches. There were relatively few direct matches using a weighted average
price (DMWAP) as cost considerations limited the amount of volume data that
could be obtained for the comparison countries.
PSL and PSUL matches, on average, accounted for about half of the total number of
adjusted matches. These two types of matches relate to pharmaceuticals produced
by one manufacturer. There was only a small number of adjusted matches using
weighted average prices (PSLWAP and PSULWAP) for the reason mentioned
above. The relatively high number of PSULMM matches obtained for the United
States (US), Canada and the UK indicates a stronger presence of multiple
manufacturers producing various pack sizes than in the other countries.RESULTS IN DETAIL E.3
Table E.2 Matching codesa
Code Short description
NMM No match molecule
NMS No match strength
NMF No match form (dosage type)
NMPS No match pack size
DM Direct match
DMWAP Direct match weighted average price
DMUL Direct match upper lower
PSL Pack size linear
PSLWAP Pack size linear weighted average price
PSLUL Pack size linear upper lower
PSUL Pack size upper lower
PSULWAP Pack size upper lower weighted average price
PSULMM Pack size upper lower multiple manufacturer
a See table C.1 (appendix C) for a full explanation of these codes.
E.2 List price comparisons
This section reports the results of price comparisons under different exchange rates
and price weights. The same qualifications applying to the results, as described in
chapter 3 of the report, also apply to these price comparisons.
Exchange rates used in the price comparisons
A number of different average exchange rate periods were used to test the
sensitivity of the results to fluctuations in official exchange rates during the
24  months to June  2000 (table  E.3). In addition, price comparisons also were
undertaken using purchasing power parity exchange rates.
Table E.3 Average exchange rates and purchasing power paritiesa
$1A= US Canada UK Sweden France Spain NZ
June 2000 0.5941 0.8756 0.3929 5.1985 4.1062 104.0875 1.2615
30 June 2000 0.6023 0.8907 0.3961 5.3195 4.1515 105.3050 1.2817
Three months to June 2000 0.5907 0.8716 0.3844 5.2216 4.1452 105.1221 1.2300
1999-2000 0.6296 0.9250 0.3944 5.3516 4.1214 104.5377 1.2474
1998-99 to 1999-2000 0.6273 0.9338 0.3876 5.2074 3.9020 98.9498 1.2143
PPPb 0.7634 0.8969 0.5031 7.3855 5.0382 100.0000 1.1221
a Each exchange rate is calculated as the average of the buying and selling rate for that period. Each rate has
been rounded to four decimal places. b Represents the average PPP for GDP for the calendar years 1999
and 2000.
Sources: ABS (2000b); The Age (2000); OECD (2001).E.4 PHARMACEUTICAL
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The sensitivity analysis reported in this appendix (summarised in chapter 3) shows
that the results of the price comparison are not sensitive to the different official
exchange rates. However, purchasing power parity exchange rates for the seven
countries differ significantly from their official exchange rates in the US, the UK,
Sweden, France and NZ. This reflects different relative price levels for non-traded
goods and services in these countries compared to Australia.
List price comparisons
Tables  E.4 to E.23 provide the list price comparisons, with prices weighted by
Australian sales volumes and the number of PBS scripts for the five different
exchange rates.
Average exchange rate for June 2000
The price comparisons weighted by the volume of Australian sales differed little
from those weighted by the number of PBS scripts. For some countries, the price
ratios are slightly higher for certain categories while in other instances they are
lower. The small differences in the price comparisons in part reflects the high level
of correlation (0.90) between the volume of Australian sales and number of PBS
scripts for each form.
Table E.4 Price ratios for all categories, list prices
Average exchange rate for June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.48 1.81 1.64 1.57 1.17 1.02 0.98
  lower est. 1.00 2.62 1.51 1.48 1.48 1.12 0.96 0.92
PBS volumes
  higher est. 1.00 3.44 1.82 1.64 1.56 1.17 1.04 0.97
  lower est. 1.00 2.61 1.54 1.50 1.47 1.12 0.98 0.92
Source: PC estimates.RESULTS IN DETAIL E.5
Table E.5 Price ratios for new innovative, list prices
Average exchange rate for June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.17 1.09 1.26 1.17 0.92 0.85 1.00
  lower est. 1.00 2.04 1.09 1.25 1.10 0.92 0.85 1.00
PBS volumes
  higher est. 1.00 2.17 1.09 1.27 1.17 0.92 0.85 1.00
  lower est. 1.00 2.07 1.08 1.27 1.10 0.92 0.85 1.00
Source: PC estimates.
Table E.6 Price ratios for me-too, list prices
Average exchange rate for June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.99 1.71 1.64 1.65 1.18 1.08 1.01
  lower est. 1.00 2.85 1.59 1.57 1.58 1.18 1.02 0.97
PBS volumes
  higher est. 1.00 2.94 1.70 1.64 1.64 1.17 1.08 1.02
  lower est. 1.00 2.80 1.61 1.58 1.58 1.17 1.03 0.98
Source: PC estimates.
Table E.7 Price ratios for generics, list prices
Average exchange rate for June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 4.63 2.15 1.77 1.65 1.28 0.97 0.92
  lower est. 1.00 2.53 1.51 1.41 1.49 1.10 0.89 0.83
PBS volumes
  higher est. 1.00 4.65 2.24 1.79 1.63 1.27 1.00 0.89
  lower est. 1.00 2.52 1.58 1.44 1.48 1.10 0.92 0.81
Source: PC estimates.
Average exchange rate for 30 June 2000
Compared to using the average exchange rate for June  2000, the price ratios
decrease for all countries using the average exchange rate for 30 June 2000. For all
countries except Sweden, the extent of the decrease is less than two per cent.E.6 PHARMACEUTICAL
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Table E.8 Price ratios for all categories, list prices
Average exchange rate for 30 June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.43 1.78 1.62 1.54 1.16 1.01 0.96
  lower est. 1.00 2.59 1.48 1.47 1.44 1.11 0.95 0.91
PBS volumes
  higher est. 1.00 3.39 1.79 1.63 1.53 1.15 1.02 0.96
  lower est. 1.00 2.58 1.51 1.49 1.44 1.11 0.97 0.91
Source: PC estimates.
Table E.9 Price ratios for new innovative, list prices
Average exchange rate for 30 June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.14 1.08 1.25 1.14 0.91 0.84 0.98
  lower est. 1.00 2.01 1.07 1.24 1.07 0.91 0.84 0.98
PBS volumes
  higher est. 1.00 2.14 1.07 1.26 1.14 0.91 0.84 0.99
  lower est. 1.00 2.04 1.06 1.26 1.08 0.91 0.84 0.99
Source: PC estimates.
Table E.10 Price ratios for me-too, list prices
Average exchange rate for 30 June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.95 1.68 1.63 1.61 1.17 1.07 0.99
  lower est. 1.00 2.82 1.57 1.56 1.55 1.17 1.01 0.96
PBS volumes
  higher est. 1.00 2.90 1.67 1.63 1.61 1.16 1.07 1.00
  lower est. 1.00 2.77 1.58 1.57 1.54 1.16 1.02 0.97
Source: PC estimates.RESULTS IN DETAIL E.7
Table E.11 Price ratios for generics, list prices
Average exchange rate for 30 June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 4.57 2.12 1.76 1.61 1.27 0.95 0.90
  lower est. 1.00 2.49 1.49 1.40 1.46 1.08 0.88 0.81
PBS volumes
  higher est. 1.00 4.59 2.20 1.78 1.60 1.26 0.99 0.88
  lower est. 1.00 2.49 1.55 1.43 1.45 1.09 0.91 0.79
Source: PC estimates.
Average exchange rate for three months to June 2000
Compared to using the average exchange rate for June  2000, the price ratios
increase for all countries except Sweden, France and Spain using the average
exchange rate for the three months to June  2000. The price ratios increase by
2.6 per cent for NZ and by less than one per cent for the US and Canada, while they
decrease by around one per cent or less for Spain, France and Sweden.
Table E.12 Price ratios for all categories, list prices
Average exchange rate for three months to June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  Higher est. 1.00 3.50 1.82 1.67 1.57 1.16 1.01 1.00
  Lower est. 1.00 2.64 1.51 1.51 1.47 1.11 0.95 0.95
PBS volumes
  higher est. 1.00 3.46 1.83 1.68 1.56 1.15 1.03 1.00
  lower est. 1.00 2.63 1.54 1.54 1.46 1.11 0.97 0.95
Source: PC estimates.E.8 PHARMACEUTICAL
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Table E.13 Price ratios for new innovative, list prices
Average exchange rate for three months to June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.18 1.10 1.28 1.16 0.91 0.84 1.02
  lower est. 1.00 2.05 1.09 1.28 1.09 0.91 0.84 1.02
PBS volumes
  higher est. 1.00 2.19 1.09 1.30 1.16 0.91 0.85 1.03
  lower est. 1.00 2.08 1.08 1.30 1.10 0.91 0.85 1.03
Source: PC estimates.
Table E.14 Price ratios for me-too, list prices
Average exchange rate for three months to June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.01 1.72 1.67 1.64 1.17 1.07 1.04
  lower est. 1.00 2.87 1.60 1.60 1.57 1.17 1.01 1.00
PBS volumes
  higher est. 1.00 2.95 1.71 1.68 1.64 1.16 1.07 1.04
  lower est. 1.00 2.82 1.61 1.61 1.57 1.16 1.02 1.01
Source: PC estimates.
Table E.15 Price ratios for generics, list prices
Average exchange rate for three months to June 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 4.66 2.16 1.81 1.64 1.27 0.96 0.94
  lower est. 1.00 2.54 1.52 1.44 1.48 1.09 0.88 0.85
PBS volumes
  higher est. 1.00 4.68 2.25 1.83 1.62 1.26 0.99 0.91
  lower est. 1.00 2.54 1.58 1.47 1.47 1.09 0.91 0.83
Source: PC estimates.
Average exchange rate for financial year 1999-2000
Compared to using the average exchange rate for June  2000, the price ratios
decrease for all countries except NZ using the average exchange rate for the
financial year 1999-2000. The price ratios decrease by around five to six per centRESULTS IN DETAIL E.9
for the US and Canada, while they change by less than three per cent for the other
countries.
Table E.16 Price ratios for all categories, list prices
Average exchange rate for 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.28 1.71 1.63 1.53 1.17 1.02 0.99
  lower est. 1.00 2.48 1.43 1.48 1.43 1.12 0.96 0.93
PBS volumes
  higher est. 1.00 3.24 1.72 1.64 1.52 1.16 1.03 0.98
  lower est. 1.00 2.46 1.45 1.50 1.43 1.12 0.98 0.93
Source: PC estimates.
Table E.17 Price ratios for new innovative, list prices
Average exchange rate for 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.04 1.04 1.25 1.13 0.92 0.85 1.01
  lower est. 1.00 1.93 1.03 1.25 1.07 0.92 0.85 1.01
PBS volumes
  higher est. 1.00 2.05 1.03 1.27 1.14 0.92 0.85 1.02
  lower est. 1.00 1.95 1.02 1.26 1.07 0.92 0.85 1.02
Source: PC estimates.
Table E.18 Price ratios for me-too, list prices
Average exchange rate for 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.83 1.62 1.63 1.60 1.18 1.08 1.02
  lower est. 1.00 2.70 1.51 1.56 1.54 1.17 1.02 0.98
PBS volumes
  higher est. 1.00 2.77 1.61 1.64 1.60 1.17 1.08 1.03
  lower est. 1.00 2.65 1.52 1.57 1.53 1.17 1.02 0.99
Source: PC estimates.E.10 PHARMACEUTICAL
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Table E.19 Price ratios for generics, list prices
Average exchange rate for 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 4.37 2.04 1.76 1.60 1.28 0.96 0.93
  lower est. 1.00 2.39 1.43 1.40 1.45 1.09 0.88 0.84
PBS volumes
  higher est. 1.00 4.40 2.12 1.78 1.59 1.27 0.99 0.90
  lower est. 1.00 2.39 1.50 1.44 1.44 1.09 0.92 0.81
Source: PC estimates.
Average exchange rate for financial years 1998-99 and 1999-2000
Compared to using the average exchange rate for June  2000, the price ratios
increase for four countries and decrease for the remaining countries. Price ratios
increase by about five per cent for France and Spain whereas prices decrease by
around five to six per cent in Canada and the US.
Table E.20 Price ratios for all categories, list prices
Average exchange rate for 1998-99 and 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.30 1.70 1.66 1.57 1.23 1.08 1.01
  lower est. 1.00 2.48 1.41 1.50 1.47 1.18 1.01 0.96
PBS volumes
  higher est. 1.00 3.26 1.71 1.67 1.56 1.23 1.09 1.01
  lower est. 1.00 2.47 1.44 1.52 1.47 1.18 1.03 0.96
Source: PC estimates.
Table E.21 Price ratios for new innovative, list prices
Average exchange rate for 1998-99 and 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.05 1.03 1.27 1.17 0.97 0.90 1.04
  lower est. 1.00 1.93 1.02 1.27 1.10 0.97 0.90 1.04
PBS volumes
  higher est. 1.00 2.06 1.02 1.29 1.17 0.97 0.90 1.04
  lower est. 1.00 1.96 1.01 1.29 1.10 0.97 0.90 1.04
Source: PC estimates.RESULTS IN DETAIL E.11
Table E.22 Price ratios for me-too, list prices
Average exchange rate for 1998-99 and 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.84 1.61 1.66 1.64 1.24 1.14 1.05
  lower est. 1.00 2.71 1.50 1.59 1.58 1.24 1.08 1.01
PBS volumes
  higher est. 1.00 2.78 1.60 1.66 1.64 1.23 1.14 1.06
  lower est. 1.00 2.66 1.51 1.60 1.57 1.23 1.08 1.02
Source: PC estimates.
Table E.23 Price ratios for generics, list prices
Average exchange rate for 1998-99 and 1999-2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 4.39 2.02 1.79 1.65 1.35 1.02 0.95
  lower est. 1.00 2.40 1.42 1.43 1.49 1.15 0.93 0.86
PBS volumes
  higher est. 1.00 4.41 2.10 1.82 1.63 1.34 1.05 0.92
  lower est. 1.00 2.40 1.48 1.46 1.48 1.16 0.97 0.84
Source: PC estimates.
Purchasing power parity for GDP, average for 1999 and 2000
Compared to using the average exchange rate for June 2000, the price ratios change
significantly for most countries using the purchasing power parity exchange rate.
The price ratios decrease for the US, Canada, the UK, Sweden and France. For the
US, the UK and Sweden, the price ratios fall by around 22 to 30 per cent. The price
ratios rise for NZ (12 per cent) and Spain (four per cent).E.12 PHARMACEUTICAL
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Table E.24 Price ratios for all categories, list prices
Average purchasing power parity for GDP, 1999 and 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.71 1.77 1.28 1.11 0.95 1.07 1.10
  lower est. 1.00 2.04 1.47 1.16 1.04 0.91 1.00 1.04
PBS volumes
  higher est. 1.00 2.68 1.78 1.28 1.10 0.95 1.08 1.09
  lower est. 1.00 2.03 1.50 1.17 1.03 0.91 1.02 1.04
Source: PC estimates.
Table E.25 Price ratios for new innovative, list prices
Average purchasing power parity for GDP, 1999 and 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 1.69 1.07 0.98 0.82 0.75 0.89 1.12
  lower est. 1.00 1.59 1.06 0.98 0.77 0.75 0.89 1.12
PBS volumes
  higher est. 1.00 1.69 1.06 0.99 0.82 0.75 0.89 1.13
  lower est. 1.00 1.61 1.05 0.99 0.78 0.75 0.89 1.13
Source: PC estimates.
Table E.26 Price ratios for me-too, list prices
Average purchasing power parity for GDP, 1999 and 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 2.35 1.67 1.30 1.18 0.97 1.13 1.13
  lower est. 1.00 2.24 1.56 1.24 1.13 0.97 1.06 1.09
PBS volumes
  higher est. 1.00 2.30 1.66 1.30 1.18 0.96 1.13 1.14
  lower est. 1.00 2.20 1.57 1.25 1.13 0.96 1.07 1.10
Source: PC estimates.RESULTS IN DETAIL E.13
Table E.27 Price ratios for generics, list prices
Average purchasing power parity for GDP, 1999 and 2000
Aust US Canada UK Sweden France Spain NZ
IMS volumes
  higher est. 1.00 3.63 2.10 1.39 1.18 1.05 1.00 1.03
  lower est. 1.00 1.99 1.48 1.11 1.07 0.89 0.92 0.93
PBS volumes
  higher est. 1.00 3.65 2.19 1.41 1.17 1.04 1.04 1.00
  lower est. 1.00 1.99 1.54 1.13 1.06 0.89 0.96 0.90
Source: PC estimates.
E.3 Diagnostic tests
The price comparisons reported in chapter 3 have been examined on an unweighted
basis using a number of diagnostic tests.
Z-statistics have been computed in order to test whether price differences between
Australia and each of the comparison countries are statistically significant. Critical
values for the z-statistic are ±1.96 and ±2.58 at the five and one per cent levels of
significance respectively. If a computed z-statistic lies in the chosen critical region,
this provides grounds for rejecting the null hypothesis that prices for the selected
PBS-listed items are generally the same in Australia and a given comparison
country. In such a case, the alternative hypothesis that price levels are different
between the two countries is accepted and, therefore, it can be concluded that the
price differences are statistically significant.
The z-statistic used for testing the null hypothesis requires that the ‘populations’ of
prices from which the samples are drawn follow a normal distribution (or that the
sample sizes are at least 30) and that the samples are randomly and independently
drawn. These requirements are meant to ensure that the samples also are
approximately normally distributed. As outlined in appendix  C, the Australian
sample of pharmaceuticals was chosen according to specific criteria (that is, PBS-
listing and PBS expenditure ranking) which, together with the form matching
procedure, determined the samples for the comparison countries. This means that
the samples were neither randomly or independently selected and, in some cases,
sample sizes were less than 30.
The Shapiro-Wilk test (also known as the w-statistic) has been used to assess
whether the price ratios derived from the samples are normally distributed. For ease
of interpretation, the following tables present the probability associated with theE.14 PHARMACEUTICAL
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w-statistic (rather than the statistic itself). This probability is compared against the
chosen level of significance. If the probability is less than the level of significance,
the null hypothesis of normality is rejected and it can be concluded that the price
ratios do not come from a normal distribution.
Kurtosis and skewness indexes also have been computed to examine the
characteristics of the price ratio distributions relative to those of a normal
distribution. (A normal distribution is symmetric about its mean value with a
bell-shaped frequency curve or distribution of values.)
The kurtosis index measures the peakedness or flatness of a distribution compared
to that of a normal distribution. A positive value for this index indicates a peaked
distribution relative to the normal distribution whereas a negative value indicates a
flatter distribution. The skewness index measures the degree of asymmetry of a
distribution. A positive value for this index indicates a distribution with a longer tail
extending to the right whereas a negative value indicates a distribution with a longer
tail extending to the left. The closer the kurtosis and skewness indexes are to zero,
the closer a given distribution of price ratios approximates those of a normal
distribution.
For these diagnostic tests, unweighted price ratios were calculated for each
comparison country relative to Australia. That is, prices were not weighted by their
Australian expenditure. For each pharmaceutical category, the number of price
ratios for each comparison country was equivalent to the number of bilateral
matches achieved with Australia. Price ratios were computed for both higher and
lower estimates of prices. The diagnostic tests were then applied to each price ratio
series.
All categories
For all categories, the computed z-statistics indicate that the price differences with
Australia are statistically significant for all comparison countries except NZ
(table E.28). In the case of NZ, at the five per cent level of significance, the null
hypothesis is rejected for the price ratios based on the higher estimate of prices and
accepted for the price ratios based on the lower estimate of prices. The null
hypothesis is accepted at the one per cent level for the price ratio series based on the
higher and lower estimates of prices.RESULTS IN DETAIL E.15
Table E.28 Diagnostic tests, all categories of pharmaceuticals
Diagnostic Estimate US Canada UK Sweden France Spain NZ
Z-statistic Higher 13.00 11.64 11.30 7.92 4.08 -3.31 2.13
Lower 10.43 8.12 10.39 7.94 2.86 -5.46 0.27
P(w)a Higher 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Lower 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Kurtosis Higher 10.87 5.36 19.47 33.16 10.75 0.28 12.46
Lower 9.12 10.70 8.19 17.18 3.95 0.53 14.33
Skewness Higher 2.77 2.06 3.52 4.72 2.68 0.60 2.51
Lower 2.53 2.79 2.25 3.12 1.60 0.71 2.45
a Probability of the w-statistic in percentage terms.
Source: PC estimates.
Based on the probability of the w-statistic, the null hypothesis of normality is
rejected for all comparison countries using the five or one  per  cent level of
significance. The price ratio distributions exhibit a very high degree of positive
kurtosis and skewness for all the comparison countries except Spain. Using the
lower estimate of prices, the price ratio distributions for Spain are nearest to those
of a normal distribution whereas those for Sweden exhibit the highest positive
kurtosis and skewness.
New innovative pharmaceuticals
For new innovative pharmaceuticals, the test statistics indicate that price differences
with Australia are statistically significant for the US, the UK and Spain (table E.29).
In the case of Sweden, the null hypothesis is rejected for higher and lower estimates
at the five cent level of significance but is accepted for the lower estimate at the
one  per cent level. For NZ and Canada, the null hypothesis that prices for the
selected PBS items are generally the same as in Australia is accepted at both levels
of significance. In the case of France, the null hypothesis is rejected at the
five per cent level but accepted at the one per cent level.E.16 PHARMACEUTICAL
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Table E.29 Diagnostic tests, new innovative pharmaceuticals
Diagnostic Estimate US Canadaa UK Sweden Francea Spaina NZa
Z-statistic Higher 7.59 1.94 2.97 3.43 -2.10 -4.94 -0.55
Lower 6.72 1.85 2.86 2.47 -2.29 -4.88 -0.55
P(w)b Higher 1.69 0.01 0.34 50.42 27.34 1.68 1.12
Lower 0.88 0.01 0.61 7.16 25.13 3.14 1.12
Kurtosis Higher 0.14 4.71 3.42 0.84 0.83 -1.13 1.89
Lower 0.55 4.65 3.28 1.66 1.10 -1.11 1.89
Skewness Higher 0.86 1.93 1.36 0.02 -0.44 -0.18 -0.71
Lower 1.01 1.93 1.32 0.39 -0.49 -0.23 -0.71
a Because the sample was less than 30, the t-statistic was computed and compared to the relevant critical
values based on the t-distribution. b Probability of the w-statistic in percentage terms.
Source: PC estimates.
The results of the normality test are sensitive to the level of significance chosen.
The null hypothesis of normality is rejected for most comparison countries using the
five  per  cent level but is accepted in most cases using the one  per  cent level.
Compared to all categories, the price ratio distributions for most countries exhibit a
much lower degree of kurtosis and skewness. The price ratios for Spain exhibit
some negative kurtosis and those for NZ, France and Spain exhibit slight negative
skewness. That said, the price ratio distributions for new innovative items are
generally more normal that those for the other categories.
Me-too pharmaceuticals
For me-too pharmaceuticals, price differences with Australia are not statistically
significant for NZ and Spain (table  E.30). For these two countries, the null
hypothesis is accepted at both levels of significance.
Table E.30 Diagnostic tests, me-too pharmaceuticals
Diagnostic Estimate US Canada UK Sweden France Spain NZ
Z-statistic Higher 9.29 7.64 8.45 7.33 4.23 1.11 0.63
Lower 9.15 9.01 9.30 6.55 4.21 0.00 -0.25
P(w)a Higher 0.01 0.01 0.01 0.01 0.19 14.53 0.01
Lower 0.01 12.12 0.01 0.01 0.15 30.49 0.01
Kurtosis Higher 1.23 7.70 9.90 0.35 1.78 -0.27 3.90
Lower 1.37 0.80 11.52 0.58 1.81 -0.27 3.42
Skewness Higher 1.34 2.17 2.60 0.99 1.03 0.07 1.33
Lower 1.37 0.63 2.24 1.00 1.04 0.12 1.13
a Probability of the w-statistic in percentage terms.
Source: PC estimates.RESULTS IN DETAIL E.17
The null hypothesis of normality is rejected for most comparison countries using the
five and one per cent levels of significance. However, the null hypothesis is
accepted for Spain and the lower estimate for Canada at both levels of significance.
The price ratio distributions generally exhibit positive kurtosis (except for Spain)
and positive skewness. Based on the lower estimate of prices, the price ratios for
Spain are closest to those of a normal distribution whereas those for the UK exhibit
the highest degree of positive kurtosis and skewness for this category.
Generic pharmaceuticals
For generic pharmaceuticals, the computed z-statistics indicate that price
differences with Australia are statistically significant for most comparison countries
(table E.31). However, based on the lower estimate of prices for NZ and France, the
null hypothesis is accepted at both levels of significance. Based on the higher
estimate of prices for NZ, the null hypothesis is rejected at the five per cent level
but accepted at the one per cent level.
The null hypothesis of normality is clearly rejected for all comparison countries
using both levels of significance. Compared to the new innovative and me-too
categories, the price ratio distributions generally exhibit higher positive kurtosis and
skewness. Based on the lower estimate of prices, the price ratios for Spain are
closest to those of a normal distribution whereas those for Sweden exhibit the
highest positive kurtosis and skewness.
Table E.31 Diagnostic tests, generic pharmaceuticals
Diagnostic Estimate US Canada UK Sweden France Spain NZ
Z-statistic Higher 10.91 10.06 8.11 5.17 2.77 -4.93 2.14
Lower 6.43 5.78 6.18 5.19 1.05 -7.03 0.49
P(w)a Higher 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Lower 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Kurtosis Higher 6.43 2.98 16.67 22.06 7.45 1.36 9.35
Lower 7.61 6.39 6.47 15.00 4.00 2.35 12.09
Skewness Higher 2.16 1.59 3.35 4.17 2.46 0.90 2.28
Lower 2.48 2.33 2.21 3.19 1.77 1.17 2.40
a Probability of the w-statistic in percentage terms.
Source: PC estimates.
As most of the price ratio series were found to be non-normally distributed, the
results of hypothesis tests using z-statistics need to be interpreted with caution.
Apart from the sampling approach adopted in this study, the use of simple ratiosE.18 PHARMACEUTICAL
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(derived from those samples) may have contributed to the positive skewness and
kurtosis detected above.
E.4 Price comparisons with Federal Supply Schedule
To examine the issue of prices paid by larger/institutional buyers in the US, prices
contained in the FSS were compared to those obtained from IMS Health.
The approach adopted involved attempting to match forms from both the FSS and
IMS Health sources, focusing on the top-selling molecules in each category
(42  molecules and 101  forms in total), accounting for around 45  per  cent of
Australian manufacturer revenue. The molecules included in the comparison are
listed in table E.32.
Table E.32 Molecules included in price comparisons with FSS
New innovative Me-too Generic
Alendronate Sodium Amlodipine Besylate Amoxycillin
Alprostadil Atorvastatin Calcium Atenolol
Ciprofloxacin Enalapril Maleate Calcitriol
Clozapine Famotidine Captopril
Epoetin Alfa Felodipine Cefaclor
Latanoprost Fosinopril Sodium Cephalexin
Leflunomide Goserelin Acetate Diclofenac Sodium
Mycophenolate Mofetil Irbesartan Diltiazem Hydrochloride
Olanzapine Lansoprazole Fluoxetine Hydrochloride
Risperidone Lisinopril Gemfibrozil
Rituximab Paroxetine Hydrochloride Isosorbide Mononitrate
Terbinafine Hydrochloride Pravastatin Sodium Medroxyprogesterone
   Acetate





From this sample, price comparisons with Australia were undertaken using FSS and
IMS Health prices (tables E.33 to E.36). The percentage difference between the two
sets of price ratios was then used to estimate discounts that larger/institutional
buyers in the US can obtain off list prices. Note that the price ratios in tables E.33 to
E.36 differ from those contained in E.4 to E.7. This occurs because they use
different samples. That is, more forms are covered in tables E.4 to E.7 compared to
E.33 to E.36.RESULTS IN DETAIL E.19
Table E.33 Price ratios, IMS Health and FSS prices, all categories
Average exchange rate for June 2000
Unit Aust. sales volumes PBS scripts
IMS Health prices
  higher estimate ratio 3.27 3.22
  lower estimate ratio 2.66 2.68
FSS prices
  higher estimate ratio 2.49 2.48
  lower estimate ratio 1.84 1.78
Estimated discounta
  higher estimate % 24 23
  lower estimate % 31 33
No. of matches no. 101 101
Coverageb %4 4 4 7
a The estimated discount represents the difference between IMS Health and FSS price ratios expressed as a
percentage of the IMS Health price ratio. b Coverage shows the percentage of total Australian manufacturer
revenue for the 150 molecules accounted for by the matched forms.
Source: PC estimates.
Table E.34 Price ratios, IMS Health and FSS prices, new innovative
Average exchange rate for June 2000
Unit Aust. sales volumes PBS scripts
IMS Health prices
  higher estimate ratio 2.07 2.04
  lower estimate ratio 1.91 1.92
FSS prices
  higher estimate ratio 1.94 1.90
  lower estimate ratio 1.86 1.82
Estimated discounta
  higher estimate % 6 7
  lower estimate % 3 5
No. of matches no. 26 26
Coverageb %5 4 5 2
a The estimated discount represents the difference between IMS Health and FSS price ratios expressed as a
percentage of the IMS Health price ratio. b Coverage shows the percentage of total Australian manufacturer
revenue for new innovative molecules accounted for by the matched forms.
Source: PC estimates.E.20 PHARMACEUTICAL
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Table E.35 Price ratios, IMS Health and FSS prices, me-too
Average exchange rate for June 2000
Unit Aust. sales volumes PBS scripts
IMS Health prices
  higher estimate ratio 2.95 2.94
  lower estimate ratio 2.80 2.80
FSS prices
  higher estimate ratio 1.94 1.94
  lower estimate ratio 1.70 1.71
Estimated discounta
  higher estimate % 34 34
  lower estimate % 39 39
No. of matches no. 33 33
Coverageb %5 2 5 4
a The estimated discount represents the difference between IMS Health and FSS price ratios expressed as a
percentage of the IMS Health price ratio. b Coverage shows the percentage of total Australian manufacturer
revenue for me-too molecules accounted for by the matched forms.
Source: PC estimates.
Table E.36 Price ratios, IMS Health and FSS prices, generics
Average exchange rate for June 2000
Unit Aust. sales volumes PBS scripts
IMS Health prices
  higher estimate ratio 4.62 4.37
  lower estimate ratio 2.73 2.75
FSS prices
  higher estimate ratio 4.00 3.93
  lower estimate ratio 2.08 1.88
Estimated discounta
  higher estimate % 14 10
  lower estimate % 24 32
No. of matches no. 42 42
Coverageb %3 0 3 6
a The estimated discount represents the difference between IMS Health and FSS price ratios expressed as a
percentage of the IMS Health price ratio. b Coverage shows the percentage of total Australian manufacturer
revenue for generic molecules accounted for by the matched forms.
Source: PC estimates.RESULTS IN DETAIL E.21
E.5 Difference between higher and lower estimates of
prices
As discussed in chapter 3, higher and lower estimates of prices were reported in
instances where there were multiple manufacturers of the same pharmaceutical,
pack size differences with Australia or a combination of the two.
Table E.37 provides summary statistics on the percentage contribution each issue
makes to the price range across countries for all categories.
Table E.37 Contribution to price range, all categories
Contributor No. of forms Contribution to price rangea
no. %
United States
  Pack size 56 15
  Multiple manufacturers 61 57
  Pack size and multiple manufacturers 32 29
Canada
  Pack size 23 7
  Multiple manufacturers 57 39
  Pack size and multiple manufacturers 40 54
United Kingdom
  Pack size 25 2
  Multiple manufacturers 98 83
  Pack size and multiple manufacturers 19 15
Sweden
  Pack size 32 16
  Multiple manufacturers 59 70
  Pack size and multiple manufacturers 6 14
France
  Pack size 27 17
  Multiple manufacturers 35 45
  Pack size and multiple manufacturers 4 38
Spain
  Pack size 2 1
  Multiple manufacturers 85 81
  Pack size and multiple manufacturers 2 18
New Zealand
  Pack size 9 20
  Multiple manufacturers 23 72
  Pack size and multiple manufacturers 5 8
a Totals may not sum to 100 due to rounding.
Source: PC estimates.E.22 PHARMACEUTICAL
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E.6 Therapeutic groups
Table E.38 presents the detailed results of the international price comparisons using
ATC groups.
Table E.38 Price comparisons for ATC groups, list prices
ATC group US Canada UK Sweden France Spain NZ
Upper 3.48 1.81 1.64 1.57 1.17 1.02 0.98 Key results, all categories
Lower 2.62 1.51 1.48 1.48 1.12 0.96 0.92
Upper 3.98 1.86 1.76 1.98 1.47 1.25 0.82 Alimentary tract and
metabolism
Lower 3.75 1.58 1.72 1.89 1.32 1.10 0.71
Upper 1.56 0.99 1.07 1.09 0.78 0.46 0.67 Antineoplastic and
immunomodulating agents
Lower 1.53 0.98 1.04 1.03 0.76 0.45 0.67
Upper 4.69 1.41 1.14 1.23 1.17 0.97 1.43 Blood and blood forming
organs
Lower 1.77 1.39 1.07 1.22 1.17 0.97 1.43
Upper 3.38 1.86 1.62 1.44 1.23 1.02 0.91 Cardiovascular system
Lower 2.49 1.62 1.48 1.34 1.18 0.97 0.90
Upper 4.35 1.54 1.05 1.20 0.87 0.71 0.70 Dermatologicals
Lower 4.03 1.45 1.03 1.01 0.87 0.71 0.70
Upper 3.49 1.06 1.60 1.45 1.05 0.79 0.91 General anti-infectives for
systemic use
Lower 1.97 0.86 1.40 1.32 1.02 0.77 0.89
Upper 5.46 3.07 1.55 1.53 0.94 1.04 1.36 Genito urinary system and
sex organs
Lower 4.19 1.26 1.45 1.37 0.89 1.02 1.36
Upper 5.77 3.00 2.49 1.87 1.02 0.97 0.96 Musculo-skeletal system
Lower 2.14 1.63 1.62 1.85 1.01 0.83 0.81
Upper 3.03 1.79 1.58 1.57 0.97 1.12 1.31 Nervous system
Lower 2.33 1.31 1.41 1.43 0.97 1.07 1.19
Upper 4.15 2.07 1.75 2.96 1.46 1.17 1.24 Respiratory system
Lower 4.11 2.01 1.70 2.83 1.43 1.11 1.20
Upper 2.39 1.33 1.31 1.14 0.94 0.74 0.89 Sensory organs
Lower 1.82 1.07 1.17 1.14 0.84 0.74 0.86
Upper 2.64 0.81 0.98 1.41 0.81 0.49 0.74 Systemic hormonal
preparations, excluding
sex hormones Lower 2.44 0.53 0.96 0.98 0.81 0.49 0.74
Upper 2.23 2.10 4.70 nm 1.18 0.40 1.30 Various
Lower 1.36 1.38 2.24 nm 1.18 0.40 1.28
nm No matches were found for this category.
Source: PC estimates.RESULTS IN DETAIL E.23
Table E.39 identifies, for each ATC group, the share of new innovative, me-too and
generic pharmaceuticals in total Australian expenditure on the top-selling
molecules. The number of pharmaceuticals in these four ATC groups account for
over half of the available forms in the sample (302 out of 584 forms). The table
shows that expenditure on cardiovascular system pharmaceuticals, especially those
in the me-too category, accounts for a large share of total Australian expenditure on
the 150 top-selling molecules. For the other three influential ATC groups, me-too
and generic pharmaceuticals accounted for the largest share of Australian
expenditure.
Table E.39 Influential ATC groups, number of forms and share of
Australian pharmaceutical expenditure
ATC group Category Number of forms in the
sample
Share of total Aust.
expenditure (per cent)a
















a Shows the share of each category in total expenditure in Australia on the top 150 molecules.
Source: PC estimates.E.24 PHARMACEUTICAL
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E.7 Molecule age and launch delay
Table E.40 Molecule launch delay, median value, multilateral
comparison (years)a
Unit US Aust France Spain Canada NZ UK
All no. 3.5 3.4 3.3 3.3 3.0 2.8 0.9
Generic no. 7.6 6.3 3.7 4.4 4.4 6.1 2.0
Me-too no. 2.7 3.0 2.1 2.3 2.8 1.8 0.7
New no. 1.9 2.2 3.3 1.8 2.2 2.2 0.4
a Comparisons are for the 100 molecules (within the top 150 PBS molecules) available across all countries,
excluding molecules with form launch dates prior to global launch dates (for example, fluvastatin in the UK and
clopidogrel in the US), and molecules without information on their form launch date. The molecule launch
delay is calculated as the time from global launch date to the first form launch date. Information on form
launch date in Sweden was unavailable.
Source: PC estimates.
Table E.41 Molecule age, median value, multilateral comparison (years)a
Unit Aust NZ France US Canada Spain UK
All no. 14.3 15.8 15.9 17.0 17.1 17.6 18.8
Generic no. 22.5 22.8 25.6 23.1 24.9 26.1 26.4
Me-too no. 7.4 7.9 7.8 8.4 8.3 8.1 9.6
New no. 5.1 6.0 4.4 6.5 7.2 6.1 6.3
a Comparisons are for the 100 molecules (within the top 150 PBS molecules) available across all countries,
excluding molecules with form launch dates prior to global launch dates (for example, fluvastatin in the UK and
clopidogrel in the US), and molecules without information on their form launch date. The molecule launch age
is calculated as the time between first form launch date and 30 June 2000. Information on form launch date in
Sweden was unavailable.
Source: PC estimates.CASE STUDIES OF
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F.1
F Case studies of price differences
Additional pricing information was provided by GlaxoSmithKline Australia
Limited (GSK) and the Department of Health and Aged Care (DHAC) for three
particular pharmaceuticals, namely ranitidine  hydrochloride  (Zantac),  paroxetine
hydrochloride (Aropax) and salmeterol xinafoate (Serevent) (box F.1). Even though
they are not necessarily representative of the sample of pharmaceuticals covered in
this study, they assist in identifying factors that may have influenced price
differences over time.
F.1 Ranitidine
Ranitidine  was launched in Australia on the private prescription market in
April  1982. While the launch price at this time is unknown, in May 1983, the
manufacturer price of the product was $41.93. It was listed on the PBS 16 months
later, in August 1984 with a manufacturer price of $34 per pack.
Figure  F.1 shows the Australian price as a proportion of the overseas price for
ranitidine at May  1983, and at 30  June 2000 respectively, for the United States
(US), Canada, Sweden and Spain. It shows that the price differences between
Australia and the comparison countries have increased significantly over the period.
Based on information provided by GSK, it appears that the changes in the price
differences were due to a combination of price reductions in Australia, price
changes in the comparison countries, and a depreciation in the Australian dollar.
Between May 1983 and June 2000, the price of ranitidine in Australia (including
any brand premiums) fell by around 61 per cent (from $41.93 to $16.42). Some of
this decline may be due to:
•   negotiations over the listing price: around one-third (19 percentage points)
occurred in the period between May 1983 and the listing of the product on the
PBS (in August 1994);
•   generic competition: between May 1983 and June 2000 the patent on ranitidine
in Australia expired and several competitors entered the market;F.2 PHARMACEUTICAL
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•   reference pricing: ranitidine is included in the H2 receptor antagonist group and
therefore its price has been subject to reference pricing reviews under the
weighted average monthly treatment cost (WAMTC) methodology; and
•   volume controls: initially ranitidine was listed as an Authority Required item.
Later this was changed to a restricted benefit.1
Box F.1 Price differences over time
Additional pricing information was obtained for three products.
•   Ranitidine (marketed in Australia as Zantac) available in 150mg tablets in a packet
of 60 tablets. It is used to treat a variety of stomach disorders (and belongs to the
alimentary tract and metabolism group). Prices were obtained for the US, Canada,
Sweden and Spain. It is classified as a generic molecule.
•   Paroxetine (marketed in Australia as Aropax) available in 20mg tablets, with
30 tablets per packet. It is used to treat mental disorders such as depression (and
belongs to the nervous system group). Prices were obtained for the US, Canada,
the United Kingdom (UK), Sweden and New Zealand (NZ). It is classified as a
me-too molecule.
•   Salmeterol (marketed in Australia as Serevent) available in a pressurised inhaler
dispensing 25 micrograms per dose, with 120 doses. It is used to treat asthma (and
is classified under the respiratory system group). Prices were obtained for the US,
France and Spain. It is classified as a me-too molecule.
These particular items were chosen by the Commission because they were available in
a number of the comparison countries.
The Commission sought prices for each of the products for four different points in time.
GSK provided prices at (or as close as possible to) the date on which the product was
first marketed (market launch), an intermediate date chosen by the Commission (which
was chosen to maximise the number of countries included in the comparisons), and at
30 June 2000. DHAC provided information on the price at which the three products
were listed on the Pharmaceutical Benefits Scheme (PBS) (in all cases this was after
market launch).
As the products were launched at different times, the time periods covered by the case
studies vary. Hence the results cannot be compared.
The information used in these case studies is summarised in appendix D.
Source: GSK (pers. comm., 20 June 2000).
                                             
1 According to DHAC (pers. comm., 29 June 2001) at 30 June 2000 the restricted uses were
substantially the same as those when first listed.CASE STUDIES OF
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Data sources: ABS (2000b); DHAC (pers.  comm., 25  June  2001); EconData (1999); GSK (pers. comm.,
20 June 2001).
According to GSK, some of the widening of the price differences between Australia
and the comparison countries was due to changes in the foreign prices. Between
May 1983 and June 2000, nominal prices in:
•   the US increased by 19 per cent (in US dollar terms). This change should be
viewed with caution because no allowance is made for discounts. The list price
for ranitidine in the US was US$91.27 at June 2000 but the Federal Supply
Schedule (FSS) price (at November 2000) was around 21  per  cent lower
(US$72.48);
•   Canada were unchanged (in Canadian dollars) due to a price freeze implemented
in 1993 by provincial drug plans, and competition from generics;
•   Sweden fell by 40 per cent, also due primarily to competition from generics; and
•   Spain fell by 2.5  per  cent due to compulsory price cuts imposed by the
Government.
The Australian dollar denominated prices of ranitidine in the comparison countries
were also influenced by changes in exchange rates. Between 1982-83 and
1999-2000, the value of the Australian dollar fell against all of the foreign
currencies thereby pushing up the Australian dollar denominated overseas prices.
The Australian dollar depreciated by 38 per cent against the US dollar; 26 per centF.4 PHARMACEUTICAL
PRICES STUDY
against the Canadian dollar; 16 per cent against the Swedish kroner; and 6 per cent
against the Spanish pesetas.
F.2 Paroxetine
Paroxetine was launched in Australia on the private prescription market in
November 1993 (at a launch price of $50.03). It was listed on the PBS
approximately nine months later, in August 1994 at $49.93.
Price differences between Australia and several countries were also estimated for
paroxetine. Figure F.2 shows how prices in Australia compared with those in the
US, Canada, the UK, Sweden and NZ at May 1993, and at 30  June 2000
respectively. At the market launch, the price of the product in Australia was
relatively close to the prices in all comparison countries, except the UK. Over the
period, price differences increased significantly for all countries except the UK.
The fall in the relative price of paroxetine in Australia was due to a combination of
price reductions in Australia, price changes overseas, and a depreciation in the
Australian dollar.




















Data sources: ABS (2000b); DHAC (pers. comm., 25 June 2001); EconData (1999); GSK (pers. comm., 20
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Over the period, the price of paroxetine in Australia fell in nominal terms by around
45 per cent (from $50.03 to $27.58). Unlike the case for ranitidine, almost all of this
occurred after it was listed on the PBS. The product is under a patent in Australia
and the other comparison countries. Although this means that there is no direct
competition from generic producers, the product faces competition from a range of
therapeutic alternatives. Paroxetine is one of a number of Selective Serotonin Re-
uptake Inhibitors (SSRIs) that were subject to reference pricing. This means that the
price of paroxetine has been influenced by the changes in prices of other SSRIs.
There is some evidence that the local price also may have been affected by changes
in the restrictions on the use of the product. According to DHAC (pers. comm.,
29 June 2001), paroxetine (and its therapeutic competitors fluoxetine and sertraline)
were initially listed as Authority Required items for ‘major depression where other
anti-depressants were not appropriate.’ This means they were to be used as
second-line therapy after less expensive agents. They were transferred off authority
after convincing the Pharmaceutical Benefits Advisory Committee (PBAC) that
they were of acceptable cost-effectiveness at appreciably reduced prices.
According to GSK, some of the change in the price differences for paroxetine were
also due to changes in the overseas prices. Between May 1993 and June 2000, the
nominal price in:
•   the US increased by 45 per cent. This change also should be viewed with caution
as the US price does not account for any discounts. It was found that the FSS
price of US$34.37 (at November 2000) was 46 per cent lower than the list price
of US$63.26 (at June 2000);
•   Canada was unchanged due to a price freeze implemented by provincial plans.
Some provinces in Canada also compared the price of paroxetine to those of
generic SSRIs (such as sertraline and citalopram);
•   the UK fell by 48  per cent. Some of the price reduction was caused by
competition from therapeutic substitutes;
•   Sweden was unchanged (no reasons were given); and
•   NZ fell by 39  per  cent due to the increased availability of a low-priced
comparator (fluoxetine).
The Australian dollar denominated prices of paroxetine in the comparison countries
were also influenced by changes in exchange rates. In the period between June 1993
and June  2000, the value of the Australian dollar rose against two of the five
currencies (by 4 per cent against the Canadian dollar and 25 per cent against the
Swedish kroner). The dollar depreciated against the US dollar (14 per cent), the UK
pound (six per cent), and NZ dollar (by nine per cent).F.6 PHARMACEUTICAL
PRICES STUDY
F.3 Salmeterol
Salmeterol was launched in Australia on the private prescription market in June
1993 (at a price of $41.90). It was then listed on the PBS in February 1995 (at a
price of $37.00).
Figure  F.3 shows the difference between the US and Australian prices for
salmeterol, as at December 1994, and at 30 June 2000. Over the period, price
differences for salmeterol have increased for all comparison countries.



















Data sources: ABS (2000b); DHAC (pers. comm., 25 June 20001); EconData (1999); GSK (pers. comm.,
20 June 20001).
Between December 1994 and June 2000, the Australian price of salmeterol fell in
nominal terms by around 36  per  cent. Approximately one-third of this reduction
occurred in the period between the market launch and it being listed on the PBS.
According to GSK, a significant portion of the price reduction occurred at the time
the volume controls on the product were altered. Salmeterol initially was listed as
an Authority Required item for ‘patients with frequent episodes of nocturnal asthma
who are receiving treatment with oral corticosteroids or maximal doses of inhaled
corticosteroids’. The restrictions on the use of the product were then eased in
exchange for a significant price reduction. At 30 June 2000, it was classified as a
restricted benefit item for ‘patients with frequent episodes of asthma  who areCASE STUDIES OF
PRICE DIFFERENCES
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receiving treatment with oral corticosteroids or optimal  doses of inhaled
corticosteroids’.
According to GSK, price changes in the comparison countries also contributed to
the change in price differences for salmeterol. Nominal prices in:
•   the US increased by 38  per  cent over the period. Again, the rise should be
treated with caution. It was found that the FSS price for salmeterol (US$42.81)
at November 2000 was around 26 per cent below the list price (US$57.93) at
30 June 2000.
•   Spain rose 12 per cent. The price initially fell due to the Government imposing
general price cuts for pharmaceuticals in September 1994. However, in April
1997 the price was increased when the supplier reached an agreement with the
Government that allowed higher prices in exchange for the company committing
to local investments in R&D and manufacturing.
•   France fell by 14 per cent due to price reductions (in July 1995 and September
1998) under the terms of a price-volume agreement.
The Australian dollar denominated prices of salmeterol in the comparison countries
also were influenced by relatively small changes in exchange rates.REFERENCES
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